

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



WIPPO | PCT



(10) International Publication Number
WO 2018/130583 A1

(43) International Publication Date
19 July 2018 (19.07.2018)

(51) International Patent Classification:

C12N 15/113 (2010.01) A61K 31/712 (2006.01)
A61K 31/7115 (2006.01) A61K 31/7125 (2006.01)

(21) International Application Number:

PCT/EP2018/050583

(22) International Filing Date:

10 January 2018 (10.01.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1715 1400.3 13 January 2017 (13.01.2017) EP

(71) Applicant: ROCHE INNOVATION CENTER COPENHAGEN A/S [DK/DK]; Fremtidsvej 3, 2970 Horsholm (DK).

(72) Inventors: LINDHOLM, Eva Marie W; c/o Roche Innovation Center Copenhagen A/S, Fremtidsvej 3, 2970 Horsholm (DK). PEDERSEN, Lykke; c/o Roche Innovation Center Copenhagen A/S, Fremtidsvej 3, 2970 Horsholm (DK). SCHMIDT, Steffen; c/o Roche Innovation Center Copenhagen A/S, Fremtidsvej 3, 2970 Horsholm (DK).

(74) Agent: TURNER, Mark et al; c/o Roche Innovation Center Copenhagen A/S, Patent Department IP (LPBG....2898), Fremtidsvej 3, 2970 Horsholm (DK).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))
— with information concerning incorporation by reference of missing parts and/or elements (Rule 20.6)

(54) Title: ANTISENSE OLIGONUCLEOTIDES FOR MODULATING NFKB1 EXPRESSION

(57) Abstract: The present invention relates to antisense oligonucleotides that are capable of modulating expression of NF-KB1 in a target cell. The oligonucleotides are complementary to mammalian NFKB1 pre-mRNA intron sequence. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of cancer, inflammation or autoimmune diseases using the oligonucleotide.



WO 2018/130583 A1

ANTISENSE OLIGONUCLEOTIDES FOR MODULATING NFKB1 EXPRESSION**FIELD OF INVENTION**

The present invention relates to oligonucleotides (oligomers) complementary to NFKB1 pre-mRNA intron sequences, which are capable inhibiting the expression of NF- κ B 1. Inhibition of
5 NF- κ B 1 expression is beneficial for a range of medical disorders including autoimmunity and cancer.

BACKGROUND

Nuclear factor kappa-light-chain-enhancer of activated B cells (NF- κ B) is a key regulator of processes such as immunity, inflammation, gene expression, cancer cell migration, invasion,
10 apoptosis, and proliferation. NF- κ B subunits share a Rel homology domain in their N-terminus. The NFKB1 (nuclear factor kappa B subunit 1) gene encodes a 105 kD protein (p105) which upon activation is processed to a 50 kD protein (p50), where p50 as homo- or heterodimer can form some members of the NF- κ B family of transcription factors. The p50/p65 heterodimer is found in most cell types whereas other NF- κ B homo- and heterodimers are specific for different
15 tissues and subsets of cells. NF- κ B subunit expression can be altered in disease, and dysfunctional NF- κ B activation contributes to disorders including rheumatoid arthritis, atherosclerosis, inflammatory bowel diseases, multiple sclerosis and malignant tumors (Park and Hong, 2016, Cells 5:15), as well as asthma and chronic inflammatory airway disease (Schuliga, 2015, Biomolecules, 5-1266).

20 There are **>700** compounds described in literature to have NF- κ B inhibitory effect, most of them with broad effect on NF- κ B signaling, but a narrow therapeutic index, poor specificity, short *in vivo* half-life of molecules, and only minor effects on signaling have limited the therapeutic use of described NF- κ B inhibitors to date. It has been suggested that specific NF- κ B subunit
25 reduction can be a way to overcome the limitations of more "general" NF- κ B inhibitors.

Interference with the p50 NF- κ B subunit by a small molecule has been reported to result in specific antitumor and anti-autoimmune inflammation activity (Kong *et al*, 2014, Oncotarget, 5:1 1354). Normalization of aberrant NF- κ B signaling through reduction of p50 levels ameliorates
30 Rett syndrome phenotypes in Mecp2-null mice, demonstrating that specific p50 reduction can improve brain function in a severe neurodevelopmental disorder (Kishi *et al*, 2016, Nat Commun, 7:10520).

Voisard *et al.*, BMC Molecular Biology 2001 , 2:7 reports on different effects of antisense RelA p65 and NF- κ B 1 p50 oligonucleotides on the nuclear factor- κ B mediated expression of ICAM-1
35 in human coronary endothelial and smooth muscle cells.

Ishige et al, Neurochemistry 47, 545-55 reports that distinct nuclear factor- κ B/Rel proteins have opposing modulatory effects in glutamate-induced cell death in HT22 cells, and discloses antisense oligonucleotides targeting NF- κ B subunits, including a compound of sequence 5-TGCCATGGTGAAGATGCGCAG-3 which targets p50.

US 5,591,840, WO95/35032 and WO04/005551 refer to antisense oligonucleotides targeting human NF-KB 1 transcripts.

OBJECTIVE OF THE INVENTION

10 The present invention identifies novel oligonucleotides which inhibit human NFKB1 which are useful in the treatment of a range of medical disorders including autoimmunity, inflammation, and cancer.

SUMMARY OF INVENTION

15 The present invention relates to oligonucleotides targeting a NFKB1 nucleic acid, capable of modulating, such as inhibiting the expression of NF-KB 1.

The invention provides for an antisense oligonucleotide of 10 to 30 contiguous nucleotides in length, wherein at least 10 contiguous nucleotides of the contiguous sequence of the oligonucleotide is at least 90% complementarity, such as fully complementary, to a NFKB1 intron sequence.

20 The invention provides for an antisense oligonucleotide of 12 to 30 contiguous nucleotides in length, wherein at least 12 contiguous nucleotides of the contiguous sequence of the oligonucleotide is at least 90% complementarity, such as fully complementary, to a NFKB1 intron sequence.

25 The invention provides oligonucleotides which consist or comprise a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90% complementarity such as fully complementarity, to an intron of the NFKB1 pre-mRNA (SEQ ID NO 21).

The invention provides oligonucleotides which consist or comprise a contiguous nucleotide sequence of 12 to 30 nucleotides in length with at least 90% complementarity such as fully complementarity, to an intron of the NFKB1 pre-mRNA (SEQ ID NO 21).

30 The invention provides antisense oligonucleotides, which are capable of inhibiting NF-KB 1 expression in a cell which is expressing NFKB1 (a target cell), which consists or comprises of a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90% complementarity, such as fully complementarity, to a NFKB1 intron sequence.

The invention provides antisense oligonucleotides, which are capable of inhibiting NF-KB 1 expression in a cell which is expressing NF-KB 1, which consists or comprises of a contiguous nucleotide sequence of 12 to 30 nucleotides in length with at least 90% complementarity, such as fully complementarity, to a NFKB1 intron sequence.

5 The invention provides for a conjugate comprising the oligonucleotide according to the invention.

In a further aspect, the invention provides pharmaceutical compositions comprising the oligonucleotide or conjugate of the invention and pharmaceutically acceptable diluents, carriers, salts and/or adjuvants.

10 In a further aspect, the invention provides methods for *in vivo* or *in vitro* method for modulation of NF-KB1 expression in a target cell which is expressing NFKB1 by administering an oligonucleotide, conjugate, or composition of the invention in an effective amount to said cell.

In a further aspect the invention provides methods for treating or preventing a disease, disorder or dysfunction associated with *in vivo* activity of NF-KB 1 comprising administering a
15 therapeutically or prophylactically effective amount of the oligonucleotide, conjugate or composition of the invention to a subject suffering from or susceptible to the disease, disorder or dysfunction.

In a further aspect the oligonucleotide, conjugate or composition of the invention is used for the treatment or prevention of cancer, autoimmune diseases, and inflammation or an inflammatory
20 disease.

In some embodiments, the oligonucleotide, conjugate or composition of the invention is an antisense oligonucleotide, preferably a gapmer antisense oligonucleotide.

BRIEF DESCRIPTION OF FIGURES

25 **Figure 1A, 1B and 1C:** Mouse *in vivo* efficacy, 16 days of treatment, Intravenous injection (tail vein).

Figure 2: Testing *in vitro* efficacy of various antisense oligonucleotides targeting human NFKB1 mRNA in HEK293 and HeLa cell lines at single dose concentration.

Figure 3: Testing *in vitro* efficacy of antisense oligonucleotides targeting human NFKB1 mRNA in HEK293 and HeLa cell lines at single dose concentration.

30 **Figure 4:** Testing *in vitro* efficacy of antisense oligonucleotides targeting human NFKB1 mRNA in HEK293 and HeLa cell lines at single dose concentration. Zoom in illustrating the data for compounds targeting the hot spot regions.

Figure 5A, 5B & 5C: Testing *in vitro* potency and efficacy of selected oligonucleotides targeting human NFKB1 mRNA in HEK-293 and HeLa cell lines in a dose response curve.

Figure 6: Human NFKB1 pre-mRNA sequence (SEQ ID NO 21) derived from the human genomic sequence NC_000004.12 (102501329..102617302).

DEFINITIONS

Oligonucleotide

- 5 The term "oligonucleotide" as used herein is defined as it is generally understood by the skilled person as a molecule comprising two or more covalently linked nucleosides. Such covalently bound nucleosides may also be referred to as nucleic acid molecules or oligomers. Oligonucleotides are commonly made in the laboratory by solid-phase chemical synthesis followed by purification. When referring to a sequence of the oligonucleotide, reference is made
- 10 to the sequence or order of nucleobase moieties, or modifications thereof, of the covalently linked nucleotides or nucleosides. The oligonucleotide of the invention is man-made, and is chemically synthesized, and is typically purified or isolated. The oligonucleotide of the invention may comprise one or more modified nucleosides or nucleotides.

Antisense oligonucleotides

- 15 The term "Antisense oligonucleotide" as used herein is defined as oligonucleotides capable of modulating expression of a target gene by hybridizing to a target nucleic acid, in particular to a contiguous sequence (a sub-sequence) on a target nucleic acid. The antisense oligonucleotides are not essentially double stranded and are therefore not siRNAs. Preferably, the antisense oligonucleotides of the present invention are single stranded.
- 20 An LNA antisense oligonucleotide is an antisense oligonucleotide which comprises at least one LNA nucleoside. In some embodiments the LNA antisense oligonucleotide is a LNA gapmer oligonucleotide.

Targeting

- The oligonucleotides of the invention are capable of targeting the human NFKB1 transcript.
- 25 Targeting refers to the ability of the oligonucleotide to form a functional complementary hybridization across the contiguous nucleotide sequence of the oligonucleotide with the human NFKB1 transcript, such as a fully complementary hybridization, and inhibit the expression of the human NFKB1 transcript in a cell.

Contiguous Nucleotide Sequence

- 30 The term "contiguous nucleotide sequence" refers to the region of the oligonucleotide which is complementary to the target nucleic acid. The term is used interchangeably herein with the term "contiguous nucleobase sequence" and the term "oligonucleotide motif sequence". In some embodiments all the nucleotides of the oligonucleotide constitute the contiguous nucleotide sequence. In some embodiments the oligonucleotide comprises the contiguous nucleotide

sequence and may optionally comprise further nucleotide(s), for example a nucleotide linker region which may be used to attach a functional group to the contiguous nucleotide sequence. The nucleotide linker region may or may not be complementary to the target nucleic acid.

Nucleotides

5 Nucleotides are the building blocks of oligonucleotides and polynucleotides, and for the purposes of the present invention include both naturally occurring and non-naturally occurring nucleotides. In nature, nucleotides, such as DNA and RNA nucleotides comprise a ribose sugar moiety, a nucleobase moiety and one or more phosphate groups (which is absent in nucleosides). Nucleosides and nucleotides may also interchangeably be referred to as "units" or
10 "monomers".

Modified nucleoside

The term "modified nucleoside" or "nucleoside modification" as used herein refers to nucleosides modified as compared to the equivalent DNA or RNA nucleoside by the introduction of one or more modifications of the sugar moiety or the (nucleo)base moiety. In some
15 embodiments the modified nucleoside comprises a modified sugar moiety. The term modified nucleoside may also be used herein interchangeably with the term "nucleoside analogue" or modified "units" or modified "monomers".

Modified internucleoside linkage

The term "modified internucleoside linkage" is defined as generally understood by the skilled
20 person as linkages other than phosphodiester (PO) linkages, that covalently couples two nucleosides together. Nucleotides with modified internucleoside linkage are also termed "modified nucleotides". In some embodiments, the modified internucleoside linkage increases the nuclease resistance of the oligonucleotide compared to a phosphodiester linkage. For naturally occurring oligonucleotides, the internucleoside linkage includes phosphate groups
25 creating a phosphodiester bond between adjacent nucleosides. Modified internucleoside linkages are particularly useful in stabilizing oligonucleotides for in vivo use, and may serve to protect against nuclease cleavage at regions of DNA or RNA nucleosides in the oligonucleotide of the invention, for example within the gap region of a gapmer oligonucleotide, as well as in regions of modified nucleosides.

30 In an embodiment, the oligonucleotide comprises one or more internucleoside linkages modified from the natural phosphodiester to a linkage that is for example more resistant to nuclease attack. Nuclease resistance may be determined by incubating the oligonucleotide in blood serum or by using a nuclease resistance assay (e.g. snake venom phosphodiesterase (SVPD)), both are well known in the art. Internucleoside linkages which are capable of enhancing the
35 nuclease resistance of an oligonucleotide are referred to as nuclease resistant internucleoside linkages. In some embodiments at least 50% of the internucleoside linkages in the

oligonucleotide, or contiguous nucleotide sequence thereof, are modified, such as at least 60%, such as at least 70%, such as at least 80 or such as at least 90% of the internucleoside linkages in the oligonucleotide, or contiguous nucleotide sequence thereof, are modified. In some embodiments all of the internucleoside linkages of the oligonucleotide, or contiguous nucleotide sequence thereof, are modified. It will be recognized that, in some embodiments the nucleosides which link the oligonucleotide of the invention to a non-nucleotide functional group, such as a conjugate, may be phosphodiester. In some embodiments all of the internucleoside linkages of the oligonucleotide, or contiguous nucleotide sequence thereof, are nuclease resistant internucleoside linkages.

Modified internucleoside linkages may be selected from the group comprising phosphorothioate, diphosphorothioate and boranophosphate. In some embodiments, the modified internucleoside linkages are compatible with the RNaseH recruitment of the oligonucleotide of the invention, for example phosphorothioate, diphosphorothioate or boranophosphate.

In some embodiments the internucleoside linkage comprises sulphur (S), such as a phosphorothioate internucleoside linkage.

A phosphorothioate internucleoside linkage is particularly useful due to nuclease resistance, beneficial pharmacokinetics and ease of manufacture. In some embodiments at least 50% of the internucleoside linkages in the oligonucleotide, or contiguous nucleotide sequence thereof, are phosphorothioate, such as at least 60%, such as at least 70%, such as at least 80 or such as at least 90% of the internucleoside linkages in the oligonucleotide, or contiguous nucleotide sequence thereof, are phosphorothioate. In some embodiments all of the internucleoside linkages of the oligonucleotide, or contiguous nucleotide sequence thereof, are phosphorothioate.

In some embodiments, the oligonucleotide comprises one or more neutral internucleoside linkage, particularly a internucleoside linkage selected from phosphotriester, methylphosphonate, MMI, amide-3, formacetal or thioformacetal.

Further internucleoside linkages are disclosed in WO2009/1 24238 (incorporated herein by reference). In an embodiment the internucleoside linkage is selected from linkers disclosed in WO2007/031091 (incorporated herein by reference). Particularly, the internucleoside linkage may be selected from -O-P(O)₂-O-, -O-P(O,S)-O-, -O-P(S)₂-O-, -S-P(O)₂-O-, -S-P(O,S)-O-, -S-P(S)₂-O-, -O-P(O)₂-S-, -O-P(O,S)-S-, -S-P(O)₂-S-, -O-PO(R^H)-O-, O-PO(OCH₃)-O-, -O-PO(NR^H)-O-, -O-PO(OCH₂CH₂S-R)-O-, -O-PO(BH₃)-O-, -O-PO(NHR^H)-O-, -O-P(O)₂-NR^H-, -NR^H-P(O)₂-O-, -NR^H-CO-O-, -NR^H-CO-NR^H-, and/or the internucleoside linker may be selected from the group consisting of: -O-CO-O-, -O-CO-NR^H-, -NR^H-CO-CH₂-, -O-CH₂-CO-NR^H-, -O-CH₂-CH₂-NR^H-, -CO-NR^H-CH₂-, -CH₂-NR^HCO-, -O-CH₂-CH₂-S-, -S-CH₂-CH₂-O-, -S-CH₂-CH₂-S-, -CH₂-S-O-CH₂-,

$-\text{CH}_2\text{-CO-NR}^{\text{H}}$ -, $-\text{O-CH}_2\text{-CH}_2\text{-NR}^{\text{H}}\text{-CO-}$ -, $-\text{CH}_2\text{-NCH}_3\text{-O-CH}_2\text{-}$ -, where R^{H} is selected from hydrogen and C_{1-4} alkyl.

5 Nuclease resistant linkages, such as phosphothioate linkages, are particularly useful in oligonucleotide regions capable of recruiting nuclease when forming a duplex with the target nucleic acid, such as region G for gapmers, or the non-modified nucleoside region of headmers and tailmers. Phosphorothioate linkages may, however, also be useful in non-nuclease recruiting regions and/or affinity enhancing regions such as regions F and F' for gapmers, or the modified nucleoside region of headmers and tailmers.

10 Each of the design regions may however comprise internucleoside linkages other than phosphorothioate, such as phosphodiester linkages, in particular in regions where modified nucleosides, such as LNA, protect the linkage against nuclease degradation. Inclusion of phosphodiester linkages, such as one or two linkages, particularly between or adjacent to modified nucleoside units (typically in the non-nuclease recruiting regions) can modify the bioavailability and/or bio-distribution of an oligonucleotide - see WO2008/1 13832, incorporated
15 herein by reference.

In an embodiment all the internucleoside linkages in the oligonucleotide are phosphorothioate and/or boranophosphate linkages. In some embodiments, all the internucleoside linkages in the oligonucleotide are phosphorothioate linkages.

Nucleobase

20 The term nucleobase includes the purine (e.g. adenine and guanine) and pyrimidine (e.g. uracil, thymine and cytosine) moiety present in nucleosides and nucleotides which form hydrogen bonds in nucleic acid hybridization. In the context of the present invention the term nucleobase also encompasses modified nucleobases which may differ from naturally occurring nucleobases, but are functional during nucleic acid hybridization. In this context "nucleobase"
25 refers to both naturally occurring nucleobases such as adenine, guanine, cytosine, thymidine, uracil, xanthine and hypoxanthine, as well as non-naturally occurring variants. Such variants are for example described in Hirao et al (2012) Accounts of Chemical Research vol 45 page 2055 and Bergstrom (2009) Current Protocols in Nucleic Acid Chemistry Suppl. 37 1.4.1 .

30 In some embodiments the nucleobase moiety is modified by changing the purine or pyrimidine into a modified purine or pyrimidine, such as substituted purine or substituted pyrimidine, such as a nucleobase selected from isocytosine, pseudoisocytosine, 5-methyl cytosine, 5-thiazolocytosine, 5-propynyl-cytosine, 5-propynyl-uracil, 5-bromouracil 5-thiazolo-uracil, 2-thio-uracil, 2-thio-thymine, inosine, diaminopurine, 6-aminopurine, 2-aminopurine, 2,6-diaminopurine and 2-chloro-6-aminopurine.

The nucleobase moieties may be indicated by the letter code for each corresponding nucleobase, e.g. A, T, G, C or U, wherein each letter may optionally include modified nucleobases of equivalent function. For example, in the exemplified oligonucleotides, the nucleobase moieties are selected from A, T, G, C, and 5-methyl cytosine. Optionally, for LNA gapmers, 5-methyl cytosine LNA nucleosides may be used.

Modified oligonucleotide

The term modified oligonucleotide describes an oligonucleotide comprising one or more sugar-modified nucleosides and/or modified internucleoside linkages. The term chimeric oligonucleotide is a term that has been used in the literature to describe oligonucleotides with modified nucleosides.

Complementarity

The term "complementarity" describes the capacity for Watson-Crick base-pairing of nucleosides/nucleotides. Watson-Crick base pairs are guanine (G)-cytosine (C) and adenine (A) - thymine (T)/uracil (U). It will be understood that oligonucleotides may comprise nucleosides with modified nucleobases, for example 5-methyl cytosine is often used in place of cytosine, and as such the term complementarity encompasses Watson Crick base-pairing between non-modified and modified nucleobases (see for example Hirao et al. (2012) Accounts of Chemical Research vol 45 page 2055 and Bergstrom (2009) Current Protocols in Nucleic Acid Chemistry Suppl. 37 1.4.1).

The term "% complementary" as used herein, refers to the number of nucleotides in percent of a contiguous nucleotide sequence in a nucleic acid molecule (e.g. oligonucleotide) which, at a given position, are complementary to (*i.e.* form Watson Crick base pairs with) a contiguous nucleotide sequence, at a given position of a separate nucleic acid molecule (e.g. the target nucleic acid). The percentage is calculated by counting the number of aligned bases that form pairs between the two sequences, dividing by the total number of nucleotides in the oligonucleotide and multiplying by 100. In such a comparison a nucleobase/nucleotide which does not align (form a base pair) is termed a mismatch.

The term "fully complementary", refers to 100% complementarity.

Identity

The term "Identity" as used herein, refers to the number of nucleotides in percent of a contiguous nucleotide sequence in a nucleic acid molecule (e.g. oligonucleotide) which, at a given position, are identical to (*i.e.* in their ability to form Watson Crick base pairs with the complementary nucleoside) a contiguous nucleotide sequence, at a given position of a separate nucleic acid molecule (e.g. the target nucleic acid). The percentage is calculated by counting the number of aligned bases that are identical between the two sequences, including gaps,

dividing by the total number of nucleotides in the oligonucleotide and multiplying by 100.
Percent Identity = (Matches x 100)/Length of aligned region (with gaps).

Hybridization

The term "hybridizing" or "hybridizes" as used herein is to be understood as two nucleic acid
5 strands (e.g. an oligonucleotide and a target nucleic acid) forming hydrogen bonds between
base pairs on opposite strands thereby forming a duplex. The affinity of the binding between
two nucleic acid strands is the strength of the hybridization. It is often described in terms of the
melting temperature (T_m) defined as the temperature at which half of the oligonucleotides are
duplexed with the target nucleic acid. At physiological conditions T_m is not strictly proportional to
10 the affinity (Mergny and Lacroix, 2003, *Oligonucleotides* 13:515-537). The standard state Gibbs
free energy AG° is a more accurate representation of binding affinity and is related to the
dissociation constant (K_d) of the reaction by $AG^\circ = -RT \ln(K_d)$, where R is the gas constant and T
is the absolute temperature. Therefore, a very low AG° of the reaction between an
oligonucleotide and the target nucleic acid reflects a strong hybridization between the
15 oligonucleotide and target nucleic acid. AG° is the energy associated with a reaction where
aqueous concentrations are 1M, the pH is 7, and the temperature is 37°C. The hybridization of
oligonucleotides to a target nucleic acid is a spontaneous reaction and for spontaneous
reactions AG° is less than zero. AG° can be measured experimentally, for example, by use of
the isothermal titration calorimetry (ITC) method as described in Hansen et al., 1965, *Chem.*
20 *Comm.* 36-38 and Holdgate et al., 2005, *Drug Discov Today*. The skilled person will know that
commercial equipment is available for AG° measurements. AG° can also be estimated
numerically by using the nearest neighbor model as described by SantaLucia, 1998, *Proc Natl*
Acad Sci USA. 95: 1460-1465 using appropriately derived thermodynamic parameters
described by Sugimoto et al., 1995, *Biochemistry* 34:1 121 1-1 1216 and McTigue et al., 2004,
25 *Biochemistry* 43:5388-5405. In order to have the possibility of modulating its intended nucleic
acid target by hybridization, oligonucleotides of the present invention hybridize to a target
nucleic acid with estimated AG° values below -10 kcal for oligonucleotides that are 10-30
nucleotides in length. In some embodiments the degree or strength of hybridization is measured
by the standard state Gibbs free energy AG° . The oligonucleotides may hybridize to a target
30 nucleic acid with estimated AG° values below the range of -10 kcal, such as below -15 kcal,
such as below -20 kcal and such as below -25 kcal for oligonucleotides that are 8-30
nucleotides in length. In some embodiments the oligonucleotides hybridize to a target nucleic
acid with an estimated AG° value of -10 to -60 kcal, such as -12 to -40, such as from -15 to -30
kcal or -16 to -27 kcal such as -18 to -25 kcal.

Target nucleic acid

According to the present invention, the target nucleic acid is a nucleic acid which encodes mammalian NF- κ B 1 and may for example be a gene, a RNA, a mRNA, and pre-mRNA, a mature mRNA or a cDNA sequence. The target may therefore be referred to as an NF κ B1 target nucleic acid.

The oligonucleotide of the invention targets intron regions of a mammalian NF κ B1 pre-mRNA, such as SEQ ID NO 21 (the human NF κ B1 pre-mRNA sequence). In some embodiments, the oligonucleotide of the invention, or contiguous nucleotide sequence thereof is complementary to an intron region of the human NF κ B1 pre-mRNA selected from the group consisting of i1, i5, i6, i11, i15 and i23. In some embodiments, the oligonucleotide of the invention, or contiguous nucleotide sequence thereof is complementary to intron region i1. In some embodiments, the oligonucleotide of the invention, or contiguous nucleotide sequence thereof is complementary to intron region i5. In some embodiments, the oligonucleotide of the invention, or contiguous nucleotide sequence thereof is complementary to intron region i6. In some embodiments, the oligonucleotide of the invention, or contiguous nucleotide sequence thereof is complementary to intron region i11. In some embodiments, the oligonucleotide of the invention, or contiguous nucleotide sequence thereof is complementary to intron region i15. In some embodiments, the oligonucleotide of the invention, or contiguous nucleotide sequence thereof is complementary to intron region i23.

Table 1. human NF κ B1 Exons and Introns

Exonic regions in the human NF κ B1 pre-mRNA (SEQ ID NO 21)			Intronic regions in the human NF κ B1 pre-mRNA (SEQ ID NO 21)		
ID	start	end	ID	start	end
e1	1	460	i1	461	24183
e2	24184	24229	i2	24230	28507
e3	28508	28586	i3	28587	32516
e4	32517	32557	i4	32558	36529
e5	36530	36628	i5	36629	65658
e6	65659	65807	i6	65808	75547
e7	75548	75711	i7	75712	77552
e8	77553	77711	i8	77712	79206
e9	79207	79311	i9	79312	81537
e10	81538	81629	i10	81630	83353
e11	83354	83492	i11	83493	92096
e12	92097	92240	i12	92241	93563

e13	93564	93653	i13	93654	94809
e14	94810	95004	i14	95005	96191
e15	96192	96333	i15	96334	99566
e16	99567	99681	i16	99682	105167
e17	105168	105369	i17	105370	105821
e18	105822	105991	i18	105992	106320
e19	106321	106423	i19	106424	109246
e20	109247	109371	i20	109372	110715
e21	110716	110782	i21	110783	111105
e22	111106	111278	i22	111279	112096
e23	112097	112253	i23	112254	115105
e24	115106	115974			

For *in vivo* or *in vitro* application, the oligonucleotide of the invention is typically capable of inhibiting the expression of the NFkB 1 target nucleic acid in a cell which is expressing the NFkB 1 target nucleic acid. The contiguous sequence of nucleobases of the oligonucleotide of the invention is typically complementary to the NFkB 1 target nucleic acid, as measured across the length of the oligonucleotide, optionally with the exception of one or two mismatches, and optionally excluding nucleotide based linker regions which may link the oligonucleotide to an optional functional group such as a conjugate, or other non-complementary terminal nucleotides (e.g. region D' or Dⁿ). The target nucleic acid may, in some embodiments, be a NFkB1 pre-mRNA

10 Target Sequence

The term "target sequence" as used herein refers to a sequence of nucleotides present in the target nucleic acid which comprises the nucleobase sequence which is complementary to the oligonucleotide of the invention. In some embodiments, the target sequence consists of a region on the target nucleic acid which is complementary to the contiguous nucleotide sequence of the oligonucleotide of the invention. In some embodiments the target sequence is longer than the complementary sequence of a single oligonucleotide, and may, for example represent a preferred region of the target nucleic acid which may be targeted by several oligonucleotides of the invention.

The target sequence may be a sub-sequence of the target nucleic acid.

20 In some embodiments the sub-sequence is a sequence present in a human NFkB1 mRNA intron, such as a NFkB1 human pre-mRNA intron selected from the group consisting of i1, i5, i6, i11, i15 and i23

In some embodiments the sub-sequence is a sequence selected from the group consisting of SEQ ID NO 11, 12, 13, 14, 15 or 16, 17, 18, 19 and 20.

The oligonucleotide of the invention comprises a contiguous nucleotide sequence which is complementary to or hybridizes to the target nucleic acid, such as a sub-sequence of the target nucleic acid, such as a target sequence described herein.

The oligonucleotide comprises a contiguous nucleotide sequence of at least 8 nucleotides which is complementary to or hybridizes to a target sequence present in the target nucleic acid molecule. The contiguous nucleotide sequence (and therefore the target sequence) comprises of at least 8 contiguous nucleotides, such as 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 contiguous nucleotides, such as from 12-25, such as from 14-18 contiguous nucleotides.

Target Cell

The term a "target cell" as used herein refers to a cell which is expressing the target nucleic acid. In some embodiments the target cell may be *in vivo* or *in vitro*. In some embodiments the target cell is a mammalian cell such as a rodent cell, such as a mouse cell or a rat cell, or a primate cell such as a monkey cell or a human cell.

In preferred embodiments the target cell expresses NFKB1 pre-mRNA.

In some embodiments the oligonucleotides, conjugates or compositions, of the invention are capable to inhibiting the expression of human NFKB1 in a cell selected from the group consisting of HEK293 and HeLa cells.

Naturally occurring variant

The term "naturally occurring variant" refers to variants of NFKB1 gene or transcripts which originate from the same genetic loci as the target nucleic acid, but may differ for example, by virtue of degeneracy of the genetic code causing a multiplicity of codons encoding the same amino acid, or due to alternative splicing of pre-mRNA, or the presence of polymorphisms, such as single nucleotide polymorphisms, and allelic variants. Based on the presence of the sufficient complementary sequence to the oligonucleotide, the oligonucleotide of the invention may therefore target the target nucleic acid and naturally occurring variants thereof.

In some embodiments, the naturally occurring variants have at least 95% such as at least 98% or at least 99% homology to a mammalian NFKB1 target nucleic acid, such SEQ ID NO 21.

Modulation of expression

The term "modulation of expression" as used herein is to be understood as an overall term for an oligonucleotide's ability to alter the amount of NFKB1 when compared to the amount of NFKB1 before administration of the oligonucleotide. Alternatively modulation of expression may

be determined by reference to a control experiment. It is generally understood that the control is an individual or target cell treated with a saline composition or an individual or target cell treated with a non-targeting oligonucleotide (mock). It may however also be an individual treated with the standard of care.

- 5 One type of modulation is an oligonucleotide's ability to inhibit, down-regulate, reduce, suppress, remove, stop, block, prevent, lessen, lower, avoid or terminate expression of NF-KB 1 e.g. by degradation of mRNA or blockage of transcription.

High affinity modified nucleosides

A high affinity modified nucleoside is a modified nucleotide which, when incorporated into the
10 oligonucleotide enhances the affinity of the oligonucleotide for its complementary target, for example as measured by the melting temperature (T^m). A high affinity modified nucleoside of the present invention preferably result in an increase in melting temperature between +0.5 to +12°C, more preferably between +1.5 to +10°C and most preferably between +3 to +8°C per modified nucleoside. Numerous high affinity modified nucleosides are known in the art and
15 include for example, many 2' substituted nucleosides as well as locked nucleic acids (LNA) (see e.g. Freier & Altmann; Nucl. Acid Res., 1997, 25, 4429-4443 and Uhlmann; Curr. Opinion in Drug Development, 2000, 3(2), 293-213).

Sugar modifications

The oligomer of the invention may comprise one or more nucleosides which have a modified
20 sugar moiety, *i.e.* a modification of the sugar moiety when compared to the ribose sugar moiety found in DNA and RNA.

Numerous nucleosides with modification of the ribose sugar moiety have been made, primarily with the aim of improving certain properties of oligonucleotides, such as affinity and/or nuclease resistance.


25 Such modifications include those where the ribose ring structure is modified, *e.g.* by replacement with a hexose ring (HNA), or a bicyclic ring, which typically have a biradicle bridge between the C2 and C4 carbons on the ribose ring (LNA), or an unlinked ribose ring which typically lacks a bond between the C2 and C3 carbons (*e.g.* UNA). Other sugar modified nucleosides include, for example, bicyclohexose nucleic acids (WO201 1/01 7521) or tricyclic
30 nucleic acids (WO201 3/1 54798). Modified nucleosides also include nucleosides where the sugar moiety is replaced with a non-sugar moiety, for example in the case of peptide nucleic acids (PNA), or morpholino nucleic acids.

Sugar modifications also include modifications made via altering the substituent groups on the ribose ring to groups other than hydrogen, or the 2'-OH group naturally found in DNA and RNA
35 nucleosides. Substituents may, for example be introduced at the 2', 3', 4' or 5' positions.

Nucleosides with modified sugar moieties also include 2' modified nucleosides, such as 2' substituted nucleosides. Indeed, much focus has been spent on developing 2' substituted nucleosides, and numerous 2' substituted nucleosides have been found to have beneficial properties when incorporated into oligonucleotides, such as enhanced nucleoside resistance and enhanced affinity.

2' modified nucleosides.


A 2' sugar modified nucleoside is a nucleoside which has a substituent other than H or -OH at the 2' position (2' substituted nucleoside) or comprises a 2' linked biradicle, and includes 1 substituted nucleosides and LNA (2' - 4' biradicle bridged) nucleosides. For example, the 2' modified sugar may provide enhanced binding affinity and/or increased nuclease resistance to the oligonucleotide. Examples of 2' substituted modified nucleosides are 2'-O-alkyl-RNA, 2'-O-methyl-RNA, 2'-alkoxy-RNA, 2'-O-methoxyethyl-RNA (MOE), 2'-amino-DNA, 2'-Fluoro-RNA, and 2'-F-ANA nucleoside. For further examples, please see e.g. Freier & Altmann; Nucl. Acid Res., 1997, 25, 4429-4443 and Uhlmann; Curr. Opinion in Drug Development, 2000, 3(2), 293-213, and Delevey and Damha, Chemistry and Biology 2012, 19, 937. Below are illustrations of some 2' substituted modified nucleosides.



Locked Nucleic Acid Nucleosides (LNA).

LNA nucleosides are modified nucleosides which comprise a linker group (referred to as a biradicle or a bridge) between C2' and C4' of the ribose sugar ring of a nucleotide. These nucleosides are also termed bridged nucleic acid or bicyclic nucleic acid (BNA) in the literature.

In some embodiments, the modified nucleoside or the LNA nucleosides of the oligomer of the invention has a general structure of the formula I or II:



Formula I

Formula II

- 5 wherein W is selected from -O-, -S-, -N(R^a)-, -C(R^aR^b)-, such as, in some embodiments -O-; B designates a nucleobase or modified nucleobase moiety; Z designates an internucleoside linkage to an adjacent nucleoside, or a 5'-terminal group; Z* designates an internucleoside linkage to an adjacent nucleoside, or a 3'-terminal group; X designates a group selected from the list consisting of -C(R^aR^b)-, -C(R^a)=C(R^b)-, -
- 10 C(R^a)=N-, -O-, -Si(R^a)₂-, -S-, -S₂-, -N(R^a)-, and >C=Z

In some embodiments, X is selected from the group consisting of: -O-, -S-, NH-, NR^aR^b, -CH₂-, CR^aR^b, -C(=CH₂)-, and -C(=CR^aR^b)-

In some embodiments, X is -O-

- Y designates a group selected from the group consisting of -C(R^aR^b)-, -C(R^a)=C(R^b)-, -
- 15 C(R^a)=N-, -O-, -Si(R^a)₂-, -S-, -S₂-, -N(R^a)-, and >C=Z

In some embodiments, Y is selected from the group consisting of: -CH₂-, -C(R^aR^b)-, -CH₂CH₂-, -C(R^aR^b)-C(R^aR^b)-, -CH₂CH₂CH₂-, -C(R^aR^b)C(R^aR^b)C(R^aR^b)-, -C(R^a)=C(R^b)-, and -C(R^a)=N-

- In some embodiments, Y is selected from the group consisting of: -CH₂-, -CHR^a-, -
- 20 CHCH₃-, CR^aR^b-

or -X-Y- together designate a bivalent linker group (also referred to as a radicle) together designate a bivalent linker group consisting of 1, 2, 3 or 4 groups/atoms selected from the group consisting of -C(R^aR^b)-, -C(R^a)=C(R^b)-, -C(R^a)=N-, -O-, -Si(R^a)₂-, -S-, -S₂-, -N(R^a)-, and >C=Z,

- In some embodiments, -X-Y- designates a biradicle selected from the groups consisting
- 25 of: -X-CH₂-, -X-CR^aR^b-, -X-CHR^a-, -X-C(HCH₃)-, -O-Y-, -O-CH₂-, -S-CH₂-, -NH-CH₂-, -O-CHCH₃-, -CH₂-O-CH₂-, -O-CH(CH₃CH₃)-, -O-CH₂-CH₂-, OCH₂-CH₂-CH₂-, -O-CH₂OCH₂-, -O-NCH₂-, -C(=CH₂)-CH₂-, -NR^a-CH₂-, N-O-CH₂-, -S-CR^aR^b- and -S-CHR^a-.

In some embodiments -X-Y- designates -O-CH₂- or -O-CH(CH₃)-.

wherein Z is selected from -O-, -S-, and -N(R^a)-,

and R^a and, when present R^b, each is independently selected from hydrogen, optionally substituted C₁₋₆-alkyl, optionally substituted C₂₋₆-alkenyl, optionally substituted C₂₋₆-alkynyl, hydroxy, optionally substituted C_{i-6}-alkoxy, C₂₋₆-alkoxyalkyl, C₂₋₆-alkenyloxy, carboxy, C₁₋₆-alkoxycarbonyl, C_{i-6}-alkylcarbonyl, formyl, aryl, aryloxy-carbonyl, aryloxy, arylcarbonyl, heteroaryl, heteroaryloxy-carbonyl, heteroaryloxy, heteroarylcarbonyl, amino, mono- and di(C_{i-6}-alkyl)amino, carbamoyl, mono- and di(C₁₋₆-alkyl)-amino-carbonyl, amino-C_{i-6}-alkyl-aminocarbonyl, mono- and di(C₁₋₆-alkyl)amino-C₁₋₆-alkyl-aminocarbonyl, C₁₋₆-alkyl-carbonylamino, carbamido, C₁₋₆-alkanoyloxy, sulphono, C[^]-alkylsulphonyloxy, nitro, azido, sulphanyl, C₁₋₆-alkylthio, halogen, where aryl and heteroaryl may be optionally substituted and where two geminal substituents R^a and R^b together may designate optionally substituted methylene (=CH₂), wherein for all chiral centers, asymmetric groups may be found in either *R* or *S* orientation.

wherein R¹, R², R³, R⁵ and R^{5*} are independently selected from the group consisting of: hydrogen, optionally substituted C₁₋₆-alkyl, optionally substituted C₂₋₆-alkenyl, optionally substituted C₂₋₆-alkynyl, hydroxy, C₁₋₆-alkoxy, C₂₋₆-alkoxyalkyl, C₂₋₆-alkenyloxy, carboxy, C₁₋₆-alkoxycarbonyl, C₁₋₆-alkylcarbonyl, formyl, aryl, aryloxy-carbonyl, aryloxy, arylcarbonyl, heteroaryl, heteroaryloxy-carbonyl, heteroaryloxy, heteroarylcarbonyl, amino, mono- and di(C₁₋₆-alkyl)amino, carbamoyl, mono- and di(C₁₋₆-alkyl)-amino-carbonyl, amino-C_{i-6}-alkyl-aminocarbonyl, mono- and di(C₁₋₆-alkyl)amino-C₁₋₆-alkyl-aminocarbonyl, C₁₋₆-alkyl-carbonylamino, carbamido, C₁₋₆-alkanoyloxy, sulphono, C₁₋₆-alkylsulphonyloxy, nitro, azido, sulphanyl, C₁₋₆-alkylthio, halogen, where aryl and heteroaryl may be optionally substituted, and where two geminal substituents together may designate oxo, thioxo, imino, or optionally substituted methylene.

In some embodiments R¹, R², R³, R⁵ and R^{5*} are independently selected from C₁₋₆ alkyl, such as methyl, and hydrogen.

In some embodiments R¹, R², R³, R⁵ and R^{5*} are all hydrogen.

In some embodiments R¹, R², R³, are all hydrogen, and either R⁵ and R^{5*} is also hydrogen and the other of R⁵ and R^{5*} is other than hydrogen, such as C₁₋₆ alkyl such as methyl.

In some embodiments, R^a is either hydrogen or methyl. In some embodiments, when present, R^b is either hydrogen or methyl.

In some embodiments, one or both of R^a and R^b is hydrogen

In some embodiments, one of R^a and R^b is hydrogen and the other is other than hydrogen

In some embodiments, one of R^a and R^b is methyl and the other is hydrogen

In some embodiments, both of R^a and R^b are methyl.

In some embodiments, the biradicle -X-Y- is -O-CH₂-, W is O, and all of R¹, R², R³, R⁵ and R^{5*} are all hydrogen. Such LNA nucleosides are disclosed in WO99/0 14226, WO00/66604, WO98/039352 and WO2004/046160 which are all hereby incorporated by reference, and

5 include what are commonly known as beta-D-oxy LNA and alpha-L-oxy LNA nucleosides.

In some embodiments, the biradicle -X-Y- is -S-CH₂-, W is O, and all of R¹, R², R³, R⁵ and R^{5*} are all hydrogen. Such thio LNA nucleosides are disclosed in WO99/0 14226 and WO2004/046160 which are hereby incorporated by reference.

In some embodiments, the biradicle -X-Y- is -NH-CH₂-, W is O, and all of R¹, R², R³, R⁵ and R^{5*} are all hydrogen. Such amino LNA nucleosides are disclosed in WO99/014226 and

10 WO2004/046160 which are hereby incorporated by reference.

In some embodiments, the biradicle -X-Y- is -O-CH₂-CH₂- or -O-CH₂-CH₂-CH₂-, W is O, and all of R¹, R², R³, R⁵ and R^{5*} are all hydrogen. Such LNA nucleosides are disclosed in WOOO/047599 and Morita et al, Bioorganic & Med.Chem. Lett. 12 73-76, which are hereby

15 incorporated by reference, and include what are commonly known as 2'-O-4' C-ethylene bridged nucleic acids (ENA).

In some embodiments, the biradicle -X-Y- is -O-CH₂-, W is O, and all of R¹, R², R³, and one of R⁵ and R^{5*} are hydrogen, and the other of R⁵ and R^{5*} is other than hydrogen such as C₁₋₆ alkyl, such as methyl. Such 5' substituted LNA nucleosides are disclosed in WO2007/134181 which is

20 hereby incorporated by reference.

In some embodiments, the biradicle -X-Y- is -O-CR^aR^b-, wherein one or both of R^a and R^b are other than hydrogen, such as methyl, W is O, and all of R¹, R², R³, and one of R⁵ and R^{5*} are hydrogen, and the other of R⁵ and R^{5*} is other than hydrogen such as C₁₋₆ alkyl, such as methyl. Such bis modified LNA nucleosides are disclosed in WO201 0/077578 which is hereby

25 incorporated by reference.

In some embodiments, the biradicle -X-Y- designate the bivalent linker group -O-CH(CH₂OCH₃)- (2' O-methoxyethyl bicyclic nucleic acid - Seth at al., 2010, J. Org. Chem. Vol 75(5) pp. 1569-81). In some embodiments, the biradicle -X-Y- designate the bivalent linker group -O-CH(CH₂CH₃)- (2' O-ethyl bicyclic nucleic acid - Seth at al., 2010, J. Org. Chem. Vol

30 75(5) pp. 1569-81). In some embodiments, the biradicle -X-Y- is -O-CHR^a-, W is O, and all of R¹, R², R³, R⁵ and R^{5*} are all hydrogen. Such 6' substituted LNA nucleosides are disclosed in W01 0036698 and WO07090071 which are both hereby incorporated by reference.

In some embodiments, the biradicle -X-Y- is -O-CH(CH₂OCH₃)-, W is O, and all of R¹, R², R³, R⁵ and R^{5*} are all hydrogen. Such LNA nucleosides are also known as cyclic MOEs in the art

35 (cMOE) and are disclosed in WO07090071 .

In some embodiments, the biradicle -X-Y- designate the bivalent linker group -O-CH(CH₃)- in either the R- or S- configuration. In some embodiments, the biradicle -X-Y- together designate the bivalent linker group -O-CH₂-O-CH₂- (Seth at al., 2010, J. Org. Chem). In some embodiments, the biradicle -X-Y- is -O-CH(CH₃)-, W is O, and all of R¹, R², R³, R⁵ and R^{5*} are all hydrogen. Such 6' methyl LNA nucleosides are also known as cET nucleosides in the art, and may be either (S)cET or (R)cET stereoisomers, as disclosed in WO07090071 (beta-D) and WO20 10/036698 (alpha-L) which are both hereby incorporated by reference).

5

10

In some embodiments, the biradicle -X-Y- is -O-CR^aR^b-, wherein in neither R^a or R^b is hydrogen, W is O, and all of R¹, R², R³, R⁵ and R^{5*} are all hydrogen. In some embodiments, R^a and R^b are both methyl. Such 6' di-substituted LNA nucleosides are disclosed in WO 2009006478 which is hereby incorporated by reference.

15

In some embodiments, the biradicle -X-Y- is -S-CHR^a-, W is O, and all of R¹, R², R³, R⁵ and R^{5*} are all hydrogen. Such 6' substituted thio LNA nucleosides are disclosed in W01 1156202 which is hereby incorporated by reference. In some 6' substituted thio LNA embodiments R^a is methyl.

In some embodiments, the biradicle -X-Y- is -C(=CH₂)-C(R^aR^b)-, such as -C(=CH₂)-CH₂-, or -C(=CH₂)-CH(CH₃)-W is O, and all of R¹, R², R³, R⁵ and R^{5*} are all hydrogen. Such vinyl carbo LNA nucleosides are disclosed in WO081 54401 and WO09067647 which are both hereby incorporated by reference.

20

In some embodiments the biradicle -X-Y- is -N(-OR^a)-, W is O, and all of R¹, R², R³, R⁵ and R^{5*} are all hydrogen. In some embodiments R^a is C₁₋₆ alkyl such as methyl. Such LNA nucleosides are also known as N substituted LNAs and are disclosed in WO2008/1 50729 which is hereby incorporated by reference. In some embodiments, the biradicle -X-Y- together designate the bivalent linker group -O-NR^a-CH₃- (Seth at al., 2010, J. Org. Chem). In some embodiments the biradicle -X-Y- is -N(R^a)-, W is O, and all of R¹, R², R³, R⁵ and R^{5*} are all hydrogen. In some embodiments R^a is C₁₋₆ alkyl such as methyl.

25

In some embodiments, one or both of R⁵ and R^{5*} is hydrogen and, when substituted the other of R⁵ and R^{5*} is C₁₋₆ alkyl such as methyl. In such an embodiment, R¹, R², R³, may all be hydrogen, and the biradicle -X-Y- may be selected from -O-CH₂- or -O-C(HCR^a)-, such as -O-C(HCH₃)-.

30


In some embodiments, the biradicle is -CR^aR^b-O-CR^aR^b-, such as CH₂-O-CH₂-, W is O and all of R¹, R², R³, R⁵ and R^{5*} are all hydrogen. In some embodiments R^a is C₁₋₆ alkyl such as methyl. Such LNA nucleosides are also known as conformationally restricted nucleotides (CRNs) and are disclosed in WO201 3036868 which is hereby incorporated by reference.

In some embodiments, the biradicle is $-O-CR^aR^b-O-CR^aR^b-$, such as $-O-CH_2-O-CH_2-$, W is O and all of R^1, R^2, R^3, R^5 and $R^{5'}$ are all hydrogen. In some embodiments R^a is C_{1-6} alkyl such as methyl. Such LNA nucleosides are also known as COC nucleotides and are disclosed in Mitsuoka et al., Nucleic Acids Research 2009 37(4), 1225-1238, which is hereby incorporated by reference.

It will be recognized that, unless specified, the LNA nucleosides may be in the beta-D or alpha-L stereoisform.

Certain examples of LNA nucleosides are presented in Scheme 1.

Scheme 1



10

As illustrated in the examples, in some embodiments of the invention the LNA nucleosides in the oligonucleotides are beta-D-oxy-LNA nucleosides.

Nuclease mediated degradation

Nuclease mediated degradation refers to an oligonucleotide capable of mediating degradation of a complementary nucleotide sequence when forming a duplex with such a sequence.

In some embodiments, the oligonucleotide may function via nuclease mediated degradation of the target nucleic acid, where the oligonucleotides of the invention are capable of recruiting a nuclease, particularly an endonuclease, preferably an endoribonuclease (RNase), such as RNase H. Examples of oligonucleotide designs which operate via nuclease mediated mechanisms are oligonucleotides which typically comprise a region of at least 5 or 6 DNA nucleosides and are flanked on one side or both sides by affinity enhancing nucleosides, for example gapmers, headmers and tailmers.

RNase H Activity and Recruitment

The RNase H activity of an antisense oligonucleotide refers to its ability to recruit RNase H when in a duplex with a complementary RNA molecule. WO 1/236 13 provides *in vitro* methods for determining RNaseH activity, which may be used to determine the ability to recruit RNaseH. Typically an oligonucleotide is deemed capable of recruiting RNase H if it, when provided with a complementary target nucleic acid sequence, has an initial rate, as measured in pmol/l/min, of at least 5%, such as at least 10% or more than 20% of the initial rate determined when using a oligonucleotide having the same base sequence as the modified oligonucleotide being tested, but containing only DNA monomers with phosphorothioate linkages between all monomers in the oligonucleotide, and using the methodology provided by Example 91 - 95 of WO01/23613 (hereby incorporated by reference).

Gapmer

The term gapmer as used herein refers to an antisense oligonucleotide which comprises a region of RNase H recruiting oligonucleotides (gap) which is flanked 5' and 3' by regions which comprise one or more affinity enhancing modified nucleosides (flanks or wings). Various gapmer designs are described herein. Headmers and tailmers are oligonucleotides capable of recruiting RNase H where one of the flanks is missing, i.e. only one of the ends of the oligonucleotide comprises affinity enhancing modified nucleosides. For headmers the 3' flank is missing (i.e. the 5' flank comprises affinity enhancing modified nucleosides) and for tailmers the 5' flank is missing (i.e. the 3' flank comprises affinity enhancing modified nucleosides).

LNA Gapmer

The term LNA gapmer is a gapmer oligonucleotide wherein at least one of the affinity enhancing modified nucleosides is an LNA nucleoside.

Mixed Wing Gapmer

The term mixed wing gapmer or mixed flank gapmer refers to a LNA gapmer wherein at least one of the flank regions comprise at least one LNA nucleoside and at least one non-LNA modified nucleoside, such as at least one 2' substituted modified nucleoside, such as, for example, 2'-O-alkyl-RNA, 2'-O-methyl-RNA, 2'-alkoxy-RNA, 2'-O-methoxyethyl-RNA (MOE), 2'-amino-DNA, 2'-Fluoro-RNA and 2'-F-ANA nucleoside(s). In some embodiments the mixed wing gapmer has one flank which comprises only LNA nucleosides (e.g. 5' or 3') and the other flank (3' or 5' respectfully) comprises 2' substituted modified nucleoside(s) and optionally LNA nucleosides.

10 Gapbreaker

The term "gapbreaker oligonucleotide" is used in relation to a gapmer capable of maintaining RNaseH recruitment even though the gap region is disrupted by a non-RNaseH recruiting nucleoside (a gap-breaker nucleoside, E) such that the gap region comprise less than 5 consecutive DNA nucleosides. Non-RNaseH recruiting nucleosides are for example nucleosides in the 3' endo conformation, such as LNA's where the bridge between C2' and C4' of the ribose sugar ring of a nucleoside is in the beta conformation, such as beta-D-oxy LNA or ScET nucleoside. The ability of gapbreaker oligonucleotide to recruit RNaseH is typically sequence or even compound specific - see Rukov et al. 2015 Nucl. Acids Res. Vol. 43 pp. 8476-8487, which discloses "gapbreaker" oligonucleotides which recruit RNaseH which in some instances provide a more specific cleavage of the target RNA.

In some embodiments, the oligonucleotide of the invention is a gapbreaker oligonucleotide. In some embodiments the gapbreaker oligonucleotide comprise a 5'-flank (F), a gap (G) and a 3'-flank (F'), wherein the gap is disrupted by a non-RNaseH recruiting nucleoside (a gap-breaker nucleoside, E) such that the gap contain at least 3 or 4 consecutive DNA nucleosides. In some embodiments the gapbreaker nucleoside (E) is an LNA nucleoside where the bridge between C2' and C4' of the ribose sugar ring of a nucleoside is in the beta conformation and is placed within the gap region such that the gap-breaker LNA nucleoside is flanked 5' and 3' by at least 3 (5') and 3 (3') or at least 3 (5') and 4 (3') or at least 4(5') and 3(3') DNA nucleosides, and wherein the oligonucleotide is capable of recruiting RNaseH.

30 The gapbreaker oligonucleotide can be represented by the following formulae:

F-G-E-G-F'; in particular $F_{1-7}-G_{3-4}-E_1-G_3-i-F'_{1-7}$

D'-F-G-F', in particular $D'_{1-3}-F_{1-7}-G_{3-4}-E_1-G_{3-4}-F'_{i-7}$

F-G-F'-D'', in particular $F_{1-7}-G_{3-4}-E_i-G_{3-4}-F'_{1-7}-D''_{1-3}$

D'-F-G-F'-D'', in particular $D'_{i-3}-F_{i-7}-G_{3-i}-E_i-G_{3-4}-F'_{1-7}-D''_{1-3}$

35 Where region D' and D'' are as described in the section "Gapmer design".

In some embodiments the gapbreaker nucleoside (E) is a beta-D-oxy LNA or ScET or another beta-LNA nucleosides shown in Scheme 1).

Conjugate

5 The term conjugate as used herein refers to an oligonucleotide which is covalently linked to a non-nucleotide moiety (conjugate moiety or region C or third region).

10 Conjugation of the oligonucleotide of the invention to one or more non-nucleotide moieties may improve the pharmacology of the oligonucleotide, e.g. by affecting the activity, cellular distribution, cellular uptake or stability of the oligonucleotide. In some embodiments the conjugate moiety modify or enhance the pharmacokinetic properties of the oligonucleotide by improving cellular distribution, bioavailability, metabolism, excretion, permeability, and/or cellular uptake of the oligonucleotide. In particular the conjugate may target the oligonucleotide to a specific organ, tissue or cell type and thereby enhance the effectiveness of the oligonucleotide in that organ, tissue or cell type. At the same time the conjugate may serve to reduce activity of the oligonucleotide in non-target cell types, tissues or organs, e.g. off target activity or activity in non-target cell types, tissues or organs. WO 93/07883 and WO2013/033230 provides suitable conjugate moieties, which are hereby incorporated by reference. Further suitable conjugate moieties are those capable of binding to the asialoglycoprotein receptor (ASGPr). In particular tri-valent N-acetylgalactosamine conjugate moieties are suitable for binding to the the ASGPr, see for example WO 2014/076196, WO 2014/207232 and WO 2014/179620 (hereby incorporated by reference).

25 Oligonucleotide conjugates and their synthesis has also been reported in comprehensive reviews by Manoharan in Antisense Drug Technology, Principles, Strategies, and Applications, S.T. Crooke, ed., Ch. 16, Marcel Dekker, Inc., 2001 and Manoharan, Antisense and Nucleic Acid Drug Development, 2002, 12, 103, each of which is incorporated herein by reference in its entirety.

In an embodiment, the non-nucleotide moiety (conjugate moiety) is selected from the group consisting of carbohydrates, cell surface receptor ligands, drug substances, hormones, lipophilic substances, polymers, proteins, peptides, toxins (e.g. bacterial toxins), vitamins, viral proteins (e.g. capsids) or combinations thereof.

30 **Linkers**

A linkage or linker is a connection between two atoms that links one chemical group or segment of interest to another chemical group or segment of interest via one or more covalent bonds.

35 Conjugate moieties can be attached to the oligonucleotide directly or through a linking moiety (e.g. linker or tether). Linkers serve to covalently connect a third region, e.g. a conjugate moiety (Region C), to a first region, e.g. an oligonucleotide or contiguous nucleotide sequence complementary to the target nucleic acid (region A).

In some embodiments of the invention the conjugate or oligonucleotide conjugate of the invention may optionally, comprise a linker region (second region or region B and/or region Y) which is positioned between the oligonucleotide or contiguous nucleotide sequence complementary to the target nucleic acid (region A or first region) and the conjugate moiety (region C or third region).

Region B refers to biocleavable linkers comprising or consisting of a physiologically labile bond that is cleavable under conditions normally encountered or analogous to those encountered within a mammalian body. Conditions under which physiologically labile linkers undergo chemical transformation (e.g., cleavage) include chemical conditions such as pH, temperature, oxidative or reductive conditions or agents, and salt concentration found in or analogous to those encountered in mammalian cells. Mammalian intracellular conditions also include the presence of enzymatic activity normally present in a mammalian cell such as from proteolytic enzymes or hydrolytic enzymes or nucleases. In one embodiment the biocleavable linker is susceptible to S1 nuclease cleavage. In some embodiments the nuclease susceptible linker comprises between 1 and 10 nucleosides, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 nucleosides, more preferably between 2 and 6 nucleosides and most preferably between 2 and 4 linked nucleosides comprising at least two consecutive phosphodiester linkages, such as at least 3 or 4 or 5 consecutive phosphodiester linkages. Preferably the nucleosides are DNA or RNA. Phosphodiester containing biocleavable linkers are described in more detail in WO 2014/076195 (hereby incorporated by reference).

Region Y refers to linkers that are not necessarily biocleavable but primarily serve to covalently connect a conjugate moiety (region C or third region), to an oligonucleotide (region A or first region). The region Y linkers may comprise a chain structure or an oligomer of repeating units such as ethylene glycol, amino acid units or amino alkyl groups. The oligonucleotide conjugates of the present invention can be constructed of the following regional elements A-C, A-B-C, A-B-Y-C, A-Y-B-C or A-Y-C. In some embodiments the linker (region Y) is an amino alkyl, such as a C2 - C36 amino alkyl group, including, for example C6 to C12 amino alkyl groups. In some embodiments the linker (region Y) is a C6 amino alkyl group.

Treatment

The term 'treatment' as used herein refers to both treatment of an existing disease (e.g. a disease or disorder as herein referred to), or prevention of a disease, *i.e.* prophylaxis. It will therefore be recognized that treatment as referred to herein may, in some embodiments, be prophylactic.

DETAILED DESCRIPTION OF THE INVENTION***The Oligonucleotides of the Invention***

The invention relates to oligonucleotides capable of inhibiting the expression of NF-KB 1. The modulation is achieved by hybridizing to a target nucleic acid encoding NFKB1 or which is
5 involved in the regulation of NF-KB 1. The target nucleic acid may be a mammalian NFKB1 sequence, such as SEQ ID NO 21.

The oligonucleotide of the invention is an antisense oligonucleotide which targets a NFKB1 intron sequence.

In some embodiments the antisense oligonucleotide of the invention is capable of modulating
10 the expression of the target by inhibiting or down-regulating it. Preferably, such modulation produces an inhibition of expression of at least 20% compared to the normal expression level of the target, more preferably at least 30%, 40%, 50%, 60%, 70%, 80%, or 90% inhibition compared to the normal expression level of the target. In some embodiments oligonucleotides of the invention may be capable of inhibiting expression levels of NFKB1 mRNA by at least 60%
15 or 70% *in vitro* using HEK-293 or HeLa cells. In some embodiments compounds of the invention may be capable of inhibiting expression levels of NF-KB 1 protein by at least 50% *in vitro* using HEK-293 or HeLa cells. Suitably, the examples provide assays which may be used to measure NFKB1 RNA or protein inhibition. The target modulation is triggered by the hybridization between a contiguous nucleotide sequence of the oligonucleotide and the target nucleic acid. In
20 some embodiments the oligonucleotide of the invention comprises mismatches between the oligonucleotide and the target nucleic acid. Despite mismatches hybridization to the target nucleic acid may still be sufficient to show a desired modulation of NF-KB 1 expression. Reduced binding affinity resulting from mismatches may advantageously be compensated by increased number of nucleotides in the oligonucleotide and/or an increased number of modified
25 nucleosides capable of increasing the binding affinity to the target, such as 2' modified nucleosides, including LNA, present within the oligonucleotide sequence.

An aspect of the present invention relates to an antisense oligonucleotide which consist or comprises a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90% complementarity to a human NFKB1 intron sequence.

30 In some embodiments, the oligonucleotide comprises a contiguous sequence which is at least 90% complementary, such as at least 91%, such as at least 92%, such as at least 93%, such as at least 94%, such as at least 95%, such as at least 96%, such as at least 97%, such as at least 98%, or 100% complementary with a region of the target nucleic acid.

In some embodiments the oligonucleotide of the invention, or contiguous nucleotide sequence
35 thereof is fully complementary (100% complementary) to a region of the target nucleic acid, or

in some embodiments may comprise one or two mismatches between the oligonucleotide and the target nucleic acid.

In some embodiments the oligonucleotide comprises a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90% complementary, such as fully (or 100%)
5 complementary, to a region of a sequence selected from SEQ ID NOs 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, and 22.

In some embodiments, the oligonucleotide comprises a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90% complementary, such as 100% complementarity, to a corresponding target nucleic acid region present in SEQ ID NO: 17, wherein the target nucleic
10 acid region is a NFKB1 intron sequence selected from the group consisting of region i1, i5, i6, i11, i15, & i23. In some embodiments, the oligonucleotide of the invention comprises or consists of 8 to 35 nucleotides in length, such as from 10 to 30, such as 11 to 22, such as from 12 to 18, such as from 13 to 17 or 14 to 16 contiguous nucleotides in length. In some
15 embodiments the oligonucleotide comprises or consists of 13, 14, 15, 16 or 17 nucleotides in length.

In some embodiments, the oligonucleotide or contiguous nucleotide sequence thereof comprises or consists of 22 or less nucleotides, such as 20 or less nucleotides, such as 18 or less nucleotides, such as 14, 15, 16 or 17 nucleotides. It is to be understood that any range
20 given herein includes the range endpoints. Accordingly, if an oligonucleotide is said to include from 10 to 30 nucleotides, both 10 and 30 nucleotides are included.

In some embodiments, the contiguous nucleotide sequence comprises or consists of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 contiguous nucleotides in length. In some embodiments, the oligonucleotide comprises or consists of 14, 15
or 16 nucleotides in length.

25 In some embodiments, the oligonucleotide or contiguous nucleotide sequence comprises or consists of a sequence selected from the group consisting SEQ ID NO 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10, or at least 12 contiguous nucleotides thereof.

Oligonucleotide design

Oligonucleotide design refers to the pattern of nucleoside sugar modifications in the
30 oligonucleotide sequence. The oligonucleotides of the invention comprise sugar-modified nucleosides and may also comprise DNA or RNA nucleosides. In some embodiments, the oligonucleotide comprises sugar-modified nucleosides and DNA nucleosides. Incorporation of modified nucleosides into the oligonucleotide of the invention may enhance the affinity of the oligonucleotide for the target nucleic acid. In that case, the modified nucleosides can be referred

to as affinity enhancing modified nucleotides, the modified nucleosides may also be termed units.

In an embodiment, the oligonucleotide comprises at least 1 modified nucleoside, such as at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15 or at least 16 modified nucleosides. In an embodiment the oligonucleotide comprises from 1 to 10 modified nucleosides, such as from 2 to 9 modified nucleosides, such as from 3 to 8 modified nucleosides, such as from 4 to 7 modified nucleosides, such as 6 or 7 modified nucleosides.

In an embodiment, the oligonucleotide comprises one or more sugar modified nucleosides, such as 2' sugar modified nucleosides. Preferably the oligonucleotide of the invention comprise the one or more 2' sugar modified nucleoside independently selected from the group consisting of 2'-O-alkyl-RNA, 2'-O-methyl-RNA, 2'-alkoxy-RNA, 2'-O-methoxyethyl-RNA, 2'-amino-DNA, 2-fluoro-DNA, arabino nucleic acid (ANA), 2'-fluoro-ANA and LNA nucleosides. Even more preferably the one or more modified nucleoside is a locked nucleic acid (LNA).

In a further embodiment the oligonucleotide comprises at least one modified internucleoside linkage. In some embodiments all the internucleoside linkages within the contiguous nucleotide sequence are phosphorothioate or boranophosphate internucleoside linkages. In some embodiments all the internucleotide linkages in the contiguous sequence of the oligonucleotide are phosphorothioate linkages.

In some embodiments, the oligonucleotide of the invention comprises at least one LNA nucleoside, such as 1, 2, 3, 4, 5, 6, 7, or 8 LNA nucleosides, such as from 2 to 6 LNA nucleosides, such as from 3 to 7 LNA nucleosides, 4 to 8 LNA nucleosides or 3, 4, 5, 6, 7 or 8 LNA nucleosides. In some embodiments, at least 75% of the modified nucleosides in the oligonucleotide are LNA nucleosides, such as 80%, such as 85%, such as 90% of the modified nucleosides are LNA nucleosides. In a still further embodiment all the modified nucleosides in the oligonucleotide are LNA nucleosides. In a further embodiment, the oligonucleotide may comprise both beta-D-oxy-LNA, and one or more of the following LNA nucleosides: thio-LNA, amino-LNA, oxy-LNA, and/or ENA in either the beta-D or alpha-L configurations or combinations thereof. In a further embodiment, all LNA cytosine units are 5-methyl-cytosine. In some embodiments the oligonucleotide or contiguous nucleotide sequence has at least 1 LNA nucleoside at the 5' end and at least 2 LNA nucleosides at the 3' end of the nucleotide sequence.

In some embodiments, the oligonucleotide of the invention comprises at least one modified nucleoside which is a 2'-MOE-RNA nucleoside, such as 2, 3, 4, 5, 6, 7, 8, 9 or 10 2'-MOE-RNA nucleosides. In some embodiments, at least one of said modified nucleoside is 2'-fluoro DNA, such as 2, 3, 4, 5, 6, 7, 8, 9 or 10 2'-fluoro-DNA nucleosides.

In some embodiments, the oligonucleotide of the invention comprises at least one LNA nucleoside and at least one 2' substituted modified nucleoside.

In some embodiments of the invention, the oligonucleotide comprise both 2' sugar modified nucleosides and DNA units. Preferably the oligonucleotide comprises both LNA and DNA nucleosides (units). Preferably, the combined total of LNA and DNA units is 8-30, such as 10 - 25, preferably 12-22, such as 12 - 18, even more preferably 11-16. In some embodiments of the invention, the nucleotide sequence of the oligonucleotide, such as the contiguous nucleotide sequence consists of at least one or two LNA nucleosides and the remaining nucleosides are DNA units. In some embodiments the oligonucleotide comprises only LNA nucleosides and naturally occurring nucleosides (such as RNA or DNA, most preferably DNA nucleosides), optionally with modified internucleoside linkages such as phosphorothioate.

In an embodiment of the invention the oligonucleotide of the invention is capable of recruiting RNase H.

The structural design of the oligonucleotide of the invention may be selected from gapmers, gapbreakers, headmers and tailmers. In some embodiments the oligonucleotide of the invention is a gapmer.

Gapmer design

In some embodiments the oligonucleotide of the invention has a gapmer design or structure also referred herein merely as "Gapmer". In a gapmer structure the oligonucleotide comprises at least three distinct structural regions a 5'-flank, a gap and a 3'-flank, F-G-F' in '5 -> 3' orientation. In this design, flanking regions F and F' (also termed wing regions) comprise a contiguous stretch of modified nucleosides, which are complementary to the NFkB1 target nucleic acid, while the gap region, G, comprises a contiguous stretch of nucleotides which are capable of recruiting a nuclease, preferably an endonuclease such as RNase, for example RNase H, when the oligonucleotide is in duplex with the target nucleic acid. Nucleosides which are capable of recruiting a nuclease, in particular RNase H, can be selected from the group consisting of DNA, alpha-L-oxy-LNA, 2'-Flouro-ANA and UNA. Regions F and F', flanking the 5' and 3' ends of region G, preferably comprise non-nuclease recruiting nucleosides (nucleosides with a 3' endo structure), more preferably one or more affinity enhancing modified nucleosides. In some embodiments, the 3' flank comprises at least one LNA nucleoside, preferably at least 2 LNA nucleosides. In some embodiments, the 5' flank comprises at least one LNA nucleoside. In some embodiments both the 5' and 3' flanking regions comprise a LNA nucleoside. In some embodiments all the nucleosides in the flanking regions are LNA nucleosides. In other embodiments, the flanking regions may comprise both LNA nucleosides and other nucleosides (mixed flanks), such as DNA nucleosides and/or non-LNA modified nucleosides, such as 2' substituted nucleosides. In this case the gap is defined as a contiguous sequence of at least 5

RNase H recruiting nucleosides (nucleosides with a 2' endo structure, preferably DNA) flanked at the 5' and 3' end by an affinity enhancing modified nucleoside, preferably LNA, such as beta-D-oxy-LNA. Consequently, the nucleosides of the 5' flanking region and the 3' flanking region which are adjacent to the gap region are modified nucleosides, preferably non-nuclease recruiting nucleosides.



Region F

Region F (5' flank or 5' wing) attached to the 5' end of region G comprises, contains or consists of at least one modified nucleoside such as at least 2, at least 3, at least 4, at least 5, at least 6, at least 7 modified nucleosides. In an embodiment region F comprises or consists of from 1 to 7 modified nucleosides, such as from 2 to 6 modified nucleosides, such as from 2 to 5 modified nucleosides, such as from 2 to 4 modified nucleosides, such as from 1 to 3 modified nucleosides, such as 1, 2, 3 or 4 modified nucleosides. The F region is defined by having at least one modified nucleoside at the 5' end and at the 3' end of the region.

In some embodiments, the modified nucleosides in region F have a 3' endo structure.

In an embodiment, one or more of the modified nucleosides in region F are 2' modified nucleosides. In one embodiment all the nucleosides in Region F are 2' modified nucleosides.

In another embodiment region F comprises DNA and/or RNA in addition to the 2' modified nucleosides. Flanks comprising DNA and/or RNA are characterized by having a 2' modified nucleoside in the 5' end and the 3' end (adjacent to the G region) of the F region. In one embodiment the region F comprise DNA nucleosides, such as from 1 to 3 contiguous DNA nucleosides, such as 1 to 3 or 1 to 2 contiguous DNA nucleosides. The DNA nucleosides in the flanks should preferably not be able to recruit RNase H. In some embodiments the 2' modified nucleosides and DNA and/or RNA nucleosides in the F region alternate with 1 to 3 2' modified nucleosides and 1 to 3 DNA and/or RNA nucleosides. Such flanks can also be termed alternating flanks. The length of the 5' flank (region F) in oligonucleotides with alternating flanks may be 4 to 10 nucleosides, such as 4 to 8, such as 4 to 6 nucleosides, such as 4, 5, 6 or 7 modified nucleosides. In some embodiments only the 5' flank of the oligonucleotide is alternating. Specific examples of region F with alternating nucleosides are



Where 2' indicates a modified nucleoside and N' is a RNA or DNA. In some embodiments all the modified nucleosides in the alternating flanks are LNA and the N' is DNA. In a further embodiment one or more of the 2' modified nucleosides in region F are selected from 2'-O-alkyl-RNA units, 2'-O-methyl-RNA, 2'-amino-DNA units, 2'-fluoro-DNA units, 2'-alkoxy-RNA, MOE units, LNA units, arabino nucleic acid (ANA) units and 2'-fluoro-ANA units.

In some embodiments the F region comprises both LNA and a 2' substituted modified nucleoside. These are often termed mixed wing or mixed flank oligonucleotides.

In one embodiment of the invention all the modified nucleosides in region F are LNA nucleosides. In a further embodiment all the nucleosides in Region F are LNA nucleosides. In a further embodiment the LNA nucleosides in region F are independently selected from the group consisting of oxy-LNA, thio-LNA, amino-LNA, cET, and/or ENA, in either the beta-D or alpha-L configurations or combinations thereof. In some embodiments region F comprise at least 1 beta-D-oxy LNA unit, at the 5' end of the contiguous sequence.

Region G

Region G (gap region) preferably comprise, contain or consist of at least 4, such as at least 5, such as at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15 or at least 16 consecutive nucleosides capable of recruiting the aforementioned nuclease, in particular RNaseH. In a further embodiment region G comprise, contain or consist of from 5 to 12, or from 6 to 10 or from 7 to 9, such as 8 consecutive nucleotide units capable of recruiting aforementioned nuclease.

The nucleoside units in region G, which are capable of recruiting nuclease are in an embodiment selected from the group consisting of DNA, alpha-L-LNA, C4' alkylated DNA (as described in PCT/EP2009/050349 and Vester *et al.*, Bioorg. Med. Chem. Lett. 18 (2008) 2296 - 2300, both incorporated herein by reference), arabinose derived nucleosides like ANA and 2'F-ANA (Mangos *et al.* 2003 J. AM. CHEM. SOC. 125, 654-661), UNA (unlocked nucleic acid) (as described in Fluter *et al.*, Mol. Biosyst., 2009, 10, 1039 incorporated herein by reference). UNA is unlocked nucleic acid, typically where the bond between C2 and C3 of the ribose has been removed, forming an unlocked "sugar" residue.

In a still further embodiment at least one nucleoside unit in region G is a DNA nucleoside unit, such as from 1 to 12 DNA units, such as 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 DNA units, preferably from 2 to 12 DNA units, such as from 4 to 12 DNA units, more preferably from 5 to 11, or from 2 to 10, 4 to 10 or 6 to 10 DNA units, such as from 7 to 10 DNA units, such as 8, 9 or 10 DNA units. In some embodiments, region G consists of 100% DNA units. In a some embodiment G consists of from 8 - 12 DNA units.

In further embodiments the region G may consist of a mixture of DNA and other nucleosides capable of mediating RNase H cleavage. Region G may consist of at least 50% DNA, more preferably 60 %, 70% or 80 % DNA, and even more preferred 90% or 95% DNA.

In a still further embodiment at least one nucleoside unit in region G is an alpha-L-LNA nucleoside unit, such as at least one alpha-L-LNA, such as 2, 3, 4, 5, 6, 7, 8 or 9 alpha-L-LNA.

In a further embodiment, region G comprises the least one alpha-L-LNA is alpha-L-oxy-LNA. In

a further embodiment region G comprises a combination of DNA and alpha-L-LNA nucleoside units.

In some embodiments the size of the contiguous sequence in region G may be longer, such as 12, 13, 14, 15, 16, 17, 18, 19 or 20 nucleoside units.

5 In some embodiments, nucleosides in region G have a 2' endo structure.

In some embodiments region G may comprise a gapbreaker nucleoside, leading to a gapbreaker oligonucleotide, which is capable of recruiting RNase H.

Region F


10 Region F' (3' flank or 3' wing) attached to the 3' end of region G comprises, contains or consists of at least one modified nucleoside such as at least 2, at least 3, at least 4, at least 5, at least 6, at least 7 modified nucleosides. In an embodiment region F' comprise or consist of from 1 to 7 modified nucleosides, such as from 2 to 6 modified nucleosides, such as from 2 to 4 modified nucleosides, such as from 1 to 3 modified nucleosides, such as 1, 2, 3 or 4 modified nucleosides. The F' region is defined by having at least one modified nucleoside at the 5' end
15 and at the 3' end of the region.


In some embodiments, the modified nucleosides in region F' have a 3' endo structure.

In an embodiment, one or more of the modified nucleosides in region F' are 2' modified nucleosides. In one embodiment all the nucleosides in Region F' are 2' modified nucleosides.

20 In an embodiment, one or more of the modified nucleosides in region F' are 2' modified nucleosides.

In one embodiment all the nucleosides in Region F' are 2' modified nucleosides. In another embodiment region F' comprises DNA or RNA in addition to the 2' modified nucleosides. Flanks comprising DNA or RNA are characterized by having a 2' modified nucleoside in the 5' end (adjacent to the G region) and the 3' end of the F' region. In one embodiment the region F'
25 comprises DNA nucleosides, such as from 1 to 4 contiguous DNA nucleosides, such as 1 to 3 or 1 to 2 contiguous DNA nucleosides. The DNA nucleosides in the flanks should preferably not be able to recruit RNase H. In some embodiments the 2' modified nucleosides and DNA and/or RNA nucleosides in the F' region alternate with 1 to 3 2' modified nucleosides and 1 to 3 DNA and/or RNA nucleosides, such flanks can also be termed alternating flanks. The length of the 3'
30 flank (region F') in oligonucleotides with alternating flanks may be 4 to 10 nucleosides, such as 4 to 8, such as 4 to 6 nucleosides, such as 4, 5, 6 or 7 modified nucleosides. In some embodiments only the 3' flank of the oligonucleotide is alternating. Specific examples of region F' with alternating nucleosides are





Where 2' indicates a modified nucleoside and N' is a RNA or DNA. In some embodiments all the modified nucleosides in the alternating flanks are LNA and the N' is DNA. In a further embodiment modified nucleosides in region F' are selected from 2'-O-alkyl-RNA units, 2'-O-methyl-RNA, 2'-amino-DNA units, 2'-fluoro-DNA units, 2'-alkoxy-RNA, MOE units, LNA units, arabino nucleic acid (ANA) units and 2'-fluoro-ANA units.

In some embodiments the F' region comprises both LNA and a 2' substituted modified nucleoside. These are often termed mixed wing or mixed flank oligonucleotides.

In one embodiment of the invention all the modified nucleosides in region F' are LNA nucleosides. In a further embodiment all the nucleosides in Region F' are LNA nucleosides. In a further embodiment the LNA nucleosides in region F' are independently selected from the group consisting of oxy-LNA, thio-LNA, amino-LNA, cET and/or ENA, in either the beta-D or alpha-L configurations or combinations thereof. In some embodiments region F' has at least 2 beta-D-oxy LNA unit, at the 3' end of the contiguous sequence.

15 *Region D' and D''*

Region D' and D'' can be attached to the 5' end of region F or the 3' end of region F', respectively.

Region D' or D'' may independently comprise 1, 2, 3, 4 or 5 additional nucleotides, which may be complementary or non-complementary to the target nucleic acid. In this respect the oligonucleotide of the invention, may in some embodiments comprise a contiguous nucleotide sequence capable of modulating the target which is flanked at the 5' and/or 3' end by additional nucleotides. Such additional nucleotides may serve as a nuclease susceptible biocleavable linker (see definition of linkers). In some embodiments the additional 5' and/or 3' end nucleotides are linked with phosphodiester linkages, and may be DNA or RNA. In another embodiment, the additional 5' and/or 3' end nucleotides are modified nucleotides which may for example be included to enhance nuclease stability or for ease of synthesis. In an embodiment of the oligonucleotide, the invention comprises a region D' and/or D'' in addition to the contiguous nucleotide sequence.

In some embodiments the oligonucleotide of the invention may consist of the contiguous nucleotide sequence and region D' and/or D'', and a conjugation group covalently attached to region D' or D''.

The gapmer oligonucleotide of the present invention can be represented by the following formulae:



F-G-F'-D", in particular $F_{1,7-G4-i2} -F'_{1,7-D}i_{-3}$

D'-F-G-F'-D", in particular $D'_{1,3}-F_{1,7}-G_{4-12}-F'_{1,7}-D''_{1,3}$

The preferred number and types of nucleosides in regions **F**, **G** and **F'**, **D'** and **D''** have been described above.

- 5 The oligonucleotide conjugates of the present invention have a region C covalently attached to either the **5'** or **3'** end of the oligonucleotide, in particular the gapmer oligonucleotides presented above.

In one embodiment the oligonucleotide conjugate of the invention comprises a oligonucleotide with the formula **5'-D'-F-G-F'-3'** or $5'-F-G-F'-D''-3'$, where region **F** and **F'** independently
 10 comprise 1 - 7 modified nucleosides, **G** is a region between 6 and 16 nucleosides which are capable of recruiting RNaseH and region **D'** or **D''** comprise 1 - 5 phosphodiester linked nucleosides. Preferably region **D'** or **D''** is present in the end of the oligonucleotide where conjugation to a conjugate moiety is contemplated.

Examples of oligonucleotides with alternating flanks can be represented by the following
 15 formulae:

$2'_{1,3}-N'_{1,4}-2'_{1,3}-G_{6-12}-2'_{1,2}-N'_{1,4}-2'_{1,4}$

$2'_{1,2}-N'_{1,2}-2'_{1,2}-N'_{1,2}-2'_{1,2}-G_{6-12}-2'_{1,2}-N'_{1,2}-2'_{1,2}-N'_{1,2}-2'_{1,2}$

$F-G_{6-12}-2'_{1,2}-N'_{1,4}-2'_{1,4}$

$F-G_{6-12}-2'_{1,2}-N'_{1,2}-2'_{1,2}-N'_{1,2}-2'_{1,2}$

20 $2'_{1,3}-N'_{1,4}-2'i_{-3}-G_{6-12}-F'$

$2'i_{1,2}-N'_{1,2}-2'i_{1,2}-N_{i-2}-2'_{1,2}-G_{6-12}-F'$

Where a flank is indicated by **F** or **F'** it only contains $2'$ modified nucleosides, such as LNA nucleosides. The preferred number and types of nucleosides in the alternating regions, and region **F**, **G** and **F'**, **D'** and **D''** have been described above.

25 In some embodiments the oligonucleotide is a gapmer consisting of 10, 11, 12, 13, 14, 15 or 16 nucleotides in length, wherein each of regions **F** and **F'** independently consists of 1, 2, 3 or 4 modified nucleoside units complementary to the NFKB1 target nucleic acid and region **G** consists of 7, 8, 9, or 10 nucleoside units, capable of recruiting nuclease when in duplex with the NFKB1 target nucleic acid.

30 In a further embodiments, the oligonucleotide is a gapmer wherein each of regions **F** and **F'** independently consists of 3, 4, 5 or 6 modified nucleoside units, such as nucleoside units containing a 2'-O-methoxyethyl-ribose sugar (**2'-MOE**) or nucleoside units containing a 2'-fluoro-deoxyribose sugar and/or LNA units, and region **G** consists of 8, 9, 10, 11 or 12 nucleoside

units, such as DNA units or other nuclease recruiting nucleosides such as alpha-L-LNA or a mixture of DNA and nuclease recruiting nucleosides.

In a further specific embodiment, the oligonucleotide is a gapmer wherein each of regions F and F' region consists of two LNA units each, and region G consists of 8, 9 or 10 nucleoside units, preferably DNA units. Specific gapmer designs of this nature include 2-8-2, 2-9-2 and 2-10-2.

In a further specific embodiment, the oligonucleotide is a gapmer wherein each of regions F and F' independently consists of three LNA units, and region G consists of 8, 9 or 10 nucleoside units, preferably DNA units. Specific gapmer designs of this nature include 3-8-3, 3-9-3 and 3-10-3.

In a further specific embodiment, the oligonucleotide is a gapmer wherein each of regions F and F' consists of four LNA units each, and region G consists of 8 or 9 or 10 nucleoside units, preferably DNA units. Specific gapmer designs of this nature include 4-8-4, 4-9-4 and 4-10-4

Specific gapmer designs of this nature include F-G-F' designs selected from a group consisting of a gap with 6 nucleosides and independently 1 to 4 modified nucleosides in the wings including 1-6-1, 1-6-2, 2-6-1, 1-6-3, 3-6-1, 1-6-4, 4-6-1, 2-6-2, 2-6-3, 3-6-2, 2-6-4, 4-6-2, 3-6-3, 3-6-4 and 4-6-3 gapmers.

Specific gapmer designs of this nature include F-G-F' designs selected from a group consisting of a gap with 7 nucleosides and independently 1 to 4 modified nucleosides in the wings including 1-7-1, 2-7-1, 1-7-2, 1-7-3, 3-7-1, 1-7-4, 4-7-1, 2-7-2, 2-7-3, 3-7-2, 2-7-4, 4-7-2, 3-7-3, 3-7-4, 4-7-3 and 4-7-4 gapmers.

Specific gapmer designs of this nature include F-G-F' designs selected from a group consisting of a gap with 8 nucleosides and independently 1 to 4 modified nucleosides in the wings including 1-8-1, 1-8-2, 1-8-3, 3-8-1, 1-8-4, 4-8-1, 2-8-1, 2-8-2, 2-8-3, 3-8-2, 2-8-4, 4-8-2, 3-8-3, 3-8-4, 4-8-3, and 4-8-4 gapmers.

Specific gapmer designs of this nature include F-G-F' designs selected from a group consisting of a gap with 9 nucleosides and independently 1 to 4 modified nucleosides in the wings including, 1-9-1, 2-9-1, 1-9-2, 1-9-3, 3-9-1, 1-9-4, 4-9-1, 2-9-2, 2-9-3, 3-9-2, 2-9-4, 4-9-2, 3-9-3, 3-9-4, 4-9-3 and 4-9-4 gapmers.

Specific gapmer designs of this nature include F-G-F' designs selected from a group consisting of a gap with 10 nucleosides including, 1-10-1, 2-10-1, 1-10-2, 1-10-3, 3-10-1, 1-10-4, 4-10-1, 2-10-2, 2-10-3, 3-10-2, 2-10-4, 4-10-2, 3-10-3, 3-10-4, 4-10-3 and 4-10-4 gapmers.

In some embodiments the F-G-F' design is selected from 3-10-2, 2-10-3, 4-9-2, 2-10-4, 4-10-2, 3-10-3, 4-10-2, 3-9-3, 4-9-2, and 3-10-3.

In some embodiments, the F-G-F' design may, optionally, further include region D' and/or D'', which may have 1, 2 or 3 nucleoside units, such as DNA units. In some embodiments, the nucleosides in region F and F' are modified nucleosides, while nucleotides in region G are preferably unmodified nucleosides, such as DNA nucleosides.

5 In each design, in some embodiments the modified nucleoside is LNA.

In another embodiment all the internucleoside linkages in the gap in a gapmer are phosphorothioate and/or boranophosphate linkages. In another embodiment all the internucleoside linkages in the flanks (F and F' region) in a gapmer are phosphorothioate and/or boranophosphate linkages. In another preferred embodiment all the internucleoside linkages in
10 the D' and D'' region in a gapmer are phosphodiester linkages.

For specific gapmers as disclosed herein, when the cytosine (C) residues are annotated as 5-methyl-cytosine, in various embodiments, one or more of the Cs present in the oligonucleotide may be unmodified C residues.

In a particular embodiment, the gapmer is a so-called shortmer as described in
15 WO2008/1 13832 incorporated herein by reference.

Further gapmer designs are disclosed in WO2004/046160, WO2007/14651 1 and incorporated by reference.

For certain embodiments of the invention, the oligonucleotide is selected from the group of oligonucleotide compounds with CMP-ID-NO: 1,1; 2,1 ; 3,1 ; 4,1 ; 5,1 ; 6,1 ; 7,1 ; 8,1 ; 9,1 ; and 10,1 .

20 **Method of manufacture**

In a further aspect, the invention provides methods for manufacturing the oligonucleotides of the invention comprising reacting nucleotide units and thereby forming covalently linked contiguous nucleotide units comprised in the oligonucleotide. Preferably, the method uses phosphoramidite chemistry (see for example Caruthers et al, 1987, Methods in Enzymology vol. 154, pages 287-
25 313). In a further embodiment the method further comprises reacting the contiguous nucleotide sequence with a conjugating moiety (ligand). In a further aspect a method is provided for manufacturing the composition of the invention, comprising mixing the oligonucleotide or conjugated oligonucleotide of the invention with a pharmaceutically acceptable diluent, solvent, carrier, salt and/or adjuvant.

30 **Pharmaceutical Composition**

In a further aspect, the invention provides pharmaceutical compositions comprising any of the aforementioned oligonucleotides and/or oligonucleotide conjugates or salts thereof and a pharmaceutically acceptable diluent, carrier, salt and/or adjuvant. A pharmaceutically acceptable diluent includes phosphate-buffered saline (PBS) and pharmaceutically acceptable
35 salts include, but are not limited to, sodium and potassium salts. In some embodiments the

pharmaceutically acceptable diluent is sterile phosphate buffered saline. In some embodiments the oligonucleotide is used in the pharmaceutically acceptable diluent at a concentration of 50 - 300 μ M solution. The invention provides a sodium or potassium salt of the oligonucleotide of the invention.

5 Suitable formulations for use in the present invention are found in Remington's Pharmaceutical Sciences, Mack Publishing Company, Philadelphia, Pa., 17th ed., 1985. For a brief review of methods for drug delivery, see, e.g., Langer (Science 249:1527-1533, 1990). WO 2007/031091 provides further suitable and preferred examples of pharmaceutically acceptable diluents, carriers and adjuvants (hereby incorporated by reference). Suitable dosages, formulations,
10 administration routes, compositions, dosage forms, combinations with other therapeutic agents, pro-drug formulations are also provided in WO2007/031091 .

Oligonucleotides or oligonucleotide conjugates of the invention may be mixed with pharmaceutically acceptable active or inert substances for the preparation of pharmaceutical compositions or formulations. Compositions and methods for the formulation of pharmaceutical
15 compositions are dependent upon a number of criteria, including, but not limited to, route of administration, extent of disease, or dose to be administered.

These compositions may be sterilized by conventional sterilization techniques, or may be sterile filtered. The resulting aqueous solutions may be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration.
20 The pH of the preparations typically will be between 3 and 11, more preferably between 5 and 9 or between 6 and 8, and most preferably between 7 and 8, such as 7 to 7.5. The resulting compositions in solid form may be packaged in multiple single dose units, each containing a fixed amount of the above-mentioned agent or agents, such as in a sealed package of tablets or capsules. The composition in solid form can also be packaged in a container for a flexible
25 quantity, such as in a squeezable tube designed for a topically applicable cream or ointment.

In some embodiments, the oligonucleotide or oligonucleotide conjugate of the invention is a prodrug. In particular with respect to oligonucleotide conjugates the conjugate moiety is cleaved of the oligonucleotide once the prodrug is delivered to the site of action, e.g. the target cell.

Applications

30 The oligonucleotides of the invention may be utilized as research reagents for, for example, diagnostics, therapeutics and prophylaxis.

In research, such oligonucleotides may be used to specifically modulate the synthesis of NF- κ B1 protein in cells (e.g. *in vitro* cell cultures) and experimental animals thereby facilitating functional analysis of the target or an appraisal of its usefulness as a target for therapeutic
35 intervention. Typically the target modulation is achieved by degrading or inhibiting the mRNA

producing the protein, thereby prevent protein formation or by degrading or inhibiting a modulator of the gene or mRNA producing the protein.

If employing the oligonucleotide of the invention in research or diagnostics the target nucleic acid may be a cDNA or a synthetic nucleic acid derived from DNA or RNA.

- 5 The present invention provides an *in vivo* or *in vitro* method for modulating NF-KB 1 expression in a target cell which is expressing NFKB1, said method comprising administering an oligonucleotide of the invention in an effective amount to said cell.

In some embodiments, the target cell, is a mammalian cell in particular a human cell. The target cell may be an *in vitro* cell culture or an *in vivo* cell forming part of a tissue in a mammal.

- 10 In diagnostics the oligonucleotides may be used to detect and quantitate NF-KB 1 expression in cell and tissues by northern blotting, *in-situ* hybridisation or similar techniques.

For therapeutics, an animal or a human, suspected of having a disease or disorder, which can be treated by modulating the expression of NFKB1, such as cancer, a neurodegenerative disorder such as Rett's Syndrome, inflammation or an inflammatory disease, or an autoimmune
15 disease.

In some embodiments, the invention relates to oligonucleotides, oligonucleotide conjugates or pharmaceutical compositions for use in the treatment of diseases or disorders selected from the group consisting of atherosclerosis, multiple sclerosis, Crohn's disease, inflammatory bowel disease, asthma, septic shock, and rheumatoid arthritis.

- 20 The invention provides methods for treating or preventing a disease, comprising administering a therapeutically or prophylactically effective amount of an oligonucleotide, an oligonucleotide conjugate or a pharmaceutical composition of the invention to a subject suffering from or susceptible to the disease.

- 25 The invention also relates to an oligonucleotide, a composition or a conjugate as defined herein for use as a medicament.

The oligonucleotide, oligonucleotide conjugate or a pharmaceutical composition according to the invention is typically administered in an effective amount.

- 30 The invention also provides for the use of the oligonucleotide or oligonucleotide conjugate of the invention as described for the manufacture of a medicament for the treatment of a disorder as referred to herein, or for a method of the treatment of as a disorder as referred to herein.

The disease or disorder, as referred to herein, is associated with expression of NF-KB 1. In some embodiments disease or disorder may be associated with a mutation in the NFKB1 gene or a gene whose protein product is associated with or interacts with NF-KB 1. Therefore, in some

embodiments, **the** target nucleic acid is a mutated form of the NFkB1 sequence and in other embodiments, the target nucleic acid is a regulator of the NFkB1 sequence.

The methods of the invention are preferably employed for treatment or prophylaxis against diseases caused by abnormal levels and/or activity of NF-KB 1.

- 5 The invention further relates to use of an oligonucleotide, oligonucleotide conjugate or a pharmaceutical composition as defined herein for the manufacture of a medicament for the treatment of abnormal levels and/or activity of NF-KB 1.

10 In some embodiments, the invention relates to oligonucleotides, oligonucleotide conjugates or pharmaceutical compositions for use in the treatment of diseases or disorders selected from the group consisting of cancer, inflammation and inflammatory disorders, and autoimmune diseases.

In some embodiments, the invention relates to oligonucleotides, oligonucleotide conjugates or pharmaceutical compositions for use in the treatment of diseases or disorders selected from the group consisting of multiple sclerosis, Crohn's disease and rheumatoid arthritis.

- 15 In some embodiments, the invention relates to oligonucleotides, oligonucleotide conjugates or pharmaceutical compositions for use in the reducing inflammation in a patient who is in need to reduced inflammation.

20 In some embodiments, the invention relates to oligonucleotides, oligonucleotide conjugates or pharmaceutical compositions for use in the reducing cytokine levels in a patient who is in need to reduced cytokines.

Administration

The oligonucleotides or pharmaceutical compositions of the present invention may be administered by any suitable means, such as via parenteral administration (such as, intravenous, subcutaneous, or intra-muscular).

- 25 In some embodiments the active oligonucleotide or oligonucleotide conjugate is administered intravenously. In another embodiment the active oligonucleotide or oligonucleotide conjugate is administered subcutaneously.

30 In some embodiments, the oligonucleotide, oligonucleotide conjugate or pharmaceutical composition of the invention is administered at a dose of 0.1 - 15 mg/kg, such as from 0.2 - 10 mg/kg, such as from 0.25 - 5 mg/kg. The administration can be once a week, every 2nd week, every third week or even once a month.

The invention also provides for the use of the oligonucleotide or oligonucleotide conjugate of the invention as described for the manufacture of a medicament wherein the medicament is in a dosage form for subcutaneous administration.

Combination therapies

In some embodiments the oligonucleotide, oligonucleotide conjugate or pharmaceutical composition of the invention is for use in a combination treatment with another therapeutic agent.

5 EMBODIMENTS

1. An LNA antisense oligonucleotide of 12 to 30 contiguous nucleotides in length, targeting NFKB1, wherein the contiguous sequence of the oligonucleotide is at least 90% complementarity to a NFKB1 intron sequence.
2. The oligonucleotide of embodiment 1, wherein the contiguous nucleotide sequence of the
10 oligonucleotide is complementary to SEQ ID NO 21
3. The oligonucleotide according to embodiment 1 or 2, wherein the contiguous nucleotide sequence of the oligonucleotide is complementary to an intron region of SEQ ID NO 21, selected from the group consisting of i5, i1, i6, il l . 115 and i23.
4. The oligonucleotide of any one of embodiments 1 - 3, wherein the contiguous nucleotide
15 sequence of the oligonucleotide is complementary to a sub-sequence of the target nucleic acid, wherein the subsequence is selected from the group consisting SEQ ID NO 11, 12, 13, 14, 15, 16, 17, 18, 19, & 20.
5. The oligonucleotide of embodiment 1 - 4, wherein the oligonucleotide comprises a sequence selected from the group consisting of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.
- 20 6. The oligonucleotide of embodiment 1 - 5, comprising one or more modified nucleosides.
7. The oligonucleotide of embodiment 6, wherein the one or more modified nucleosides is a 2' sugar modified nucleoside.
8. The oligonucleotide of embodiment 7, wherein the one or more 2' sugar modified nucleoside is independently selected from the group consisting of 2'-O-alkyl-RNA, 2'-O-methyl-RNA, 2'-alkoxy-RNA, 2'-O-methoxyethyl-RNA, 2'-amino-DNA, 2'-fluoro-DNA, arabino nucleic acid (ANA), 2'-fluoro-ANA and LNA nucleosides.
- 25 9. The oligonucleotide of any one of embodiments 6 to 8, wherein the one or more modified nucleoside is a LNA nucleoside.
10. The oligonucleotide of any one of embodiments 1-9, where the oligonucleotide comprises at
30 least one modified internucleoside linkage.
11. The oligonucleotide of embodiment 10, wherein the internucleoside linkages within the contiguous nucleotide sequence are phosphorothioate internucleoside linkages.

12. The oligonucleotide of embodiment 1 - 11, wherein the oligonucleotide is capable of recruiting RNase H.
13. The oligonucleotide of embodiment 12, wherein the oligonucleotide is a gapmer.
14. The oligonucleotide of embodiment 12 or 13, wherein the oligonucleotide is a gapmer of formula 5'-F-G-F'-3', where region F and F' independently comprise 1 - 7 modified nucleosides and G is a region between 6 and 16 nucleosides which are capable of recruiting RNaseH.
15. The oligonucleotide according to any one of embodiments 1 - 14, wherein said oligonucleotide consists or comprises of an oligonucleotide selected from the group consisting of: GCAGaagtgataAGG (SEQ ID NO 1), GCAAatgggtaaggTT (SEQ ID NO 2), GGatttgtaggaCTC, (SEQ ID NO 3), TAGatgtaggagCAGA ,(SEQ ID NO 4), AGggatttgtagGAC ,(SEQ ID NO 5), GCAAatgggtaagGT (SEQ ID NO 6), TGAttacgggagtGG ,(SEQ ID NO 7), GCAGttaaggaggTT (SEQ ID NO 8), GTGttatgagaaTCC ,(SEQ ID NO 9), and GATAttggcttagtGG (SEQ ID NO 10),
- 15 wherein capital letters represent LNA nucleosides and lower case letters represent DNA nucleosides, and cytosines are optionally 5-methyl cytosine.
16. The oligonucleotide according to embodiment 15, wherein all LNA nucleotides are beta-D-oxy LNA.
17. The oligonucleotide according to embodiments 15 or 16, wherein all LNA cytosines are 5-methyl cytosine.
18. The oligonucleotide according to any one of embodiments 15 - 17, wherein all internucleoside linkages present in the indicated sequence are phosphorothioate internucleoside linkages.
19. The oligonucleotide according to any one of embodiments 1 - 18, wherein the compound is selected from the group consisting of GCAGaagtgataAGG (SEQ ID NO 1), GCAAatgggtaaggTT (SEQ ID NO 2), GGatttgtaggaCTC, (SEQ ID NO 3), TAGatgtaggagCAGA ,(SEQ ID NO 4), AGggatttgtagGAC ,(SEQ ID NO 5), GCAAatgggtaagGT (SEQ ID NO 6), TGAtta^mcgggagtGG ,(SEQ ID NO 7), GCAGttaaggaggTT (SEQ ID NO 8), GTGttatgagaaTCC ,(SEQ ID NO 9), and GATAttggcttagtGG (SEQ ID NO 10), wherein capital letters represent beta-D-oxy LNA nucleosides, all LNA cytosines are 5-methyl cytosine, lower case letters are DNA nucleosides, ^mc indicates a 5-methyl cytosine DNA nucleoside, and all internucleoside linkages are phosphorothioate internucleoside linkages.

20. A conjugate comprising **the** oligonucleotide according to any one of embodiments 1 - 19, and at least one conjugate moiety covalently attached to said oligonucleotide.
21. A pharmaceutical composition comprising the oligonucleotide of embodiment 1 - 19 or the conjugate of embodiment 20 and a pharmaceutically acceptable diluent, solvent, carrier, salt and/or adjuvant.
22. An *in vivo* or *in vitro* method for modulating NF-KB1 expression in a target cell which is expressing NFKB 1 said method comprising administering an oligonucleotide of any one of embodiments 1 - 19, the conjugate according to embodiment 20, or the pharmaceutical composition of embodiment 21 in an effective amount to said cell.
23. A method for treating or preventing a disease comprising administering a therapeutically or prophylactically effective amount of an oligonucleotide of any one of embodiments 1 - 19 or the conjugate according to embodiment 20 or the pharmaceutical composition of embodiment 21 to a subject suffering from or susceptible to the disease.
24. The method of embodiment 23, wherein the disease is selected from the group consisting of cancer, neurodegenerative disorders (such as Rett's syndrome), inflammation and inflammatory disorders, and autoimmune diseases.
25. The method according to embodiment 24, wherein the disease is selected from the group consisting of multiple sclerosis, Crohn's disease and rheumatoid arthritis.
26. The oligonucleotide of any one of embodiments 1 - 19 or the conjugate according to embodiment 20 or the pharmaceutical composition of embodiment 21 for use in medicine.
27. The oligonucleotide of any one of embodiments 1 - 19 or the conjugate according to embodiment 20 or the pharmaceutical composition of embodiment 21 for use in the treatment or prevention of cancer, inflammation and inflammatory disorders, and autoimmune diseases.
28. The use of the oligonucleotide of embodiment 1 - 19 or the conjugate according to embodiment 20 or the pharmaceutical composition of embodiment 21, for the preparation of a medicament for treatment or prevention of cancer, a neurodegenerative disorder, inflammation and inflammatory disorders, and autoimmune diseases.
29. The oligonucleotide or use according to any one of embodiments 26 - 28, wherein the oligonucleotide is for use in the treatment of a disease selected from the group consisting of multiple sclerosis, Crohn's disease and rheumatoid arthritis.
30. The oligonucleotide or use according to any one of embodiments 26 - 28, wherein the oligonucleotide is for use in the treatment of Rett's Syndrome.

EXAMPLES

The work reported herein has received funding from the European Union Seventh Framework Programme [FP7-2007-2013] under grant agreement "HEALTH-F2-201 3-6021 14" (Athero-B-Cell).

5 **Materials and methods**

Oligonucleotide synthesis

Oligonucleotide synthesis is generally known in the art. Below is a protocol which may be applied. The oligonucleotides of the present invention may have been produced by slightly varying methods in terms of apparatus, support and concentrations used.

10 Oligonucleotides are synthesized on uridine universal supports using the phosphoramidite approach on an Oligomaker 48 at 1 μ mol scale. At the end of the synthesis, the oligonucleotides are cleaved from the solid support using aqueous ammonia for 5-16hours at 60°C. The oligonucleotides are purified by reverse phase HPLC (RP-HPLC) or by solid phase extractions and characterized by UPLC, and the molecular mass is further confirmed by ESI-MS.

15 *Elongation of the oligonucleotide:*

The coupling of β -cyanoethyl- phosphoramidites (DNA-A(Bz), DNA- G(ibu), DNA- C(Bz), DNA-T, LNA-5-methyl-C(Bz), LNA-A(Bz), LNA- G(dmf), or LNA-T) is performed by using a solution of 0.1 M of the 5'-O-DMT-protected amidite in acetonitrile and DCI (4,5-dicyanoimidazole) in acetonitrile (0.25 M) as activator. For the final cycle a phosphoramidite with desired
20 modifications can be used, e.g. a C6 linker for attaching a conjugate group or a conjugate group as such. Thiolation for introduction of phosphorothioate linkages is carried out by using xanthane hydride (0.01 M in acetonitrile/pyridine 9:1). Phosphodiester linkages can be introduced using 0.02 M iodine in THF/Pyridine/water 7:2:1. The rest of the reagents are the ones typically used for oligonucleotide synthesis.

25 For post solid phase synthesis conjugation a commercially available C6 aminolinker phosphoramidite can be used in the last cycle of the solid phase synthesis and after deprotection and cleavage from the solid support the aminolinked deprotected oligonucleotide is isolated. The conjugates are introduced via activation of the functional group using standard synthesis methods.

30 *Purification by RP-HPLC:*

The crude compounds are purified by preparative RP-HPLC on a Phenomenex Jupiter C18 10 μ 150x10 mm column. 0.1 M ammonium acetate pH 8 and acetonitrile is used as buffers at a flow rate of 5 mL/min. The collected fractions are lyophilized to give the purified compound typically as a white solid.

35 *Abbreviations:*

DCI: 4,5-Dicyanoimidazole

DCM: Dichloromethane

DMF: Dimethylformamide

DMT: 4,4'-Dimethoxytrityl

5 THF: Tetrahydrofuran

Bz: Benzoyl

Ibu: Isobutyryl

RP-HPLC: Reverse phase high performance liquid chromatography

T_m Assay:

10 Oligonucleotide and RNA target (phosphate linked, PO) duplexes are diluted to 3 mM in 500 ml RNase-free water and mixed with 500 ml 2x T_m -buffer (200mM NaCl, 0.2mM EDTA, 20mM Na-phosphate, pH 7.0). The solution is heated to 95°C for 3 min and then allowed to anneal in room temperature for 30 min. The duplex melting temperatures (T_m) is measured on a Lambda 40 UV/VIS Spectrophotometer equipped with a Peltier temperature programmer PTP6 using PE
15 Templab software (Perkin Elmer). The temperature is ramped up from 20°C to 95°C and then down to 25°C, recording absorption at 260 nm. First derivative and the local maximums of both the melting and annealing are used to assess the duplex T_m .

Example 1: Testing in vitro potency and efficacy of selected oligonucleotides targeting mouse Nfkb-subunit1 mRNA in RAW264.7 cells in a dose response curve.

20 RAW 264.7 cell line was purchased from ATCC and maintained as recommended by the supplier in a humidified incubator at 37°C with 5% CO₂. For assays, 2500 cells/well were seeded in a 96 multi well plate in culture media. Cells were incubated for 24 hours before addition of oligonucleotides dissolved in PBS. Concentration of oligonucleotides: from 50 μM,
25 1:1 dilution in 8 steps. Three days after addition of oligonucleotides, the cells were harvested. RNA was extracted using the PureLink Pro 96 RNA Purification kit (Thermo Fisher Scientific) according to the manufacturer's instructions and eluted in 50 μl water. The RNA was subsequently diluted 10 times with DNase/RNase free Water (Gibco) and heated to 90°C for one minute.

30 For gene expressions analysis, One Step RT-qPCR was performed using qScript™ XLT One-Step RT-qPCR Tough Mix®, Low ROX™ (Quantabio) in a duplex set up. The following TaqMan primer assays were used for qPCR: Nfkb1, Mm00476361_m1 ; Nfkb2, Mm00479810_g1 ; Rela Mm00501346_m1 ; Relb, Mm00485664_m1 ; or Rel, Mm01239661_m1 (FAM-MGB); each combined with endogenous control Gapdh, Mm99999915_g1 (VIC-MGB). All primer sets were
35 purchased from Thermo Fisher Scientific. IC₅₀ determinations were performed in GraphPad

Prism6. The relative mRNA levels at treatment with 50 μ M oligonucleotide is shown in the table as % of control (PBS).

SEQ ID NO	Target	Motif	CMP ID NO	Compound	IC50 [μ M]	mRNA level at Max KD
23	Nfkb2	agatttcgattagac	M1,1	AGATttcgattagAC	2,5	38
24	Relb	tagaattgaagtaaa	M2,1	TAGAattgaagtTAAA	1,1	13
25	Rela	ataactgtgtttc	M3,1	ATaactgtgttTTC	2,7	41
	Rel				3,5	65

Example 2: Mouse *in vivo* efficacy and tolerance study, 16 days of treatment, Intravenous (tail vein).

Animals

Experiment was performed on female C57BL/6JBom mice (Taconic). Five animals were included in each group of the study, including a saline control group.

Compounds and dosing procedures

- 10 Animals were injected intravenously (tail vein) with 15mg/kg compound at day 0, 3, 7, 10, 14 until the study was terminated at day 16.

Euthanasia

At the end of the study (day 16) all mice were euthanized with CO₂ before tissue samples of liver, kidney and mesenteric lymph node were dissected and snap frozen.

- 15 Quantification of Nfkb subunit RNA expression (Figure 1A, 1B and 1C)

Tissue samples were kept frozen until lysed in MagNA Pure LC RNA Isolation Tissue Lysis Buffer (Product No. 03604721001, Roche) and RNA extraction continued using the MagNA Pure 96 Cellular RNA Large Volume Kit (Product No. 05467535001, Roche) on a MagNA Pure 96 Instrument (Roche) according to the user's manual and RNA diluted to 5ng/ μ l in water.

- 20 For gene expressions analysis, One Step RT-qPCR was performed using qScript™ XLT One-Step RT-qPCR ToughMix®, Low ROX™ (Quantabio) in a duplex set up. The following TaqMan primer assays were used for qPCR: Nfkb1, Mm00476361_m1; Nfkb2, Mm00479810_g1; Rela Mm00501346_m1; Relb, Mm00485664_m1; or Rel, Mm01239661_m1 (FAM-MGB); each combined with endogenous control Gapdh, Mm99999915_g1 (VIC-MGB). All primer sets were
25 purchased from Thermo Fisher Scientific. The relative mRNA expression levels are shown as % of control (PBS-treated animals).

Example 3: Testing *in vitro* efficacy of antisense oligonucleotides targeting human NFKB1 mRNA in HEK293 and HeLa cell lines at single dose concentration.

Also known as: p50; KBF1 ; p105; EBP-1 ; CVID12; NF-kB1 ; NFKB-p50; NFkappaB; NF-kappaB; NFKB-p105; NF-kappa-B

Assembly	Chr	Location
GRCh38.p7 (GCF_000001405.33)	4	NC_000004.12 (102501329..102617302)

5

The Human NFKB1 pre-mRNA sequence is provided as SEQ ID NO 21 (Figure 6).

HEK-293 and HeLa cell lines were purchased from ATCC and maintained as recommended by the supplier in a humidified incubator at 37°C with 5% **CO**₂. For assays, 3500 cells/well (HEK-293) or 3000 cells/well (HeLa) were seeded in a 96 multi well plate in culture media. Cells were incubated for 24 hours before addition of oligonucleotides dissolved in PBS. Final concentration of oligonucleotides: 25 μM. Three days after addition of oligonucleotides, the cells were harvested. RNA was extracted using the PureLink Pro 96 RNA Purification kit (Thermo Fisher Scientific) according to the manufacturer's instructions and eluted in 50 μl water. The RNA was subsequently diluted 10 times with DNase/RNase free Water (Gibco) and heated to 90°C for one minute.

15

For gene expressions analysis, One Step RT-qPCR was performed using qScript™ XLT One-Step RT-qPCR ToughMix®, Low ROX™ (Quantabio) in a duplex set up. The following TaqMan primer assays were used for qPCR: NFKB1 , Hs00765730_m1 (**FAM-MGB**) and endogenous control GAPDH, Hs99999905_m1 (VIC-MGB). All primer sets were purchased from Thermo Fisher Scientific. The relative NFKB1 mRNA expression level in the table is shown as percent of control (PBS-treated cells).

20

A total of 77 oligos were designed at a length of 15-16 nucleotides with varying LNA patterns (3x3; 2x4; 4x2; 3x2; 2x3) across SEQ ID NO 21. A waterfall plot of relative NFKB1 expression in both cell lines is shown in Figure 2.

25 **Oligonucleotides used:**

SEQ ID NO	Motif	CMP ID NO	Compound	Rel. mRNA level HEK-293 at 25µM	Rel. mRNA level HeLa at 25µM
1	gcagaagtgataagg	1,1	GCAgaagtgataAGG	17	10
2	gcaaatgggtaagggt	2,1	GCAAatgggtaaggTT	27	11
3	ggattggtaggactc	3,1	GGattggtaggactc	21	19
4	tagatgtaggagcaga	4,1	TAgatgtaggagCAGA	34	8
5	agggattggtaggac	5,1	AGggattggtagGAC	34	11
6	gcaaatgggtaagggt	6,1	GCAAatgggtaaggGT	35	13
7	tgattacgggagtgg	7,1	TGAtta ^m cgggagtGG	28	21
8	gcagttaaggaggttt	8,1	GCAgttaaggaggtTT	32	19
9	gtgttatgagaatcc	9,1	GTGttatgagaaTCC	29	22
10	gatattggcttagtgg	10,1	GATAttggcttagtGG	33	17

For Compounds: Capital letters represent LNA nucleosides (beta-D-oxy LNA nucleosides were used), all LNA cytosines are 5-methyl cytosine, lower case letters represent DNA nucleosides, DNA cytosines preceded with a superscript ^m represents a 5-methyl C-DNA nucleoside. All internucleoside linkages are phosphorothioate internucleoside linkages.

- 5 The data obtained from the two cell lines is shown in Figure 3, which illustrates that the above compounds were particularly effective in both cell lines in targeting human NFKB1, as compared to a library of other compounds targeting human NFKB1. Each of the 10 sequences aligned to the following regions of the NFKB1 transcript, illustrated in Figure 4, referred to as hotspot regions A, B, C, D, E, F, G, H, I, & J:

Hotspot Region (NFKB1)	Hotspot Region - NFKB1 pre-mRNA position (start)	Sequences	Compounds	Target Sequence	Target SEQ ID NO
A	47885	1	1,1	CCTTATACTTCTGC	11
B	39941	2	2,1	AACCTTACCCATTTGC	12
C	96661	3	3,1	GAGTCCTACCAAATCC	13
D	3227	4	4,1	TCTGCTCCTACATCTA	14
E	96663	5	5,1	GTCCTACCAAATCCCT	15
F	39942	6	6,1	ACCTTACCCATTTGC	16
G	75123	7	7,1	CCACTCCCGTAATCA	17
H	88465	8	8,1	AAACCTCCTTAACTGC	18
I	114844	9	9,1	GGATTCTCATAAACAC	19

J	19399	10	10,1	CCACTAAGCCAATATC	20
---	-------	----	------	------------------	----

SEQ ID NO 22 = GAGTCCTACCAAATCCCT and encompasses both SEQ ID NO 13 & 15 and is therefore a preferred hotspot region for antisense targeting.

5 **Example 4: Testing *in vitro* potency and efficacy of selected oligonucleotides targeting human NFKB1 mRNA in HEK-293 and HeLa cell lines in a dose response curve.**

HEK-293 cell line and HeLa cell line was described in Example 1. The assay was performed as described in Example 1. Concentration of oligonucleotides: from 50 μ M, 1:1 dilution in 8 steps. Three days after addition of oligonucleotides, the cells were harvested. RNA extraction and duplex One Step RT-qPCR were performed as described in Example 3. n=2 biological replicates per each cell line. IC₅₀ determinations were performed in GraphPad Prism6. The relative NFKB1 mRNA level at treatment with 50 μ M oligonucleotide is shown in the table as percent of control (PBS).

SEQ ID NO	CMP ID NO	IC ₅₀ HeLa	mRNA level at Max KD in HeLa	IC ₅₀ HEK-293	mRNA level at Max KD in HEK-293
1	1,1	2,1	18	1,8	12
2	2,1	1,4	14	1,9	25
3	3,1	2,3	22	2,2	23
4	4,1	2,5	7	3,7	23
5	5,1	1,3	21	1,6	22
6	6,1	1,8	20	2,1	31
7	7,1	2,3	32	3,2	25
8	8,1	1,8	22	2,0	28
9	9,1	3,5	26	4,5	30
10	10,1	1,0	23	0,9	31

The data and IC₅₀ curves are shown in Figures 5A, 5B and 5C.

CLAIMS

1. An LNA gapmer antisense oligonucleotide of 12 to 30 contiguous nucleotides in length, targeting NFKB1, wherein the contiguous sequence of the oligonucleotide is at least 90% complementarity to a NFKB1 intron sequence, wherein said LNA gapmer antisense oligonucleotide is capable of inhibiting **NF-KB1** expression in a cell which is expressing NFKB1, or a pharmaceutically acceptable salt thereof.
2. The LNA gapmer antisense oligonucleotide according to claim 1, wherein the contiguous nucleotide sequence of the oligonucleotide is complementary to an intron region of SEQ ID NO 21, selected from the group consisting of i5, i1, i6, i11, i15 and i23.
3. The LNA gapmer antisense oligonucleotide of claim 1 or 2, wherein the contiguous nucleotide sequence of the oligonucleotide is complementary to a sub-sequence of the target nucleic acid, wherein the subsequence is selected from the group consisting SEQ ID NO 11, 12, 13, 14, 15, 16, 17, 18, 19, & 20.
4. The LNA gapmer antisense oligonucleotide of claim 1 - 3, wherein the oligonucleotide comprises a sequence selected from the group consisting of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.
5. The LNA gapmer antisense oligonucleotide of any one of claims 1 - 4, wherein the LNA gapmer antisense oligonucleotide comprises a gapmer of formula 5'-F-G-F'-3', where region F and F' independently comprise 1 - 7 modified nucleosides and G is a region between 6 and 16 nucleosides which are capable of recruiting RNaseH.
6. The LNA gapmer antisense oligonucleotide according to any one of claims 1 - 5, wherein said oligonucleotide consists or comprises of an oligonucleotide selected from the group consisting of: GCAGaagtgataAGG (SEQ ID NO 1), GCAAatgggtaaggTT (SEQ ID NO 2), GGatttgtaggaCTC, (SEQ ID NO 3), TAGatgtaggagCAGA, (SEQ ID NO 4), AGggatttgtagGAC, (SEQ ID NO 5), GCAAatgggtaagGT (SEQ ID NO 6), TGAttacgggagtGG, (SEQ ID NO 7), GCAGttaaggaggtTT (SEQ ID NO 8), GTGttatgagaaTCC, (SEQ ID NO 9), and GATAttggcttagtGG (SEQ ID NO 10), wherein capital letters represent LNA nucleosides and lower case letters represent DNA nucleosides, and cytosines are optionally 5-methyl cytosine.
7. The LNA gapmer antisense oligonucleotide according to claim 6, wherein all LNA nucleotides are beta-D-oxy LNA.
8. The LNA gapmer antisense oligonucleotide according to claims 6 or 7, wherein all LNA cytosines are 5-methyl cytosine.

9. The LNA gapmer antisense oligonucleotide according to any one of claims 1 - 8, wherein all internucleoside linkages present in the gapmer are phosphorothioate internucleoside linkages.
- 5 10. The LNA gapmer antisense oligonucleotide according to any one of claims 1 - 9, wherein the gapmer region (F-G-F') or LNA gapmer antisense oligonucleotide compound, is selected from the group consisting of GCAGaagtgtataAGG (SEQ ID NO 1), GCAAatgggtaaggTT (SEQ ID NO 2), GGatttgtaggaCTC, (SEQ ID NO 3), TAGatgtaggagCAGA ,(SEQ ID NO 4), AGggatttgtagGAC ,(SEQ ID NO 5), GCAAatgggtaagGT (SEQ ID NO 6), TGAtta^mcgggagtGG ,(SEQ ID NO 7),
10 GCAGttaaggaggtTT (SEQ ID NO 8), GTGtttatgagaaTCC , (SEQ ID NO 9), and GATAttggcttagtGG (SEQ ID NO 10), wherein capital letters represent beta-D-oxy LNA nucleosides, all LNA cytosines are 5-methyl cytosine, lower case letters are DNA nucleosides, ^mc indicates a 5-methyl cytosine DNA nucleoside, and all internucleoside linkages are phosphorothioate internucleoside linkages.
- 15
11. A conjugate comprising the LNA gapmer antisense oligonucleotide according to any one of claims 1 - 10, and at least one conjugate moiety covalently attached to said oligonucleotide.
12. A pharmaceutical composition comprising the LNA gapmer antisense oligonucleotide of claim 1 - 10 or the conjugate of claim 11 and a pharmaceutically acceptable diluent, solvent,
20 carrier, salt and/or adjuvant.
13. An *in vitro* method for modulating **NF-KB1** expression in a target cell which is expressing **NF-KBI** said method comprising administering an LNA gapmer antisense oligonucleotide of any one of claims 1 - 10, the conjugate according to claim 11, or the pharmaceutical composition of claim 12 in an effective amount to said cell.
- 25 14. The LNA gapmer antisense oligonucleotide of any one of claims 1 - 10 or the conjugate according to claim 11 or the pharmaceutical composition of claim 12 for use in medicine.
15. The LNA gapmer antisense oligonucleotide of any one of claims 1 - 10 or the conjugate according to claim 11 or the pharmaceutical composition of claim 12 for use in the treatment or prevention of cancer, inflammation and inflammatory disorders, and autoimmune
30 diseases.
16. The use of the LNA gapmer antisense oligonucleotide of claim 1 - 10 or the conjugate according to claim 11 or the pharmaceutical composition of claim 12, for the preparation of a medicament for treatment or prevention of cancer, a neurodegenerative disorder, inflammation and inflammatory disorders, and autoimmune diseases.

17. The LNA gapmer antisense oligonucleotide or use according to any one of claims 1 - 16, wherein the oligonucleotide is for use in the treatment of a disease selected from the group consisting of multiple sclerosis, Crohn's disease and rheumatoid arthritis.
18. The LNA gapmer antisense oligonucleotide or use according to any one of claims 1 - 16,
5 wherein the oligonucleotide is for use in the treatment of Rett's Syndrome.

FIGURES
Figure 1A




Figure 1B




Figure 1C




Figure 2




Figure 3




Figure 4




Figure 5A




Figure 5B




Figure 5C




Figure 6

gtgagagagt	gagcgagaca	gaaagagaga	gaagtgcacc	agcgagccgg	ggcaggaaga	60
ggaggtttcg	ccaccggagc	ggcccggcga	cgcgctgaca	gcttcccctg	cccttcccgt	120
cggtcggggc	gccagccgcc	gcagccctcg	gcctgcacgc	agccaccggc	cccgcctccg	180
gagcccagcg	ccgccgagge	cgcagccgcc	cggccagtaa	ggcggcgccg	ccgcccggcc	240
accgcgcgcc	ctgcgcttcc	ctccgcccgc	gctgcggcca	tggcgcgccg	ctgactggcc	300
tggcccggcc	ccgcgcgcgt	cccgcctgcc	ccgaccgcga	ctcggggccc	cccgggctcc	360
ggcctgccgc	cgctcttccc	ttctccagcc	ggcaggcccg	cgccgcttag	gagggagagc	420
ccaccgcgcg	caggaggccg	aacgcggact	cgccaccggg	gtaagccaaa	ctcgggagag	480
tggggggccc	gcaggggacg	cgtggcccaa	gtcctgcccg	ccagccctcc	gcaccccctc	540
cagccccact	cggaacttct	cattcctgcg	ctaaccgctg	ggctagaccg	tgggaggagg	600
ttgacagtag	ctgagaggca	catgggatta	gcgacagcgg	ggaaagacac	atccggacct	660
cgcaggggct	agtcggccga	agggccgcgg	ccgcccggcg	gtcatttctc	ttcacgtccc	720
tccgcggggc	gggaacgcga	accggagggg	aactcttaca	aactttttaa	atccccaaacc	780
ccagccccac	ctgggggatg	gtgagaaggt	tggagtgcgc	tgcggcgccg	aggagagagg	840
gaaggtgggt	ggtgcagtgc	agaaccagat	ttcacctaag	ggcgttccat	gaaatgaaag	900
cagaagtgct	tgtcagtctc	cttggctggg	aaagccctcc	ccagctcccc	agaattgaat	960
aggagagtct	attcatccct	ctcctacttc	taaaagaaac	ctggctcgct	ctctgtctct	1020
ctctctctcc	cccctcccc	cctccgtgcg	cgcgcgcgcg	cgcacacaca	cacacacaca	1080
cacacacaca	cacacacacg	atatagtcac	ctgctatagg	acttgattct	gatcctccgg	1140
ggcctggcat	ttgagagaga	aaataaatta	cctacctgga	tacttagagc	actttttaga	1200
cttgattatg	taaaactctt	ggacagtgcc	accatgcatt	atgcatgacc	gctgaaacaa	1260
aaataatgta	aaaacaaggc	ctatcctaaa	tgcaagtttt	tctatgggcc	ttaaaaacag	1320
acaccagggg	atgtttgccc	tgacttgctg	gtttatcctg	aaactcaaat	gggacttaat	1380
gatacaggat	ttaattatca	agattgacat	gttcatggac	tttgtaagt	agagggtttc	1440
agcattacag	tttatgaaat	aaccatattt	aactcaaaga	tttttttata	aagctcataa	1500
tctgaaaaaa	tgcttatggg	attactaaaa	catttaatat	ctctggcatc	aaaatattct	1560
acatactggt	gatcttttag	taaatagtaa	aggttagggg	caagatattc	aataattttt	1620
ttctagcaga	atcccacaac	tgaatattgt	caagcagttt	aaactgcatt	cgtgtttggt	1680
aaaactttta	aagggaaact	taaaactaaa	gtagttagtt	tttctgattt	taattattgtg	1740
ctttctagag	atgaatcctt	ttactgtttg	aggcactata	ggaattatgt	atttaaatgt	1800
atgtatttaa	atttgaagca	atgtactttt	ttgagtttat	aaacttggga	agacaggaaa	1860
taaaaagatt	tgtttcctgt	agaattttac	atctatgatt	taattgaatt	gctaaaaatgg	1920
aaagaacatg	tacgattaat	ggagacttgg	aatctgagat	tattcatcca	tattgataca	1980
cctgcaattc	ctaaatgccc	tcccctgctt	gtttagataa	aatgtcttcc	tgggctgcag	2040
cctactggac	aaacttgaac	acaaaggaac	acacggtata	tgtacattta	atactggaac	2100
cgaaaagctg	cttgcagtga	aaagcaaacc	acttctaaac	tctttgagac	tttttaaaga	2160
aggtagtata	atccttttag	gggttgggtg	tgatgtgaaa	atctattatc	tttttgctga	2220
aatttcattc	ttatgttagg	cattggcact	cacttgtgct	gagtaaattgc	ccgtgttttt	2280
caaaccaga	tagtaaatac	tgggggtata	catacaaaaa	tagtccttcc	cctttgtaag	2340
cattgctttg	atctttgcac	ttccttttta	ctctacctct	taacaagat	ctgtgttgat	2400
tgagttgatt	aaagcacaat	taatctgaaa	taggcagaat	tttagattta	gtgattatat	2460
tccttacatt	tctgttgтта	ctgttccctg	aaacaaattg	aagtagtttg	agaaactaat	2520
atttatgcag	gttgttttta	ctacactttt	agacttgcag	ataattgatt	aagtaagtta	2580
ctacctgcag	tttcagggat	tgctcattgt	ggtagatagc	aggtctagat	agggaaattg	2640
cagctacatg	aatgttggac	tatcattcca	tcagcaagac	cttattttta	cctaatttat	2700
gagaggtatt	tctctgttca	gaagaggtga	aagttctggc	ttctgggggg	aagtggttac	2760
ttcataacct	tcaattgggt	tgaacttggg	agaagtaaga	aaagtagtcg	atattttcaa	2820
acagtaaaat	aattgtatct	gagttgctgt	atggattttt	gatgaagtac	tcaaaatgtc	2880
atcttttgca	tcttcgggtc	ttagtagatg	tgctattctg	agtatagaat	tgactgcagt	2940
aggaagtgta	tctggaaatg	cacagtactg	ttgtataacc	aatagagtaa	attctcagat	3000
tatgctcttc	tgggtccacag	attgatcaga	aatcacatta	acaggaatgg	atgtctatgc	3060
aaaatttctc	attaattttc	ttacttttag	taggaagttt	gttttattcg	gttggctctg	3120
tggttttctg	tttacaaggt	gaattgtcta	cagtagtggg	attgttatat	tagaagagaa	3180
ggagaaggaa	aaatagaagt	tagtgctaga	ggatatgtta	agatgttctg	ctcctacatc	3240
tacattttgt	tctaatacag	attaattgat	gactacgtct	tggtaaacag	tagaccatac	3300
tggagcaatt	tactctgctt	tttgggaatt	agttctcatt	tgcactcttg	cacctcccat	3360
aaatactgaa	ctcacttgta	gtgttcttag	aggtcagcaa	taaaccatca	agagcatatg	3420
atctctcttt	gaattttgtc	actacttttg	agacagacag	tttggaaaga	ctgaaggtag	3480
tcagcctcag	ggagaaaggt	ttgaacgttt	tggcatagtc	ctgcaagtca	gtttggctcc	3540
ttgactgtga	atttttttta	tcaaaaaaga	ttaatatttg	aaaccacata	atttggacag	3600
ttaatagttc	tggtaacata	accaagcctt	ttatctttgt	agtatttcat	taattagtat	3660

ccagtgccctc	acttttagaa	gaaaaaaga	gaaaaagta	gtaacattct	tttaaatgatg	3720
atgaaattgc	ttcatacctt	tggctctctgc	tgtattaggg	gttgctcctg	ggtgcaaatt	3780
aataactgt	cttttacatt	tccggagggt	gttgacctgg	ccttgaagat	cagccaacag	3840
tttagaaaat	aagttgtgca	aattgcattg	ctacacctca	aataatttaa	agcctgacag	3900
ttctgtacag	aataagagtc	acataagatg	tgatttgta	aagattatag	aaatctcaga	3960
agatagatta	tgatgaaaa	tatttgttta	atthagagta	ctaataataa	aaatagtgca	4020
ttttacattt	taaaaagaaa	acaattttta	ttgtgtcata	ttttctgtag	taacaaacag	4080
aattaattat	cagtaataca	aatttcatct	gctttaattt	attgcctggt	tttgaaatta	4140
gaataatgat	atatttggtt	taattatcca	ttacaaattg	ccttattatt	tttcattcat	4200
ctttcacat	taatccagaa	accttaaaat	agcttttatt	ttgacctatg	ccttcagtag	4260
atatcaacag	acttgagttc	atctatggat	cctattagtt	taaactgtga	caaattttga	4320
ctgcttaagc	tttagaaaag	aattttattct	ttaaaatagc	caaaattata	aaaaatgaaa	4380
taaagaaaaa	gctgtttgag	agaatcaaat	actctagttt	aactaaaaat	aaataatatic	4440
taatcaatac	tgacgaaaga	aatatctgat	gcttagcatt	gtacttggtg	gtacatagta	4500
agcaatcatt	aactgttaaa	tgaatgaatg	atatgaagtt	gttgcaaaat	ttttttttaa	4560
atggacagcc	atcttctata	aggaacaaaa	attacattat	tttgctttgc	cttctggaaa	4620
gaaaggagca	caaaatagtc	cttgtgtctt	agatattatg	gaaatcttat	ctaaagacca	4680
cttgaagttt	actagaacaa	ataatttatt	aaaaagtatc	tggcgccttc	caaaagggga	4740
acatttcatt	ctgaaagagg	catttatgaa	ctagaaaaaa	aatgcctttt	agtttcaaag	4800
ttttagaggc	accagagcaa	gattataaag	taattggaat	gataaaagg	gcttgtaaaa	4860
ttgaaaaatg	taattttttg	gtgaagttag	aatttctgta	cactccattg	aaactgtaat	4920
atcaaatact	aatacctcca	aaaaagaaac	aatgctacaa	gcactgcttg	gtaatctaag	4980
aattgttaac	acttatctaa	attaatcaac	caaaaagtta	aaacaaaata	tgttattttg	5040
ttatgttacc	tctagaatta	aacacctatc	accataaat	ctgtgactgt	taaaagttac	5100
tagatggcaa	acctcaggaa	caagcaggga	gttagcaggg	tttactgtac	tttccacttt	5160
catactttaa	tgattttttcc	aacactatag	aagctggggc	ctcatcctag	cacagtttgt	5220
tcattatttt	tcagttgtag	cattttttaa	agttggcct	tgaatttctg	aattgaaacca	5280
tttatttttt	tctggacaca	gttttttaaa	tgaatatatac	catttagact	agaaaagagc	5340
aaaatgccaa	tactccctgt	cctagtgtca	ttgtgcccc	tgggaaccct	aatgcagttc	5400
tgtgggaaaa	caaccatttt	attgagcgt	gctcacttca	gttcattctg	ctttgctgcc	5460
acttagttct	ggttctgacc	ctgatctccc	ctcacatcac	tcacaacaaa	cattcaagtt	5520
taaaaattaa	gttaaaagtt	agttacatat	atatgttaact	aatgtgtata	ttaaatatac	5580
tgatatatat	tagttacata	tacagatatg	gcaacaacaa	aaaaggttat	atatatacat	5640
atgtgtaact	aatatgtata	ttaaatataa	tgatatatgt	ataaatacat	atgtgtaact	5700
aatataatta	tatttaatat	atattagtta	caaataatgta	tatataatat	ttttgtttgt	5760
tgccagcaaa	atgagaaaga	aattaaatgt	taacatctat	aacaattgca	ctgtaaagcc	5820
gtcattggtg	aaaagtactc	cgaagattaa	tagcggcagt	gtttgttaa	ataataaaat	5880
aatccaggca	ctctgcctgt	gacttcccc	tgagatggct	tccagaaaa	gataaatttt	5940
tgtgtgttcc	cttacgagtt	cagtctgcag	cttctgggca	tgaagagaag	cataaacaaa	6000
acaaacaagg	ctctaacttt	gttataatcc	ttacgctact	agtagaaatg	tatggacaat	6060
tcatgcattt	catattggaa	aataaagcta	ttagattttt	ctttgagatg	aacctttttt	6120
ttgtaattta	ttttttattt	tttatttttt	ttcagtagag	atgggatttt	gctctggttg	6180
ccaggctggg	ctcaaactcc	tgacctcaag	tgatccacc	gcctcagcct	cccaaagtgc	6240
cgggattaca	ggcgtgagcc	acctagcttg	gccaaggtga	acctttttga	taaatgagcc	6300
tcactaatat	ttctaggatt	tacttttcac	taacttgaac	taaagaaagt	ataagaccctg	6360
cataaagttg	agcataacct	tataatgtcc	catttttaaaa	agcaatttgt	ttttaatgac	6420
ttttatttgt	taaaagcagt	tatttcaaaa	aattattttt	attattttatc	atgtcatttg	6480
gactgaaaat	actataccat	atctcagttg	tagggcacac	ctatccctct	ttatcccaga	6540
cgtcaattct	accatataac	aagtatgtaa	aaaagaaaac	ataaaagtga	tgacagactc	6600
cctaatacaac	ctattttattg	gttctaagcc	caagcctgca	gttcatttaa	atagtgaaaa	6660
tagattactt	aattgtctta	gaaaatatgt	cttccatgac	aagaatttta	ggaatgagaa	6720
aataactatt	tttggtatgtt	ttaacacaaa	ttcccaaatc	atgttttatt	gatatttgaa	6780
gaacctcttt	gtctaccagt	tcttaagtat	aggcttattt	tgttaaggctt	aaacatgtat	6840
tggtgtttga	ctgttaagac	ttgatctata	accttcagtg	tctttttctt	ttaaatgggg	6900
tatggacttg	gtaatgaggg	cagaggagaa	taccttaca	tttatagcat	ctgcatataa	6960
tacaagaacc	ttcatgattt	ataaaattaa	aatgatgatg	atgtggaatg	atggaagaag	7020
catgtgtggg	tggtatattt	tgtagaggaa	attagaagtt	gaaagcaatg	ttagaatta	7080
aaattaaatt	acacttaatt	ttttgctcag	ttggatagtc	aggaaagtac	ttaaatcagc	7140
aattgattta	cgtaaaatca	aaactgaaaa	ctgaatatac	aatctaggaa	ataggaaaaa	7200
aatttttagt	gtgttcatac	tgctaatttc	aaaccaagca	aaaaacctgg	ggaactactt	7260
ttcagaggag	atggcttaaa	atgaacaaa	aatatagcca	tttctctacc	ctattcattt	7320
aatgcattca	tttattatac	tgctaataca	tgataaggtg	aataggttaa	gcatcgtttg	7380
tatatgtgta	tgtgattttta	aacctgagtc	ttttgaaaga	ttggtcaaag	caaaggataa	7440

tgaaagcata	aagatttagg	gggaagagtc	ctctataaaa	ctaagactta	aactttgtta	7500
tcaacttgaa	tgtgaagata	gaataatcta	gaaagtgaat	gagaattata	aataaaagga	7560
caaatcatat	atctcatggg	tgagaaatac	aatgagataa	attgtatata	tcatctcatg	7620
gagggtcata	atgaaagaag	taagagagat	tgcccttgga	tagaaccttt	cggcagacat	7680
ttcataatgg	attatcatat	ttttgctaaa	ctggtaagaa	tggacttttc	accacattat	7740
gaaaaaacac	tttagaagtc	agttgcgatc	aagcaaatat	aagtacctgg	gaaattaaaa	7800
tcaaaagcac	agcagtccaa	caatagtcaa	atgcatttac	tcactctcat	accatatcat	7860
agcgttaatt	tgagataatg	tctttatggg	gtctctttat	atatttactc	gatttcccat	7920
ttaagacatt	taaccaaat	taaaaagcaa	tccttagaaa	ctttaaaaat	atttcctatt	7980
ttaaacatt	acataatcat	ttaccctgca	gttacaattc	ttttttgtg	atgggtggg	8040
aagtatccca	tttctcttag	aaagtcttct	gtaaatgcca	aataggagtc	aatccaagtt	8100
gcttagagag	gtagttcaat	cctgtgttga	aatagatgac	ttttggagta	attgtgctat	8160
atthactgag	tatctgttga	actgtaggag	tccagtcatt	caaggcaagc	tacagaaatg	8220
atthatttgc	tgaggcactt	aagtatcttc	acatctatat	gccaatatta	aatttctcat	8280
catccttgat	ccccaccctt	ttgcacagat	tggtatcccc	agcacattag	ggaatgctgt	8340
tgttagcctg	ttaggggtcca	ttcagtagat	ttctcatgcc	agaaatctag	aagcccttct	8400
tatacattca	gctttcttct	tcagtcagtc	accaagttct	atcaaggcag	cctcctcatc	8460
tccagaatcc	atcccttctt	cgttgaatth	ctagatthta	tttttgcatt	gtctcctgct	8520
tctaaccat	cgttcatttc	gcataatggt	cagctttcta	aagtgtaaat	cggatcatgt	8580
ctctgcagtg	aatcccagtt	gtcttcacaa	gctgattctc	gcacacctca	cccccttact	8640
ccctccgggtg	ttcccccaacc	atcccccaat	ctcaaatcct	ccacaccgac	tttcagtttc	8700
ctatccacag	tttctgactt	tgaatgcctt	tgttatggc	ctccctgtat	gagaagtggc	8760
ttttctttcc	tagccatcct	gctaacttct	aaacccttag	gcctgggtttg	agcatcacca	8820
tttctctcac	ttgcctttct	gttttctccc	tcccctttcc	ataaagagtt	atgtgcccc	8880
atthctgtgtt	ctcctgaatt	cctgtgggtc	ctagaaaaga	aacatcttga	gggcaaggag	8940
ttcatcttat	ttactthttta	tttgcacagc	acctgggtgtg	tttgtctaat	aagtaaatat	9000
cgaacaagat	atcaagagac	agtgtctgca	atthactgtg	tggctctgag	caagttaatt	9060
aacttctctg	agtctthatt	ttgttctgta	aaaaaatgga	ggtttgacaa	aatgagctac	9120
tctctctaaa	atthctgtgtt	tctttgatgt	aattgtatta	attggaagac	ttcagattht	9180
cttgccatat	caagatagggt	caacttaaga	aaaatgcatg	tgagtaagta	ccaagccaat	9240
tcttgattat	cagtatgata	atthctggaa	ctgcccattt	tgtcgataat	aagttataat	9300
ttttgggtctc	agtgtagggt	ctttctcaaa	tccagatggt	tctgggtgtt	cattttttca	9360
ttattattca	gtctctcgca	ttcatattht	tccaaagaaa	ttthctggaa	acttgagaca	9420
aaaattgaa	gtaagthttta	atthtttaaat	gctagattga	ttcaaggctt	cactaattat	9480
aactatattt	ggaggggagaa	gaaggggagg	tggtggtagt	atgagctgaa	tctcctctg	9540
ttccttccca	gaaggaacac	aacgtcctac	atcaagaaaa	aagacagaag	catatcttgg	9600
agatatgaaa	agaaccacca	ggtaactaa	aaagaaaaag	agtgttaaaa	agtcagcctt	9660
taaaaagcag	gattggagat	gaggaggggt	ggagtggggg	aagcattgct	tgthttataga	9720
agctcttcca	tcttctgata	gtgtgattth	tattthttta	ttattthttc	cttcccttht	9780
tttgacctcc	agctthtagta	tagtacagtt	gacagaaatt	atthctgtht	atgggtacaca	9840
agatgatggt	ttgatataca	tatgcattgt	gaaatgatta	aatcaagctg	atthacataa	9900
gtagggttht	atthctthta	cagtgattth	ttgaaatata	tgttgagtcc	tttctatgtg	9960
ccagacacag	ttctaaaggac	aaggcacaca	gtgccaacaa	agacagaaat	ccagaaattc	10020
atgagcttta	aatcatgtag	tctthctcag	ttthaaatt	ttcttctgtg	gcgtagtgcc	10080
tcatactctg	aatcccagta	cttcaggagg	ccgagaaggg	aggattgctt	aaaccagga	10140
atthctgagcc	agcatggaca	aaatagcgag	accctagctt	ctacaaaaaa	ttthaaatt	10200
agctgggcat	gggtggcacat	gcctgtgggtc	ccagctcttc	aggaggccga	ggtaggaggt	10260
tcacttgagc	ctgggagggt	gaggcttcag	tgagcagcga	ttgtgcccact	gcagtcctcag	10320
ctaggcaaca	aagcaagact	gtctcaaaaa	aggaaaaaaa	aaatagaaag	agaaacttht	10380
tttttacatt	agcctthttt	aagttgaaga	atcccatagc	taaaaaagta	cacaaatatt	10440
aatgctgcaa	ctthctagtgat	ttatctcaag	gtgaacacgt	ttaacctagt	gggtggtcaa	10500
gaaatagaac	actggcagca	ctgcaaaagc	atcctatctg	ccctthctta	gttaggacct	10560
cttccctcca	ctgtcattth	aaagattthca	caaacactt	ttggattata	tgtatgtcaa	10620
ttctgtgact	catatatact	cacatagaca	atggagcgtt	gactgaaatga	atthcattatt	10680
ccaaggtgct	aataatgagc	ttcacaccag	cggaactctt	gctgtgtcag	ttgggctcta	10740
agctcagttc	atthctagata	ttcctcacta	aacaaaatct	tgtthttcct	cagttgthtag	10800
taaaaaatag	aaaacagatt	acattctcat	ttactthatta	ctthctgaaatg	taaaagtaaa	10860
tattthctgct	aataccaagt	agccaggggtc	actgacagag	acatgggaga	aagaagattt	10920
cacatctgat	gtthctcagac	atagaagaga	gaggataggt	tcacctatth	ctccccactc	10980
agthttataca	ttgacatctg	tatgtgtgtt	gtthttgttht	gtthttgttht	ttgtthttga	11040
gatgtgggtg	cgctctgtca	cacaggctgg	aatgcaagtg	cgcaatcatg	gctcactgca	11100
gcctcgactt	cctgggtccca	agctatctct	ccacctcagc	cacccaagta	gggtgggacta	11160
caggcatgca	ccaccacacc	tggcaaaatt	ttaatthttat	tttactthttt	aaaattthttg	11220

tagagatggg	gtctccctat	gttgcccaagg	cttgtcccca	aatacctgga	cctcccaaag	11280
tgctgggatt	ataggtgtga	gccaccacac	ccagccatgt	atatgttaa	gcgtttatct	11340
gtatgagtgg	tcagtgtaga	aagggcttca	tggagcctga	ttttgatggc	ttgcaaat	11400
ttatatttgt	gtatgtgtaa	tcggaaggcc	ttcgccgtga	ttatttcttc	aaaggaaccc	11460
tttgtccctc	caggggtgatt	gtacccatgt	tcataggacc	aacattgct	ggttcacata	11520
atgactcttt	ttcttttaaa	acataaagga	catattttta	tggatttttg	aggattaata	11580
gaataaaaaat	ctaaagtcac	attcagattc	aagagaactg	gatcagtttc	tctgtatttg	11640
aacaaaagaa	tactaatctc	taattcataa	tgcattgagg	ctacttcttc	ctcagtctga	11700
aaatatgaat	attccaaaat	ggtactcaag	gcagaggcta	tatatcaaaa	ttaaaattct	11760
gtgatactat	gttttttaggg	aagaagaaaa	ctgtagcatt	agaaatgtag	acgcaaaagg	11820
tcagaacaaa	gtccagtatg	tcaagtcctt	ttataatgcc	atctgaatga	aagacctcac	11880
accatgaaca	gaggtattga	agcagttttt	atgtggaaat	ggtaggcagc	aatatctcag	11940
gagtgacttt	aattataaca	tttaaggttt	tatctaactt	attataatcc	ttagagaact	12000
tctctagctc	tacaagttat	tcttggcaga	atltgtccta	acatagtatt	aataaaaaata	12060
aattttactt	gagtatgata	taaattactc	tttaattaca	tataatttta	aaatgcccaa	12120
aacatctttt	gatcttatga	atltcagtca	gctatgatta	agaagacaac	cataggcaaa	12180
aattttctttc	ttatggaaca	cgttggaaatg	cattctaatac	acttctctaa	gaaaatccct	12240
gtcccccattg	attatagtga	atatgataca	gcaataatlt	agatgcttct	ttcagggggg	12300
tgaggttatg	tattctacag	tctattgatt	ctaagaggca	ctttttctc	ccccaaat	12360
acagttttgt	tttaattatat	acatttcagg	atlttttggg	gatatttttc	tatcactggg	12420
ttctgattta	attccactgt	atlttagataa	catattccgc	atgctttcaa	ttctttgaaa	12480
tttattgaga	cttactttat	ggctcgggac	gtgggtctatc	ttcgtgaata	ttccgtgtgt	12540
atlttaaaaaat	aatgtggact	ctgggcccggg	cgcgggtggct	cacggctgta	atcctagcac	12600
tttgggagtc	cgaggcaggc	aaatcatgag	gtcaggagat	cgagaccatc	ctggctcaca	12660
cggtgaaacc	ccatctctac	taaaaaaata	caaaaactta	gccaggcgtt	gtgggtggcg	12720
cctgtagtcc	cagctactca	ggaggctgag	gcaggagaac	agcgtgaacc	caggaggcag	12780
agctgtcagt	gagccagat	ggcggcactg	cactccagcc	tgggtgacag	agcgagactc	12840
catctcaaaa	aaaaaaagaa	aataataata	ataataatgt	ggactctaaa	atcattcagt	12900
ggggtgttgt	agacacacta	ggttcttttg	attgacagtt	ttgttcctaa	gccttctata	12960
tctttcctac	catggtttga	atgtgtcccc	accaaattca	gggtttgaaa	caggatgacc	13020
aatgtgatgg	taggaaaagg	tagagcctgt	aagaagtgat	gggattaggt	gcccttttaa	13080
aagggcttgc	tggaggaaat	ttgtctctc	ttgcctttcc	gccctctgcc	agttgcggac	13140
acagcattcc	tcccctctag	aggatgcac	cctcaccaga	taccaaatgc	tgggtgcctg	13200
atcttgggct	tcccgttggc	agaactgtga	gaaataaacc	tgggctcttt	ataaattacc	13260
cagtctcagc	tattctgtta	tagcagcatt	gacagactaa	gacatttctt	gacactctgt	13320
tgatttgctt	tgatcaatta	ccgagagagg	aatgttaaaa	atcttaactg	taattgtgga	13380
tttgtcattt	tttccattag	ttctgccacg	ttttgtctc	atgtattttg	aagctttgtt	13440
aataggtgcg	tacacaataa	gatcattgtt	tttctttgat	gagttggccc	tttgattctt	13500
atatgcaatg	ttcctctttg	tccctggtaa	tgtttattct	cttgaagtct	actttatctg	13560
atattttaga	atgtagcctg	cttttcttat	atlttagcatt	tgcattgatat	aactagccca	13620
gtgtaccatc	ttcatacatt	taaactgtgt	ctttaatatt	aaagtacaat	tcttatgaaa	13680
agcgtatact	ttaatcttgt	tttttaaaaa	tccagtctga	tcatctctgt	cttctagatg	13740
agttcagtc	agttccatgt	aatattatta	ttattattat	tttttttttt	tttttttttt	13800
gagacggagt	ctcgcctctg	cggccaggct	ggagtgcagt	ggcgggatct	cggctcactg	13860
caagctccgc	ctcccgggtt	cacgccattc	tctgcctca	gcctcccaag	tagctgggac	13920
tacagggccc	cgccactacg	cccggctaat	ttttgtatt	tttagtagag	acggggtttc	13980
accgttttag	ccgggatggg	ctcgatctcc	tgacctcgtg	atccgcccgc	ctcggcctcc	14040
caaagtgtcg	ggattacagg	cgtgagccac	cgcgcccggc	cccatgtaat	attattactg	14100
gtatgttggg	tttaagtctc	tcatcttggg	aatttaattat	ctatttgtgc	tatctcttct	14160
ttattctttt	ttttctcctt	tcttgcacac	ctttgaataa	atcaagttaa	gtgtttttaa	14220
ttccattttta	tctccttcat	tggttacttt	ctaaagtggg	tactttacca	ctttagaaaa	14280
gtatttggtt	attacaatat	gcattctttga	gtctctaatt	aatgtgagaa	cttgacaatg	14340
ttatacttct	gtttgtcctt	ctgtgctgtt	atltgttatac	atltttacttc	tttatatgtt	14400
ataaactcca	aaatatattg	tcttgttttg	ctgtgaacag	tcaatcgtct	gtttaggaaa	14460
ttaagaaaga	agaaataaaa	gtcttctgct	tactcacata	tttatcatta	ttgatgcttt	14520
ttattctttc	atacaggctc	aagtgtctat	catttccctt	cagcatgaag	aacttctttt	14580
tagcatgtct	tttagcaggg	ctgctgggta	tgaatactct	tagctcttgt	ttacttgaaa	14640
atgtcaattt	cacctttatt	tttaaaagat	ttatttggctg	aatattctgg	accaatcttt	14700
ttttttcttt	tatcactgta	aaggtgcctt	tacattgcct	tctagcttgt	actgtatcta	14760
atgatcatca	gaaacatcat	gcttatcatg	cttatcaatt	gttcccccat	atataaatatg	14820
tcctttcttg	tcctttgcta	ttttgggatt	tttttttctt	ctagcattag	tttttaacag	14880
tttggctgta	atatgcctaa	ccatggtttt	atlttgcctt	atccagcaga	gagatctttg	14940
agattcttgg	atctgtgggt	tgattttttta	aaaatcaaat	ttataaaaaat	tctcaactgt	15000

tccagctgtg	acaggcaaaa	atgtcttcaa	acgttgccaa	atgaccctg	ggggcaaaat	18840
gcaaacagtt	tatctagcag	tgacacatag	ccagccacct	tagaaagggg	attgtcagcg	18900
tacccataag	tgtagaatgg	gaaacaaaat	acttgagtct	tctcagaatg	tctaaacctt	18960
ttgctgtcta	tattcctctt	tttataat	accacaaaca	tatattgctt	attatgccat	19020
ctaataaaa	ggctaacatt	tgtctgtgat	tatactcggg	gttaataagc	tttgtatgaa	19080
ctcactagct	gaatgttgta	tatgtatctg	ccatacctgt	tggattgaca	ttccactgta	19140
aacaggtacc	ttatctttac	cagctccaag	cacaatgtat	ttggatatatc	aggtagctat	19200
tctacatggt	aattgatcac	attgcaccca	aatgaaacat	ggatgtggaa	gtggaaggag	19260
gagctttaaa	acatggaaaa	ttagtttata	caaatctaaa	tgttgtagtg	caccaaattg	19320
atcccttttt	aaaaactttc	agaaatcagc	ttttaaaaaa	aaaaagtaac	taagccatga	19380
tcaacttttc	tttcatcacc	actaagccaa	tatcagaaag	ttgtcaatca	acagctcttt	19440
taaagttgaa	atTTTTctat	tgtatTTctt	atgaagatTT	cagtagtgct	tagaagTTTT	19500
tggctcattt	atcatgTTTT	attcactgta	tgtcattaat	tgttaaagat	gtcagagtca	19560
aaccttaaat	tcaggagaga	tttaaatttt	tctTTTTtcc	tatttaaata	tatgTTTTcta	19620
attacataat	tcagttagaa	aattacaata	tagaaacata	taacttagta	aaagTTTTcca	19680
gttactgtat	acagattata	ttgtatactg	tattatTTTT	aacagttgca	tatttaactt	19740
ataaatgtgg	ataattataa	ttaaacaatc	tgttatcaaa	ggacatacag	attatTTcca	19800
gttccttgct	gcagtgaaata	tccttgtact	tattTTTTtta	cacacttgct	cagataaattt	19860
ttaagtacaa	atccttgagg	tagaattgca	gaatcaaaag	atactctcat	ttgagtgttt	19920
cacatTTTTat	gcaaagtatt	ttgTTTTcctc	cagaaaattc	ctctgtggaa	gaggcttctc	19980
cacattcttt	atcagtttat	tagccagcag	agaaatgatg	aaaagccacc	cTTTTcttg	20040
tagtttcatc	ctcattgcta	tccaagatga	ggtattaaaa	tcacacctaa	gtgggtgctg	20100
ttgtggctga	atataatctt	gaaagtagag	acacttctct	ctgattccca	actgtactct	20160
ctggatggca	cctaaaattt	tattTTTTtca	aactgaaaat	cattttaaag	agttcgaaaa	20220
ggttttattt	tttaaaatga	aatcctatag	aaagaataca	ttttcttaca	gtgggtcatg	20280
gtcaaaagtg	tgaatactctc	tgatcctaga	aagtttcccc	agttacaagg	acaggcgtgc	20340
ccccactcc	atccttaatg	gctcaattct	gtggctttca	agttaatcca	ctcagctcta	20400
cagccttcac	caagaagctc	atgtgctaca	ctttggtgtt	agtgggggca	ttgtcacaca	20460
ggttcagaaa	ataaccattt	aggcatttta	tagaactcat	cacatgttca	gaactaagct	20520
agttgtaaca	ttatgTTTT	catgtgaaaa	aacacaagca	attcactggc	tattttattt	20580
gttgctagct	agctataactt	tctatTTctt	tttccatggg	gtgaaaatct	tcttagaaac	20640
ctcactactg	ggaaaagaga	tgcagagatt	agtcccatct	tctcccctgg	aaatTTacta	20700
tcgccctttt	ggcttcaagg	tccttctctca	aaagcaaaga	attgaacaag	ggaaagttag	20760
gggaagggct	gggggaacag	ggaggtagaa	ggggTTTTcc	ctggcttttt	ctaactcctt	20820
agttccagac	gcttagttgg	tatttcaaca	ttttagaat	aaaacctgct	tttataatta	20880
atgcaaatat	tacttagtga	ttcatccttt	ccaaatgatt	cttggtttct	tttgacattt	20940
cattttttaa	ttgtgaatta	acattgacat	caccatagcg	ttactgttac	ctcagctctt	21000
tacagtgaac	tgtattgcaa	aggctataaa	agttcaaatt	ttaactatca	cccacgtgag	21060
ccttgactg	ctgttaggct	tttgaaactg	tgatcctttg	gcaagaattg	gtgtataaat	21120
catggggagg	atattgaagg	ggaagatcat	gtttaatttg	gcagttgggt	gcctgcaatt	21180
gacagatTTt	cattaagggt	ttagctatag	tagtgatcat	gcatcagttc	taataaagta	21240
ggtttcgttt	gaatTTttaa	aattagagtg	aggactgctt	tatgttaact	gtttacattc	21300
agaagtctgg	aaaaccatcc	acaggTTtaa	atgtatataa	tcagtataat	taacacatca	21360
acagcctcac	ctctgTTTT	gaggaccata	ggctaataat	atTTatgaag	gttcaggaga	21420
tcagctaga	tcgacagaaa	gcttaagggc	aaagatggtt	ttaataTTTT	tcttggaagt	21480
ttgagcttct	gtggatattct	aaggataggg	atTTtgacat	tgattgttct	agctggattt	21540
cagtactgta	tttaagtgta	atgTTTTtac	tagtattctt	cttataactg	aaaactatgc	21600
taatgattct	ttactataga	tataactca	taaatcgtg	taaaaatcca	agtttaccac	21660
aaaatattaa	gacttagggg	atatgTTctt	tgaataggca	tttatttgct	aattaacata	21720
ttctaactctc	aacaaggTTa	tattcTTTTc	aaaaatccat	tccatcaaaa	tctgtcattt	21780
ttacagatga	agaaacaaag	gccacagtga	gtttagTTaa	tatccaagat	cacacagcca	21840
gcatgataga	actcTTaaat	ttcaagcgac	ttaccctctt	tactctatca	ggtcaaatTT	21900
ccctTTTTtta	actgcttgctc	ttaatTgaga	tttgTTtaat	tgtggctgtc	tgtatatctt	21960
caatcaatac	tttcttgTTt	tagacaaatg	ttccctgca	aatctgcatg	aacttcatgt	22020
tctgaaggac	tcagagctgc	cctttccttt	ttgttaaagt	tgtacactgc	tctgcatccc	22080
cctagaatgc	tcatcagctt	tctcactctt	cctcactcac	acagtgtctc	agcaggagag	22140
gatttctttg	aaaatcagat	tctTTTTtgg	agggtcttgg	gcttattgga	gtgttatgtg	22200
atataattcat	tcgggtgagg	gctaaactct	ttgaacaaag	agacctgaca	gtgcatTTgg	22260
gttaaagaac	aaagTTtatt	tctttctctc	atcaccacca	gcatgagcag	cctggatggt	22320
cagagcagat	ctgtctcatg	gcattgTTca	gggatcctca	ttccttccct	ctcatttatc	22380
tgccatcccc	taggctatta	atcatcatgt	ttttggtaga	agccaggtct	tctccatgtc	22440
tgagttttta	tggaggaagc	atgtcaaggg	ccttaagccc	agacctggaa	gtggatgca	22500
agagttctga	cattgcactg	gtgagcattt	ggtcagatgg	ccatctctaa	ctccaacgaa	22560

gtgtagggtg	tacactaggt	aagcagtcac	atctccagct	acaatactaa	ttctatggaa	22620
aaggagacaa	catatcttga	tgggtagctg	acattctcat	ctgcagtcct	aagtactcat	22680
gactgctaga	tagactttat	gaaaaaaaaa	aagaaaaata	accccaggaa	ttaatattta	22740
ccctcagcct	tgtgttttct	taatcttctc	atcttctcatg	tcacatatct	aaaatttgat	22800
ctaaataaat	ttaaataaaa	ttaaccttta	tttgaataat	aataaggaca	tttctcaagg	22860
aagtaaatct	caaatgatat	gtgattttag	atactatctt	tatctgacca	tgtggttcct	22920
tgcttctatc	agggagggcc	tctgggtaat	agaagattgc	tagggcctgc	agtatattaa	22980
tgtttagctg	gagttgatta	aatctgagac	ctatagcctt	gataataagg	acttttattt	23040
ttgtatcttt	attgcacttt	taatattaca	gagtttctgt	accagcttga	caacagcaga	23100
aacatggctt	gcttctgtgg	aacacgctag	agcagcagtc	cccaaccttt	ttggcatcag	23160
ggaccagttt	cgtggaagac	agcgtttcca	cagactgggg	gctgggggtg	atcttctgat	23220
gattcaagca	cattacatat	attgtgcaact	ttatctctat	tattattaac	attgtaatat	23280
gtaattaaat	aattatacaa	ctcaccataa	tgtagaatca	gtaggagacc	tgagctgctt	23340
ttcccacaac	tagacagtc	catctgggag	tgacgggaga	cagtgacca	tctggagaca	23400
gtgacagtg	tcatcaggcg	ttagattctc	ataaggagcg	ggcaatctag	atcccttgca	23460
tgacacagtt	acaataggg	ttatgctcct	atgagaatct	aatgccactg	ctgatctgac	23520
aggacacgga	gctcaggcag	taatgcaagc	gatggggagc	agctgtatat	acagatgaag	23580
cttggtctgg	ttgcctactg	ctcacctctt	tttgtgctgc	gttatccata	gccagggtt	23640
tggggacgcc	tgactagag	gacagagcct	ggtacactat	agcagtcctc	cccttctggt	23700
atgcagagta	ctgatcagtc	ccttttgagc	ttctcaacct	tgtataaac	tttgagacag	23760
ttctgggacc	atcacaaggt	ttatgaaggg	ttagaaaaca	atacacttaa	ggaactaaga	23820
ctgtaaatcg	ttgaagttca	gagggcgata	aaaagaaatg	gcttctaaga	atcccagtat	23880
gtatgatctt	ttatacaaa	cataaagatg	atctgtacca	aactcaggac	actgtggcga	23940
gcttaacacg	agggatttga	atcatacgt	agtggtaatt	cctagattat	gcaatctcct	24000
tgctgttaga	tttagatacc	aaagaggaac	tacatcatgt	cctcctccta	tggtcttcaa	24060
aaaaggatta	tatttggctt	tactgggata	atacagttta	ttcctgcatg	aattccatgg	24120
tgatagaatt	tttaaagttc	attctagttg	tacagttttg	ttttgttttg	ttttaataca	24180
cagcttcaga	atggcagaag	atgatccata	tttgggaag	cctgaacaag	taagtgcac	24240
aatctcactg	ataactttat	ttaaatatat	tcatatttca	aaaatatgca	aaggcaacat	24300
tagtaagtta	gcattaggaa	aattctaaaa	ttagtaaatt	ttttttta	ttcagtttct	24360
ctgtcctttc	atgtgaagtt	ggagaggata	tgtcatgtga	aatgagtaac	ttacaccgc	24420
tttcacacat	attgttgca	aaaaattgta	tatgctacag	gatagctatt	gtattagctt	24480
tctagagcta	ccataacaga	tcaccacaaa	cctgatggct	taaaacaaca	aaatacatta	24540
tttcacagtt	ctgggggcta	gaagtatgaa	atcaaggtgt	tggcagggtt	ggttccttct	24600
ggaggctctc	aggaagaatc	tgttccatgc	ctctccccta	gcttctgggt	ggttgctggg	24660
aatccttggc	ttgtagcttt	atcgctccaa	tctcttctc	cattgtcacg	tgcgcttctt	24720
cccggcgtgt	ctctactgtg	tctctaaacc	taaatctcct	cttttttct	tccaaaggca	24780
tcattggatt	tagggtagac	ccttatccaa	tatgacttca	tcttaatttg	tttatatctg	24840
cgaagaccct	atctccaaat	aaagtccat	tcacaggtac	cggggattag	gagttaaagg	24900
tgtctttttg	ggagggaaaca	cagtttaacc	cactacagcc	ccttgacata	tttattta	24960
gtgtacacat	ggatgtagag	agtggaaatga	cagaccatgg	agattcagaa	aggtgaggg	25020
tgggagggca	gtgggatggg	ggtggatgat	aagaagttac	ttaatgggta	caatgtatgt	25080
tatttgagtg	ttggataccc	taaaaacct	gttttgacta	ctatacaatc	tatgcatgta	25140
acaaaattgc	acttgatccc	catcaattta	taccaaaaaa	aaattttatt	taaaactcat	25200
ctagtaagga	gacagattgt	tgaagtga	agatcttga	actcagaatt	tgaagatcct	25260
tatataagta	ctgactacta	cagatcagct	cctcagactt	gaagaatcac	ttagctccc	25320
taatcctcac	ttttctcatt	tgtaaaatag	aaatgctagc	accacactaa	cagggatgag	25380
tcaaaaaat	tcaatgaatg	tgttttgtaa	gcataaaact	gttcctatca	ttatattagt	25440
agttatgaaa	ggatagcag	gtcctttttt	ctttttctcc	tatatattat	tttgaaaaa	25500
gttggaaaaa	ataaatagaa	atggttggat	aatctaaca	atctacattg	gttcttaaaa	25560
ccgacatctt	cgcttttctc	tttgctctct	ttttcgtgtg	tgtgtgtgtg	tgtatatatg	25620
tatatatgta	tatgtatata	cataatcatt	tggagcaat	tttcagactc	tggagcaatt	25680
ataatggcaa	tattaaatta	tttatgtaat	gattccaaga	agtattttaa	acatggagat	25740
ttgttcattc	atcagctatt	tattgaggt	ttactacgtg	ccagaacatt	ggcttagtgg	25800
ggaaaaaata	agtgatata	acactcta	ttcaggaacc	tactatttta	ataggaagaa	25860
cagagacatt	gttttcatat	ggtgatata	gctgtagtag	tagtctgctg	agagcgggat	25920
agaaatgta	ataagcagca	tcactaggtg	ctaccttgga	ggaagagcag	agttacggag	25980
gactttccga	aggaagtctt	cgtaagctgt	gttttgaaag	atgtagtttg	ctagactaga	26040
aaaggtgaag	gaacactagg	tgccaggata	gctgtgtcac	atttaaattt	tagtggaaat	26100
cattttaa	agtggatttc	tgaaattaca	cgtgcaaaga	atcagccaga	aaaataaaaa	26160
cagaagtgga	atatgtttta	aaggctctgg	tatcatttct	ataaataaaa	tggacatata	26220
tagcatttat	cacttcgggt	gatattctga	ttgattttag	aagaatgact	gcattgcttt	26280
tcacattaag	atgctccttt	ctaattttat	ttttaaaatg	gtgatattag	ataaatctag	26340

gaacattttc	ttttattgca	gcaaagacat	ttggctaatt	gtattatcaa	aaccgtttgt	26400
tttacctttc	gcttttattg	tgctttctct	aacaattaag	ggcgaactaa	ccagcatgag	26460
gattgtgtct	gcttgatttt	aaaccatcct	ttcctgtctg	tacacaggaa	atcctatcaa	26520
caagagatga	ttctttatgc	cacagaagag	taaaatctgc	tgaaaacatt	cattttgaaa	26580
gtttttctta	tgtgggcatc	tttgcgatca	tcaagtaacag	gggtggggca	tattctgaca	26640
tttccatttt	tgaggcaagc	ggtcttgaag	tttttttctt	tcttggcttg	agcttgggtg	26700
tttatatttc	ctaaagtttg	catgtcctca	gtgttttagt	ggagtctgga	atcttgcctc	26760
caccctgacc	taataaacia	tgcaagctgc	agcacaacac	aacttctctc	ttagtctgaa	26820
gtgaagagta	tatctctctc	ctaaggtgag	cccttttgcc	cactcgccag	tcatttagcc	26880
accacaggaa	agagttttcc	tgctaggtta	tcacgtttgc	tctgagactg	ttaaaatcct	26940
gtatgaaatg	aggcccattt	ttgcagaaca	tggtttttca	ttcctgtatt	tccttttcag	27000
caaacaatga	atagcatcag	tgagctttta	atcttataag	cattgaagtg	aagcgcattc	27060
tttgttcctc	agttgaaaat	ttgcatccct	caaatggatc	tgaagtactg	tttattttaa	27120
cgagattttt	cttactctta	attttaactag	gcatacgaag	atcttcagta	ccccagaact	27180
ttcaataaatt	tactactaag	ggcaggagac	aaactgtaat	actggctact	aaaagaaacg	27240
aaaagctagt	tcagcacact	tactagtctc	tcataaaaag	taaaatatgg	ctggtttcca	27300
tgctgtccac	agacatttca	aacatataac	ttcttttagc	taaaataaat	agcaagctca	27360
gaaatacagt	tttaaagtcc	taaatgagcc	agcggttaca	atgttttttg	ataagtaatg	27420
aatagtaatt	tattaagata	aaatgtactt	tcttcaaaat	attctgcatg	cccactctgt	27480
tgctgcctta	acacattacc	acatacttgg	ggcttaaaac	aacacaaatt	tatacttctg	27540
agtcaggagc	tcagaaatct	agaatcaagg	tgttggcagg	gctgctttcc	ttcttgcagc	27600
tctcatctct	ttgccttttg	agcttctagt	ggctgcctgc	tttccctgtg	caccctctca	27660
tcactccagc	ctcttgcttc	ctttgtcata	cttccacta	ttcagtgatg	tttccctgaa	27720
ccctctcatc	aggcccacct	ggacaattca	agacactctc	ttcatcttat	tatcattacc	27780
ttaatgacat	acgtaaattt	ccttttgtca	tataaggtag	cactcacagt	ttctgaggat	27840
taggatgagc	acatgtttag	ggggtcgtta	ttcagcttaa	cacaccact	agattccagg	27900
tattttgtgt	tatgctagga	aactgaaggt	aaaagaaatg	agtgagctca	gtgcttagtt	27960
gtctactcct	tgtactgtca	gttatatttt	cagttattct	gtaaatagtc	ccagagggtg	28020
tctctagcat	tctttcaggc	cttgacattg	gatagctaga	tgaggggtat	atcttaccacc	28080
atagaggaaa	tactgatttc	taggattata	ttattttggt	tatacttcta	agagagtaca	28140
agcttcaaat	cattcattca	acaactattt	aagtatctgt	tctgtgataa	gcatgtactt	28200
ggccctgaag	atataccagt	aagcaagcta	gaccaggctc	ctgcctctgg	ggactttata	28260
gccaagttat	gcttctcaaa	tccttttggt	acgtaaacgt	tgtccaacc	tatgtaaagt	28320
tttgtagaca	tgagaactac	ctaggtctca	tgaagatctt	ttaaaaccct	gattttaaatt	28380
atcttcagat	ttttgttttt	ggcttttagt	tcattcctat	tattacattt	taggtgtccc	28440
aacttcaaat	ttttcatata	atataggaaa	aataatgatt	gaaacattta	aatgttcttc	28500
tttacagatg	tttcatttgg	atccttcttt	gactcataca	atatttaatc	cagaagtatt	28560
tcaaccacag	atggcactgc	caacaggtaa	gaaaactcat	ccctgttacc	ctgttgttct	28620
gctttcagtc	ttagtaaaat	gcaggatttg	ttaatagtct	gtcctagaaa	ctcagttgtg	28680
tacctagaaa	ggaaatggtg	atltgtttta	aaaaccaatc	ttttaacata	ctttcttgaa	28740
atataatttg	acaaaaatat	ttcatctcaa	ttacccttg	tatggtttac	tgcatttcat	28800
atctgctagg	actactcaga	aggaatttct	ttagtcaaca	taaggatttt	ctttattatc	28860
tctgtatttc	ttttaagtcc	tttctcccag	attcacacga	ggcagtctcc	actcttcatt	28920
tctgatttcaa	acattttaaga	gggctgtgtg	tgtactacca	gtgtgccagt	cactggggaa	28980
tcaaagtgtg	cagaaatcat	aaaaatcatc	tcattagaaa	aatcatcttt	ataaaagctt	29040
ataactttgc	actctgacaa	gttggataaa	actcataatc	cttcttcta	ccatgactgt	29100
attaattgtg	ccgattggca	actgtttaat	ttcgtaagag	taataaaaaa	aaaactctct	29160
ttcttaaaaa	aagtgattta	tttgtatgta	agcttgggtg	gatggctctt	tttatgttct	29220
gtttctctcc	tcacttcacc	cgtcaccagt	gggacttaac	agatgttcaa	aagcagtggt	29280
agtgaattat	ggaagttatg	tgtaaaacag	agtttggtaa	tcgctgaagg	aggcatcagc	29340
tcttttattt	accagggact	tgcttgtctt	cattggggga	ctttatccca	tttgtattat	29400
tctcatttaa	aattatcatg	gttactacag	tacttacttt	tcttttgttt	tagatcagaa	29460
aactttttct	gcatttata	ctttagtatt	tctaggagtt	catgggagg	aaaaagtag	29520
atctactata	ctttcacctt	cactagtaaa	ggtgtatttc	agaggttttt	ctgtctttac	29580
ccctacaaaa	cattattttt	aggctgccat	gtctgagatc	ttgtgaagtg	ctgtccaatt	29640
tgagctctag	gtcagcttcc	tgtgaacaag	taaatgtgtt	ggtagtgtgt	gtgtttcttg	29700
ggaacttttt	aattctggag	ttcaaagtat	ttttcttagt	attaatgat	tactgaaaat	29760
ataagaactt	ggttctgtcc	acaggaaata	cacacatttt	cacttaatgt	cttgtgaata	29820
caaaacagta	tcttgaggca	gacgttttct	taattttatt	ccttcggatt	tatgggcatg	29880
aaaataagat	tatcaagata	accatctcag	taaatattct	gtggtcacag	ctttatgttg	29940
tagaaattat	tttgccataa	tattagaaaa	actattcaaa	ttacacctaa	aaatctaatt	30000
tgtagttgtg	tgttacacca	tcattttttac	ctgtatgttt	ttccctcttc	attgcagtg	30060
catagtacaa	tttttatagt	ccaagatata	taggatgttg	tattcaaatt	tttaaagagg	30120

tagagaggtt	gattatctaa	accaatatta	acttgtaact	ctaaaatgga	ttattttagt	30180
cttctagatt	ttttgaaatc	taaaaccttt	agtagatcta	gtacttggtg	aagactatgg	30240
gatgcgacat	aactccttagg	tctaaagtta	aatttctctg	cacagtggaa	tgctccttttc	30300
atggcacaga	aatgtggcca	aaagaatggt	ggccttaaaa	caacaaatac	atgcatatca	30360
aatctaantt	tctagttgat	ttaactttta	tgtggtgcct	gaaagaggaa	aaatggctct	30420
attttacatg	aattttcaca	tatttaaagg	aaattaaatc	ctacaggaaa	aataatagca	30480
aatttgcagt	tgtttttagc	agagttaata	aaaagtgaga	gacttgaagt	ttaatgtaaa	30540
catgcttcca	actcctctgt	atttttcatg	acatccaaat	attgctctgt	tagaggactg	30600
tcttgatag	ttctttcacc	attttaacag	ggaatgtttt	tataagtgtt	acattgtcat	30660
acaggctgta	tcttagtgtg	aaaatatttc	tatttcta	caattttatt	tccatatcca	30720
aaattaaatt	ctagccattt	ggtgggggaa	tttttaaatt	atgattatgt	ttctaaaagt	30780
aatttaaaat	gtccaggggt	gaatttcata	cagacaaaag	atggtaattt	aatacattga	30840
ccagtgactc	cccctttttt	ttcttgtgta	tgcttcattt	cagatgcatt	catttttcaa	30900
ctcgcttcc	tgtaaatttc	ttgaataata	acaggaagta	attataccct	tgttttctcc	30960
agttctctag	ccttatcctg	atttatcata	atattgaaaa	gataaaaata	aattctctgg	31020
ccgggtgagg	tggtctacgc	ctgtaatccc	agcactttgg	gaggccaagg	caggtagatc	31080
acgagctcag	gagttcaaga	ccagcctggc	caagatgggtg	aaaccccgtc	tctactaaaa	31140
aaatacaaaa	attagctggg	catggtggta	ggcgctgta	attccagctc	ctctggaggc	31200
tgaggcagag	aattgcttga	accaggaag	cagagattgt	ggtgagccga	gattgtgcca	31260
tggcactcca	gcctgggtga	cagagtgaga	ctctgtctca	aaaaaaaaata	aaaaaaaaattt	31320
tgagaaaatt	ctcttttgtg	ttatagttta	tttttaattt	caacctgaag	gtttatctcc	31380
ttacaaaatt	atttaaaata	agaggtcctt	agcttctttc	tgagagaaaa	tgaagattaa	31440
aatggacata	caagcattct	cctaaaatat	tttttagcacc	aaacatctta	atttacattc	31500
aaataaatga	gaaccaccat	atgcctttat	ttattgcaaa	gctatggatt	attgtactat	31560
tgacataaaa	atcagctggg	aagcttaagg	actttttcat	attgaacagt	ttgtacttat	31620
gttgtcagag	attctgattt	tcctttgaat	tttcaagtca	gataccatta	gggtatggat	31680
taagcttcta	gttttctttg	cgtttttaca	ataactaatt	tgcatgtacc	tatcttcaat	31740
taaacttatt	tcagtatatt	ataaaatgcc	tgagatgttt	tagaacacag	tttatatgat	31800
agcacaatat	tcaaaattgc	ttataaacat	caaaagttat	ggattaatat	gaaaatttta	31860
ccatgtctga	tagaccagat	tacattggga	gtgtcgggga	ggaaagggga	aacaaactaa	31920
ccagttaagg	aatgaaggca	gtactttccc	ttcaagtaaa	gacgggaaca	gaaaacctag	31980
tgtaaggaaa	aagagatagc	ctgagatcat	tatctgtcta	tcagacgtat	acatacaggt	32040
tgctagatca	gtatctttta	atttcacatt	aagcacactc	tctttgagga	aggaaagtca	32100
gtgtctaatt	atgtgaaggc	caaagaaaat	gtcatagtgc	ccagaagtgg	ttgctgcttt	32160
taattggtat	ttgtcatttt	aaaatgcttt	gtaggagac	aagattatga	aggctgttga	32220
catcaattct	tgccggccat	atgcctttta	ttgggttagg	aatgtgcca	tcacctttca	32280
acaaacattt	acttattgtg	gttcgctaaa	ctcgtaaaac	tattgttaa	ataagggtta	32340
atttaatatt	tcagacaagg	aagagaaatt	atatocttgt	ggaattttta	ccaaaaattg	32400
atttgaaatt	tctacataaa	aacataattt	cagtttttta	cttgctttac	gttttataacc	32460
aaatttgaga	agcctcacag	tttcttttgg	tttctgtttg	ttgttttgt	tttttagcaga	32520
tggcccatac	cttcaaatat	tagagcaacc	taaacaggta	agattaaagg	ggtgggactt	32580
taaagttag	attccagtgt	ctaataattga	gatcataagc	actgaagaat	agtaaagtag	32640
ttctatgaag	gaagttagtt	atctgaaaga	tcaacaacct	gacaaattat	gtaacagctt	32700
tattcattca	ctttacattt	ctcttactca	ttgttcacac	tgtcctgagc	ctcagtatgt	32760
agttctgtaa	aactgcagtt	aattacagta	ttagaattac	agtttaattac	agtattctgc	32820
tgtctctacc	agcttaactt	accagccact	cccaggaaag	gcagaggtga	tttccattca	32880
ttttcattta	taaggaaata	cgatgcata	cagttcacat	gcactgagcg	atatccatct	32940
attatccttg	cacatgtagt	acctcttagc	cttctcctt	cctttggtag	ccccagcctt	33000
ttctgtgctg	cctttggaac	atgtaaccta	acatactgaa	agtaccagtg	ggaagtaaaa	33060
tgttagaatg	aactattgaa	ttctcttccc	tctgggtgca	gcctctttgg	agtcaggaga	33120
ggaacatttt	ttcaggtgct	tccccttacc	actagagtct	gtagagaata	gctcagaact	33180
gaaatggcct	cctcactgta	tccaactctg	tggatattta	taggaaattg	gatgggacca	33240
atgctgtgaa	agagaaagaa	aggcaatctt	taatgtctgc	ctataggagg	tttcagttat	33300
tagggaatgg	aaataatggt	gtagttcccc	acagaatgag	gacagtcagt	aaatctttgg	33360
atggataaac	taatcacatt	tgtgtgtgac	tgaggatatg	gatacctgtc	ctcttgcagc	33420
tgtattacc	aatacatttt	ctaagtattc	ttttcattag	ctcaggtgag	tgaaacactt	33480
ttgcattttg	taacatttta	cacatgctaa	ctaggtcaca	agcttaata	aagcatccac	33540
tgcgttgtgg	tttccagaat	cgtgacatta	tatatgtgtt	atatttggtc	agcatttgat	33600
ataaatgtct	taatgattgc	tgaacaggct	atccttataa	ggttgaaatt	agatgaaagt	33660
ttttgctgtg	ggggcaagaa	tgccacatga	aactttgggg	catggttcta	gttcttgcag	33720
gtgtcacatc	ctgactcctc	aggttgccag	taaacctcca	ttgctctacc	tccatgttca	33780
actcttttaa	gcagttattt	ctcagagaag	gtcatcaatt	cccagtgaaa	ttttatccct	33840
taaagttctg	tgggctctgg	catcctggaa	aatttcccag	cttttaagat	ctaggtagtc	33900

tatgaaacag	aaatcaactg	aaatTTgtct	gcatatgcc	aagtattttt	tccaatatca	33960
ttttcataag	catagcacta	caataagaat	ttttaaatgt	aattccttat	tatggatcca	34020
acagttataa	ggaaaaattg	gcatttatga	tttacctgaa	gggttaatgt	agttccaaaa	34080
ttcaaaatTT	aattcatata	aaagcttatg	tgagtaaaac	aatgtgttta	ccaaagtgat	34140
gctatTTTga	tatctgaatt	cagtgaaagt	aagaaggTtg	tattcaagtc	agactttctg	34200
actgaatgga	tgtagccttg	cctttgaggt	tgatgactca	ttttaagcaa	atggagttac	34260
tgagatgagt	gaatgtggat	taaaggcaaa	atTTTgatct	cagaaatTTa	gaatcagaaa	34320
tgcacccaga	caatgcattt	gacgacatct	tcttgaaaac	agTtgtaa	tttcatcctc	34380
agattaaaaa	cttctgagga	tttagatact	cgtatgtaac	catgaaaaat	atctattaag	34440
tattgtctat	ttgacaccac	tcccaataag	atataaacac	atacgtgtct	atatttttcc	34500
aactgtccca	aaggaatTTT	gtgattaaag	ataatgaatt	gtgtgtgtgt	ggTTTTgggg	34560
TTTTTTTTgt	TTTTTTTTT	taagttagaa	aaagattcct	TTTTctTtg	gacctcttag	34620
ccacagattt	tccccagctc	tgacggagat	gagtcatagc	atagactact	aatTTTTtaga	34680
acatccagtt	ctgttgcata	ttaatcagtg	ttaattaact	aatactgttc	aaaaactcaa	34740
gTtgTgtTTa	aatttagcagt	caagtaa	tctattctta	tggttagcta	attctgcagg	34800
ctattataca	tgtgtTgtTt	TTTTcatggT	tttagaa	tcattta	atttaaaaa	34860
ccaacagTgt	Ttgcttacia	aaggcatagg	gctgaa	taaatt	ttaaat	34920
attgtgtgag	aatcaaaaca	aaggaattac	ctctgaa	tcactc	aggcttccct	34980
tgtgtTTaga	tctggaatct	cccaaggaat	tgtTTtaggt	ctcactgtga	tgagttgatc	35040
ataaactTTa	gacattTgtg	tgcat	aaatTTcca	gaccgggaa	tttacttttag	35100
gccttactta	tctggta	gtgtTtaggg	actgatctt	ggaaatcagg	aagTTTTTgg	35160
ataatatagg	aacagttcca	gatgcttccc	agagatttaa	atcagttcaa	ggcacctgga	35220
ctgctcagag	actgcaagac	cctactTggc	ataatgaa	gtagtatagt	ctaagtagtg	35280
catacgtTTt	acattTgttc	atgagctcaa	agctgtcaa	atctgcatgt	ttgctggggT	35340
tccacaatTT	aatgagtaag	ggagtgaacc	cccaccagca	gctagtgggt	gtgatgagct	35400
gatgggcaga	tgatctagtg	ctgtatagtc	agagtTggTc	ccacaataga	aacaaaaggt	35460
gagaatgttc	cttaaaaaat	cttaacgtat	tttctTTTca	ccaaaagtg	aatctgtaaa	35520
aagaaaaatca	tctgtTtaag	cgactatgtg	gttataa	actaacacta	ccacaaatTg	35580
attgacatca	ttataaagTt	gaatcaggaa	atacagcgaa	acctccctta	atatgatgat	35640
gaggtcataa	ttatcctTgt	tttattctt	gtataca	atgaataagT	taactTTtata	35700
aatcataaaaa	agttaga	ggagttagacc	ttaaagatgg	tctggTataa	tcttccctt	35760
tgtacaaatg	aaaaaatatg	acacttctta	ggTgtTtatc	agccacagT	agTttatata	35820
gtgaaggctt	ccagctaa	tcattaa	actatatct	taaaatttct	gggttagata	35880
gtattTaa	gaactaccta	gtTttgga	cattctggT	ggTtaatt	caactctgag	35940
cttgaccata	ttaaatca	taaaaacaaa	aatcttatcc	tctgaaatgc	tgagagaagc	36000
ttaacagatg	cagggTctag	cacagggTgt	gttctaca	gctgaaacag	tatatctaaa	36060
taaacatgtc	tgtagTccct	gctgaaccag	ctgtaatcag	agtagataaa	ggaatgtctt	36120
taagtaagag	tcaaggaagc	ataactTTTa	ttaatatggT	acagTtcaga	gcttggcagc	36180
agcaattTaa	gacaaggaag	ctctgactag	aacaagccgt	aacatgtTaa	gtctaaagcc	36240
taaactcttc	agcagattac	tctccacaca	tgcatagcat	gagaggtTcc	atgggcttag	36300
gtacctggct	TTTTagccat	atcttagTgt	acaaatataca	attaatacca	TTTTctgtag	36360
taagattacg	ggaaaagTga	TtctTgtTTa	cggagccctc	tttccacagTt	tcatgtTTTT	36420
cttctctcat	ttagtagaca	taagattTaa	aaattTgtat	gtacctTgt	tgccgtaatt	36480
TTtaataagT	atTTctcaaa	cttaattggc	TTaacgtTca	cctTtgCaga	gaggattTcg	36540
TTTccgtTat	gtatgtgaag	gccccctca	Tggtggacta	cctggTgcct	ctagtGaaaa	36600
gaacaagaag	tcttaccctc	aggtcaagT	aagTttgtgg	tagctctcct	tctattTgaa	36660
Ttctggaat	TTTgattTcc	tacgattTcc	aaggaattgc	TTTaaatgag	tacgggtTgc	36720
cttgcTcct	aagctgaagT	gttcacatga	Ttattaaa	TTTTaaatag	aaattTgtct	36780
cctagcaata	gaagtGacag	atactaaa	TTTgtTaa	TTTcaatt	gtagaaatgt	36840
cttcagcatt	agctaa	cttactatt	cttgatcatc	TtaaataTTT	TTaaaaattg	36900
gatactTcct	gaaactTTtag	taagtctTtg	aaagaaatgg	TtgattTtga	ctctTtgag	36960
atTTtagTgaa	aaaccaaa	agtgactgag	Tgtatggatt	atatagtata	TtattTaa	37020
TtatgaatTT	ggatccagac	TTTgtTatta	gctgtgtagc	TTTgaaatag	TTTaaaccaat	37080
actTcta	Ttcagtctct	taatgtataa	aatacaaaa	TattaatagT	atatactTca	37140
taaggtcctt	tagagattaa	atgagaaa	gtgtacatgt	Tccatagaga	gcctgaaagT	37200
accctagggc	ctTggcctga	gcagatgtgt	ggccctctTg	gaatgaa	ctacgtgaca	37260
TgctggTggT	gtattTggTc	atacctTTTa	ccatgtTcag	gctgtTtgt	TattTtagaaa	37320
TatTTTctt	taagTtaata	TgagactTTT	aattTcataa	Tatgctatgt	Ttcatagact	37380
gactgatgat	aaacatagac	TggTaatcat	TTTgcagata	aacgcagTca	acaattgtaa	37440
TTtagTTTT	TataaaagTt	attatTTtagT	cagTaatTca	aggctTggac	aaaatagTtc	37500
Tcactatgtg	Tgtgtgcccc	TcagggTgta	acatactTTT	ggactcagTc	TTTTattTg	37560
TTTgtTTTTg	taagtagatg	aagctcagTa	gagcaggccc	TcagcaaagT	TgtgatgTaa	37620
agaaatctgg	ccgggctcgt	Tgactcatgt	ctgTaatccc	agcactTtg	gaggccgag	37680

ctagcagatc	acaaggtcag	gagttcgaga	ccagcctggc	caatatggtg	aaaccccatc	37740
tctactaaaa	atacaaaaat	tagctgggtg	tggtgggtgta	cacctgtagt	cccagctagt	37800
caggaggctg	aggcacaaga	atcgcttgaa	cctgggaagc	ggaggttgca	gtgagccgag	37860
actgtgccac	tggactccat	cctggacaac	agagcgagac	tctgtctcaa	aaaaaaaaaa	37920
aaaaaaaaaag	aaagaaatca	gtctttgggt	ttgccagcct	tgcatTTTTgt	ttcttccttt	37980
tcctcttatac	catcttctag	gcccaggcct	gttaaatttc	ttatccttat	tcccaaacaa	38040
aagacaaaaat	gttgtgacgt	cgttctttac	ctttcaagtg	aaactcacc	attatTTtagt	38100
atgggtacta	ctagtcatag	ttgcatttta	agtctcttag	ctccaattgt	ggaatgaaag	38160
atgTTTTttc	tattaaaggt	aattaggcgg	gtaaatatga	tggcttaagt	ccacagaagc	38220
agaccacggt	cttatggcct	cacatccttt	agaaccttga	tgaggaatga	ggagacgcaa	38280
taaagaacta	atTTgcactt	atTaaacacc	aaagacttgc	caagtggttt	gtataacatt	38340
atctctTTta	atctcttaga	aatctcagta	ggtaaaaagt	gcaatgcctg	tgaacccaaa	38400
cagactcaga	gaatggaatt	ataataactg	gcctttctca	caagactagt	ggctctatat	38460
cctgcagcag	gctattgctc	accgaacctc	tcagatataa	tgtgtgcatt	tggggTactg	38520
ggggcagggg	gataagggac	aaattatggg	cagacaatgg	tgtaaaaagg	catggtgaat	38580
gataactctt	gaaaacaagg	gagagagagg	ctcactggtc	aatgggtact	caggtattgg	38640
ggaagccagg	cccagcactt	acctTTTTaa	cacatgtgtc	tgtgtgtcac	atgtataaat	38700
attgtgcctt	tatgtatgtg	tatattttgtg	agaaggggat	tgaagacac	atgttatcag	38760
cattgacact	gactataatg	actgaagaat	taactTTaag	cgaaaaactg	ggagtTTTTt	38820
ctgactggct	tggcacaana	aatataaatt	atggTatttt	gTTTacttct	attgctctag	38880
tattttgtga	ctaagtaaca	attcttgata	ctaacaana	catggcatta	actttcttat	38940
aaatttattg	gctaagaaaa	aactttatac	atccatttat	tcccagTctt	catacatctt	39000
tctcatgtag	aggTTTcatc	tactcaaaaa	catattgctg	cctcagTcac	aaaataattt	39060
acaaatgaaa	caacttagtg	ggcattagat	gTtcttTtag	aatgaaagTt	tctatatcaa	39120
ggagTtttagt	acttactggg	aaatatagat	atgTaaacga	ctaataataa	agcaggtTca	39180
actacagTca	cattattTca	ccaaatcatt	tattTTTTat	tcactaattc	agtatccatt	39240
tataagcatt	taatcaactt	gtaagaggag	gaggaaacta	gaggttagag	aatatgacta	39300
tacaagctgt	cattgttccc	ttagctTgtc	attgtTcact	gaaaattgaa	atggtTctgc	39360
tgttcctaac	agttatagga	agTaatTTta	tttatccaag	aaattcttaa	ttggaaggat	39420
gggtaggaga	gaaagaaaga	gacaacggcc	aggTattTTt	TTTTccaga	gctctTctcc	39480
aaatatccct	TTtaatagTt	atTTctgctc	aggatgacct	tTaaagTttac	aaaggaattt	39540
Taaatccctt	ttccctctaa	TgtTTaagca	gaggaaaaaa	ttgtTctcca	TgcatctTtc	39600
Taatcaggaa	gacctTTaaa	attgtgcatg	tctTTTctgt	ggTactTTac	Taagcacctg	39660
ctcggcgaga	gactgtAagg	gaaacagTgg	gatagataca	tctaaagTtt	ctcaaactTg	39720
gcattattga	cattTggggc	ttgaaaattc	TgtgtTgtgg	gaggctgtct	gacacgttat	39780
aaaatattta	gcagcctccc	TgacctTgac	tcactagatg	ctaataggat	tctataaatt	39840
gtgacatcca	aaaagTctcc	acattgacaa	atgtcccctg	gggggcaaaa	tcaccctctc	39900
ttgagaacca	ctgatgtgga	Tgcaacaaag	aatcaacctt	aacctTacc	atTTgcatac	39960
TTTTctacta	TaaagTtTgtc	Tcgcatagat	Tacgtagaat	TgtccaagTg	TattattTTta	40020
Taaacgtgcc	TTtctTggTt	attagTtagat	atTTcttatt	tTcaagatgg	TgatcatggT	40080
gtctgtataa	TTtctgtTtag	aatatcagag	TtagTgtacc	Tggatactaa	ggagaaagat	40140
agaaaagata	aaatatgtat	ctTcaacatt	Ttgtattctg	Tgatgaccct	aaaagctaat	40200
gtgggagTtc	Tattgactgt	Tataaactat	Tacagaagaa	aaagTgaaag	TggagagTta	40260
ggtccactgt	gtgtgaacaa	Tgggagggtc	Tatggaatga	TgctTtcagg	Taggcagagg	40320
cctcgtggag	ggTggcccca	cactcacccc	cagaatccag	aagccattcc	cacaggaact	40380
Tcagagggag	agcattTaca	TTTcacaggaa	agaaatgata	ctTctgagcc	TacattTgcc	40440
acataTtcat	TaagTgcatt	TgtTcaggca	TTcacagTaaa	atgccatggg	ctgtgctTTt	40500
cctcagctac	agcctctctc	ctTccaacct	cacacctgtg	ctTcctgtca	TgcctTtTgtg	40560
agagcgccac	cactctgcgg	Tgcctggaga	ggaaacctgga	aacgctgata	gtTcagTgca	40620
Tactcggtca	Tatggagaca	gcaggaaaga	gtcaggggcc	aaactgaaag	atTTggggcc	40680
TggctgtggT	TtgCaggctg	Tagacaccaa	actatactTt	atagaacatg	Tgaaaatata	40740
gcctgtatgg	gtTactctct	Tactgattgt	ctagattTga	TgcctTacat	Taaatcattt	40800
Taaaaccaac	TctagaagTc	Tactcaaate	ctgcattTtc	Tactggaata	gtgtcccattg	40860
cataaaacc	TgtTtcgcat	aggTgtaggc	TagctTcacag	accctctTtac	catgtTgaga	40920
TtattTctag	aactcaggct	actgaacct	ctggTgctct	gcctgtgtct	Ttcacatagc	40980
Taagaagaaa	atTTccattt	agctTtctga	TatctTgctg	TgcaagTctt	catgctctTt	41040
TTTTaaaaaa	aatTTtaatt	ataaattctt	Tcaagcatat	agaaagTtta	aaaattgaca	41100
Taacagacac	Tatgtactac	aacacaaatt	TaataggTat	Tagcatctta	cctTattTgc	41160
TTTTgatagc	Tctctctctc	Tctctctgtc	ctctctctct	ctcaaataaa	atagTtacag	41220
ctaaaacccc	actTatccat	cactTtTgtc	TcctTccttc	TcttaggTaa	gctgctactc	41280
TgaactTtca	ctcccaaga	TgtTTTTata	TTTTtactac	ataagaatgc	atctataaat	41340
actggcattt	TcaagaaagT	TaattTTTtac	TaactTcaac	ccaaattTgc	cattgtatag	41400
gatggctcct	TTTcagggca	aacataggTt	caaactggac	gccattgaaag	attaactggT	41460

actcactttg	atcctattga	ttcctctttg	ctgtctagat	aaaaatgtat	ttgtcacaat	41520
gtagtttgta	ctaactctta	tagcaaaaaa	taatattcag	agaaaaatct	aggggaagta	41580
agtatgcaga	ctaactctta	tatctttgtcc	tttcataaga	aaaatttccc	atcattaaac	41640
atthtaataat	ctattatact	gcctataaaa	tttcccttta	aagttttttc	catttctaatt	41700
tcatcacgga	gctcctaata	ggagaggctg	gcagaaaagc	acaggaacct	tctcttaggc	41760
caagcttgtc	cctgcctgct	tttgactcag	caaggagtgc	caggggaaggc	tcacttccct	41820
atthttcccg	aaagccacgc	gtgaagtttt	aaaaatcaaa	ctgtgttccc	tttcacagag	41880
gtgggtgaca	agagaagcag	ccccatggga	cttcagaaac	tctcaccaat	cctcctctag	41940
agtgaccaga	aagtaccctt	tcctatccta	actaatgtga	cacgtccttc	tgtgtggctc	42000
actctatgca	aaaccagaaa	ttgacaagaa	tgcatttgat	tgtaaagtac	aaatagctta	42060
ccagttagta	ttcttagttt	ctctttagtt	ataaatatca	aatgcaaggg	acttgaaacc	42120
cagctgatag	aagtgtaaact	atthtttaatc	aaacatthttc	tgaaagctgg	ttctcacata	42180
tgtttgtcttt	cctgagtgtt	ttatgtttgag	tggagacgt	gttgaaatgt	ttagggtcaac	42240
aacagctttt	ttgtttgtccc	cttccaactac	tgatttataaa	aaaaaaaaaa	aaggctccac	42300
tcttcgtgcc	tttccctaaa	aatcctaaat	gttaagtttc	tgtcagaggtc	gaatagagac	42360
tacccgatct	gctgtggcat	ttgaggatat	cacatatacct	tgcataatct	ccctttcctt	42420
tgtatagact	tgtctgattc	acgtggtttg	gatctatttg	gagtactaat	ttaaaataat	42480
ttaacctgac	tcaattactt	aaaacaacag	gggagaaaat	caccaataat	cagctatgtg	42540
tgcgtataga	acctagtcca	tatcatttat	taggatttcc	attgaacccc	taagctgttc	42600
actgcgcaag	tatttaatta	gggaaaataa	ccatacccct	atgtacatta	tactgtgtgt	42660
tttgtaaacc	atgagaaaag	ctgcttattg	aacagaaggg	ctttgtaacc	tggggctctat	42720
ggatccctgt	tgggtgthttc	agacgctthtt	tagattccta	aattttatatg	cagacttaca	42780
catgtatgta	tgtgcatttt	ttcttggggag	atgagtataa	ctthtttatca	tattttcaaa	42840
gggaaagatt	taacatgggt	aagaatcatg	ctatagcttg	tatcacttta	gctthtttgat	42900
agcagctatc	thtttaaatg	atctatgtaa	tattthtttaa	gattthtttct	thttthtattc	42960
ttgcattthtt	aatcaattthtt	aatgaagtg	aatgctthta	tgttgctcaa	cacatagccc	43020
agaaagcctc	ccttcagthtt	tccagtaggt	ggaaaaaaga	tgaaactgaa	ttgatggcca	43080
aaagatthga	atgggcttca	ctgctthttc	thttctgtctc	ttccatgcat	ttgcagatta	43140
agcatgaagc	tcaccattag	tgattgaagc	caaaagagag	aaggcaattc	attgaacaaa	43200
tattgattga	gcactgtgtg	tcaggtactg	ctctagacaa	gcagacaaaa	ctccctccca	43260
tatgtaacca	caattgagac	ttataggtaa	thtttgthttgc	aagtagttca	gaagthtttgt	43320
atthttgtcct	aaaacaaaat	attactthttgt	aaaatathttt	thtaaatagc	cctctaaatc	43380
cgctgtatat	attcaaaagtc	actattataa	agtggagaaa	gctactcatt	agagaaaacc	43440
tatcacacag	ataatagctg	ggaagcttaa	cccttagaaa	ttattaggag	agatatacac	43500
tccttgaatt	taagaactgt	ctgaathttta	aathtttgthtt	tgtcagttct	ggcttggtga	43560
ccttccctcta	ttggccattc	ccathtttct	gccctccact	cttccctgac	acatgattat	43620
ttctgggacc	actgthtcaat	ccgaaacaaa	tctctggtgg	cttctthttaa	accagtggt	43680
ctcagctctga	aggtatagtg	gggcaactct	cggcattcca	ttctggagtc	ttgacctcat	43740
aaagtcacat	attggcaatt	cgccttgata	aggtcaagtg	aacacacaga	agcactaaga	43800
tccccacatg	tgttccactg	cctcctccac	agacaagttg	thtttcaacc	catctgcagg	43860
tccagaggtg	aagctggagg	ctaccctgca	gtctcagttc	thttctccca	ccctccagat	43920
ggattccaaa	taagaagcct	ccagactacc	ttcacctccc	tggggctctca	tggacatggg	43980
ctggaaagtg	cttgcagact	ttcacagaca	atgctthtttg	cccttaggtc	cccttctacc	44040
caacagaatg	attataataa	tggcttgatg	tgcttactta	catcatctca	thtaatcatc	44100
acagtaatcc	actgactgcag	gttctgtgat	ccgcattthta	taaatgagga	aattgaagcc	44160
tagagaaatt	aagaagctta	acttgggtct	cacaggtthtt	tagagatgga	gccaagatt	44220
tcagttcatg	ccatatgggt	taagggctcg	cactcttaac	cattgtggaa	taccattcat	44280
tatcataatg	thtaaggatct	gthttctactt	tgcaggaatc	thtttaaatct	atggttcaca	44340
atcatgggtg	ggcttcagaa	tcgtccaaaa	atgthttcaac	cacagagacg	cctgggaacc	44400
actgcacaat	tgtctaaatca	cagtgcataca	tctagccaat	cttggattct	acaataattc	44460
tatgacagtt	tctaaagaata	catgccatta	tataatggca	acatattaca	acagataatt	44520
gaatagatat	tcaatgtata	ccgtggaata	gaatattatg	ccactgtgtt	thaaaaagat	44580
aattaagagg	atacggcaca	acgtggaaaa	ctgcttataa	cataatatta	aggataaacc	44640
tcagctgggc	atagtggtct	acgcctataa	tcccaacact	thttgggaggc	caaggcagga	44700
ggattgcttg	agcccaggat	thttgaggcca	gcattgggcaa	catagtgaga	ccctgtctct	44760
ataaaaaaaaa	thttthtaag	aaaaaaaaaca	ggattthcaaa	thatttgctaa	tatttgtagt	44820
gattacaaat	attagctthct	thtttataaag	cctgggtgga	agcatataga	tgtatctthta	44880
gctthtattta	ttcatccatg	actthaaagaa	gatttggttaa	cacctgactc	caccttgagt	44940
agcagaacat	tggactgaag	gaaaaaaaaaa	aatgtgaagc	tgtcttactt	agctacagtt	45000
tccagcatgt	thttctcagga	gctctatggg	agacagtgca	gtgtggctct	caaaccttac	45060
taccataaaa	aatctgcttc	aaaacctact	thaaatatcg	atthttattcc	atthtccaaag	45120
cctggtagag	taggtaattc	tcccactaca	atacacttag	thaacactaga	aaaaaaaaat	45180
aacathttct	thaatgcata	gctgagthttta	thtagaaagta	tgaaaactac	tggggcgccc	45240

taagacaaaa	gaaaactttg	ggaaaacaca	ataggatgatg	ggtggacttt	ggggccacag	45300
ctgccctgga	aatatttgct	gacctagata	atcaagaagc	ttggttttta	acagcttcct	45360
agagacaaaa	gataaggcct	tgggcctttc	caatctgagg	aattgaaact	gcaatcacc	45420
acttaattca	ggactctctc	agggctatag	tttctgttga	tgggtgatcc	tcaggcagag	45480
aggtgatgag	gaagttgcct	gtctcagcct	agggggaatc	agaagataaa	atgcctctct	45540
tgagaatcaa	taactacaag	cccaattctt	acagattcag	agttaaagtgt	atgctccctg	45600
aatagagtag	gaaaccccaa	gtctagaaat	gaatatgaag	ttgttccaca	ttggggatag	45660
cctcagagcc	ttgcagaaaa	gcataaaaaat	gtatgtggct	caaagaatca	tgagctcctg	45720
atcaaaaatt	agaaaaatag	tatgcaaaata	agccactctg	tttaagaact	ggcagaacaa	45780
tgaaaagcag	aattaaatcc	tcagaatctt	cagataattg	aattaccaat	tgtttgatag	45840
ataaatataca	aataagtttg	gaatagaaaa	cagaccaggc	agaatgaaaa	taaaaccaag	45900
tcgaatTTTT	aaaattaaat	gtgcgacact	gaaaatgatt	caacatagtt	aacatggata	45960
atTTgaaaga	aaggatgagc	tggcaggtac	aaaagaagga	gtaagaggtg	tctagttgaa	46020
gtcctagaaa	gaggtattac	aactgcagat	ttctggctct	acatttacag	tttctaggtc	46080
tggggtgagg	tttaggtggt	tgtggaccac	acttttaggt	tttaaagcat	tggctctgaa	46140
gtcattttggt	tcagggctgg	gcatgatggt	ggttcctagt	tttgcgactt	gcagtgttac	46200
ttactttggc	taagcatcag	cttccttctc	tatgaaactg	aaaaataaat	acctatgtca	46260
taggatatat	gtgtaaataca	agttattcag	tacatgccac	acagtaagca	cttaaaaatg	46320
acagttgctt	ctatTTTTat	ataaccaaat	acactactac	aaatattgag	tggcagcttt	46380
gctggttcat	ttatggattc	atggagctac	acaaaacctt	caccagtcta	ttaatTTatt	46440
tttagtacag	tctctcta	cagtattgct	tccactgtat	attgacccca	tatcctttct	46500
tctgtctggg	gttaagatag	gagactgaga	tcagctgtgt	caaaagcttt	cttttagatg	46560
taacacatga	tttcttatga	aatctcata	ggtaggatag	cagaaaggaa	tttattaaat	46620
tcttgttagg	ctccttagtt	gtattagttt	tgtagggcag	tgttttaatt	taggatactt	46680
atgatagaga	gcaccccttc	cataatcagg	agaaacacaa	gatggaaata	aagattttat	46740
tacttagtgg	tcttggggag	cacacagcac	tccagggag	gccacacacc	aagatcaggg	46800
agcatgtgga	gaaagagaga	gaaaggaact	cacgggcaat	tgcccttact	gggtccagga	46860
cattatccaa	acaggtttcc	cacagggagt	tttaataggt	gggtttcaag	caagcaggtg	46920
tgagttccag	gaggtcacag	tgtgatgaag	aagaagtcac	tgtggcatat	ctgcacagtc	46980
catgagaggt	gtgagcatca	gtgaagacca	gtcaggtagg	ctatatgtag	ctggcccatg	47040
gggagggcat	caccaggtgg	caattgtata	atgcagatat	ctagattggc	cacatagagg	47100
aaccgggagg	aggtgtagta	ctggaaaactg	cgctgacggg	cactgagccc	tgctttaggt	47160
atgagaaagt	ccagcttata	ttcagaatgg	atgcaaaggc	agcataaaat	taaaagcatt	47220
cactgccagc	tgccataaca	agttaccaca	aactaggtgg	tttaaagcaa	ccgaaattta	47280
ttctttcaca	gttctggatg	ctagaagtcc	aatatcatgg	tcttcgcagg	gccgtgcccc	47340
ctttgaaggc	tctaggaat	aatccttctc	tgcctgtttc	tagcttcttg	tggttgctga	47400
caattcatgg	cagtttgtga	cttgcagctg	catcattcca	atttctgtct	ccatcttcac	47460
atgaatactg	tcttctctct	gcgtccctgt	gtccaaaatct	ccctcttctt	tctcttagag	47520
acctgtcatt	gtgtttacgg	catccataac	cctatgtgac	ctcatcttaa	ctaatcataa	47580
ttgcaacgac	cccatttcca	gataatacaa	tattctgagg	ctctgggtag	atgtgaattc	47640
tgggggtaca	ccattcagcc	cactacaaaac	atattgtggc	attgaggtta	taagccagta	47700
gccctacgag	tataggatga	tgccattttc	agcctgataa	tacactccga	aagagatcac	47760
atggtaaacat	tgttgccctca	gttaatcata	gaaatactca	attagtatag	aaataacaag	47820
aaaaatgctt	tgttattctc	atgtgtcatt	tatcgagttc	ttactatgta	tctgttattg	47880
ttactcttat	acacttctgc	acaaaagatg	gttttatccc	aagttttagc	ttagaaaactg	47940
aggcttaatg	agtaacttga	ccaagaatgg	cttctctttc	tccatttctc	tctctcatg	48000
gtgttgTTTT	atatacataa	aataatatat	attattctat	taatatagat	taataatagt	48060
atTTatatat	gtacatttta	tatatgtata	aaacttatgt	tgtaaagttt	atatacatat	48120
aatatataat	ctgtttatata	attgaaattta	tatatatata	aaacttaaca	ctattaagtc	48180
ttaacactat	taagtttcat	ggtgttgagt	tatatagttc	tattaattat	atataatagg	48240
ggggaggggt	gtttctccag	cctagacttc	cactttgaaa	tgtagtctcc	aggctcagcc	48300
acttgtttga	cattgccact	tggatgtctg	gtagacttaa	catattcaca	actgaatttc	48360
aaatcttccc	caccaatctg	ctctgcctca	tagcttcccc	ttccggaat	gtggttgctc	48420
catccttcca	gttgtagcag	ccccaaatct	tggagttttc	cttgactcct	ctcttcttct	48480
caaatcccac	atgtaatcca	tcaggtagtc	ttattggctg	tgccttcaca	cttttttcag	48540
aaactaatta	ttcttcagca	cctccaatgc	tgccaccctg	gtataagcta	ccatcctcag	48600
catctttctt	ccagtggtatt	ttagcatcca	tgaatgatta	tttctctaat	caattatcaa	48660
taattgttat	aaatttgtga	tttttctatt	tctatccttc	ctgtcacttt	tcttggtttt	48720
tttaaaagag	ctttcttcat	tcttctttaa	aaaaaattaa	aattagcatc	agtatgaact	48780
cgtggattct	tttgttattc	attgtactat	aagccattcc	tgtcattatt	cattttgatt	48840
cttaaatgtg	cctattcttg	gccagtgagg	gtctttcatg	ctagctccta	tgtctttttg	48900
atagtccct	atctTTTTtt	tcctaacact	ttccttattt	ctgaaattgt	aagctattct	48960
aggttcacc	tataccttca	ctacccagct	ccaggcatcg	tctgtctctc	taagaagtcc	49020

tagttccttt	tagcaggaga	agtttttcta	gactctttca	ttaggcagag	ctacaaaatt	49080
gattatttta	aaaatctcga	gttcatacac	taattcataa	ttctaattcc	aatccaacac	49140
tgcaggcttc	ttccctccct	cccctcatcc	catacttgta	tttggatttg	agatatgaaa	49200
tgtgtatctc	atatcccata	tttcttcagt	aactgaaaac	cctcatcatc	aatgatagca	49260
gcatgcttac	tcattttgct	cagtccaata	attcacacac	atltgtagaa	aaatagaata	49320
gttttagaat	ggctatacca	atatctgcaa	gcttactata	ttcggttcaa	aatttctttg	49380
tagttctttt	gaccaaatgt	attcaacaga	gagcattcag	tcagagtaat	gtgtacaaaa	49440
gttacttgga	ttagattttt	tccttctgtg	tattttatgt	tccattgagc	tatagagtta	49500
agctattttt	ttatttctat	tccattttag	gggttttccc	atccctgttg	atlttagtaat	49560
tttatttttt	gaatatcaac	atltgtcagt	ttcacatctt	tcatttatat	gagattaact	49620
agacccttta	gaaatcatta	taaagtcagg	ttgttctatt	aattttttaa	ataggtgtat	49680
aaaaaccaa	gggatcaatc	agagccttga	tttaaagtac	gttctgaatt	atltcagaca	49740
cccgaatcca	tctaaaccca	gaacatttca	tttgtagatt	tcaaagactt	cttggccttc	49800
ctaccttctc	tacatttatg	tagcatgtgt	ttatccaagg	cacaccacct	gccaggcaca	49860
gtgctgggct	ctgtgttgac	acacatgaat	gtgatcatct	ttctgtagcc	cccaggttac	49920
atggcaccac	agccaagata	cagacatgtg	tgagagagta	atcagggtat	tactcaggat	49980
ttgctggagg	aatccctctt	caaaggatat	tctaaattgg	tgtgtgtgtg	tgtgtgtgtg	50040
cgcgcgcgca	tgtgtgtgtg	tgtgtgtgtt	gaggtggact	gggagaaaat	ataccctcct	50100
tgagatcacc	tcctggctag	atagtctctc	ccttctctgt	ttgtgataga	atgcaagtgg	50160
aatttgacag	gtgtacttct	caaactagaa	actagagagc	tgctatctca	gtcaccgtaa	50220
gaagaacgaa	tcacaccaa	cctacatcat	tgtcttctat	gacaggattt	ctacaagggg	50280
gagatagtga	gatgctggag	atccctgttt	tggtagtcca	gggattcaca	gcatctccca	50340
tgctggtgat	gtcaacctga	agagatattt	ctagtgatag	gttccaggga	tctttcacca	50400
aacactttta	tatattttat	cattgtcctg	aatacagccc	tataaggttc	ttactaaatt	50460
tgcaggtgac	atgaagtgat	agacaacaaa	caatttgaat	tcaaattaat	tttgaaagct	50520
gagacaattg	acccaattct	tcagcaatta	tattttaaag	atataaatac	atgcagaaaa	50580
caaattacaa	gtcacagagc	gaagagagat	gatttagcag	caacgcacgc	aaagcactct	50640
aggagtttta	gttaataaca	gactcaacat	gaaccagcaa	tgcaatgtga	ctacgaaaca	50700
agtaattcct	cattaggctg	cattaatgga	aacacgatac	ataagaccaa	ggaagtgggtg	50760
gtctcatttg	cactctgtga	tgaaggcca	caccaggaat	acagtgtagt	actgctgggc	50820
accacatttg	tagagaaata	gaaaccaact	tgagtgtctt	cagagcagaa	tggtgagaga	50880
actcaaactt	cattcaaagt	aggagtgtt	actgagcctg	agaaatttat	agcctggagg	50940
atltgggtgt	cttcaaatat	atgaatggct	gtgatgggga	aaaaaggatt	aaatgtgtcc	51000
tgttgtcaca	agaggatgaa	ataaggagcg	gtgaatggaa	gccccaggcg	atagaggttt	51060
cagttgctgc	tgacagtcag	ggctgtctga	ggatggaatg	tattgcctca	ggacaaagtg	51120
agttcattgt	cactgaattg	gttcaaaaa	gaccaggaag	actacagggc	agggaaagcta	51180
acttgatatta	caataagtaa	ttttttctt	ttttatttgt	atgcccttag	aaagatgttt	51240
acttaacttg	ataaatctgt	aacaagggat	aatcaagatt	tggttatagg	acaattacaa	51300
ttttctgaca	gatcccccaa	aataatagaa	attaatagct	tacacactac	tttatccaag	51360
ctgtagaatg	tataacttac	ttcatatact	ttgtgtttag	tcagtttata	caggctgaac	51420
aacataaagt	taagacataa	aagggttttt	tttgcagggt	taaagtacta	ccattttttcc	51480
aaattactgg	ctgatcctag	aacttttgaga	aactttgggtg	tttccccctt	tcctactttt	51540
gtttacatca	tagtacgtag	atggtacaat	atlttgggtta	acctcagtct	gacacttaga	51600
ttgtgttctc	ttttgcccata	ttaatgtcta	gagtgtaaaa	agaccagtaa	agtgcacca	51660
agaaatcaaa	gaaaatttcc	cagttctact	cacttgtaat	tctcttaatt	tagtaggggc	51720
tttccacag	aaatcacaat	agaatagttg	aaatgtctct	tatcttatgt	actttccttc	51780
tgaagaaagg	gacagttaat	tggctttgtt	cccaacatgg	tccaaatttt	tatacagggc	51840
agctgtatlt	actgtagtac	aaaggagatt	ctacaccgaa	tgatgtctct	aagtatltttc	51900
aataatlaag	aacctaattg	cttctctagc	cagtgggttt	cagtgaaagt	gataaaaatag	51960
atltttctaag	caagaaaaat	acataatgag	gggtggttgta	tacctttaag	aaaaaagaaa	52020
tcagtgatat	tcaatcccaa	gtaaatlttg	atatcacaga	gtcagagata	ttcttaatta	52080
ttttaaatta	aatlttgagtc	aaaaacaatg	tgtttaaaga	ctttaaaatc	atltttaaag	52140
aatgttagaa	atlttacatta	ataatlttcta	ttttcaatga	ataaatgaga	aacctagaat	52200
ttttgttttg	gacacacttt	gatcatatct	aatgtgttct	acttctctca	attatltttta	52260
tgttattagg	atlttttaaaa	aatctcttag	atltaaaatlt	ctcagtgat	ctttgtttgc	52320
gtgtcttttt	ttctctctcc	acttatgtaa	ttgaagcatt	tctgacatat	cctcagaaca	52380
cacagattct	tatcaggact	taactacca	gggcagggcc	ctccttggat	ttactgaaaa	52440
taaacacttt	gggtactcag	tctcagtttt	aatgacaaaa	gttgaaatct	ttgcctaaca	52500
tgaaggtttt	tctttgtctc	taaatlttga	ttttccatgc	tatcagagg	cccattgcaa	52560
caggtaatlt	gagtgttgat	tgtatgtttt	ctcagtttgt	aatgtgggtg	aaatgtatlt	52620
aaaatgttca	caatltttaa	gttaagttta	octataaggt	tctttccaac	tcagaaatlt	52680
tgtgatggta	aactlttttt	ttgtagtttg	aaaatgtgat	ctttggatgt	tgtcttctgt	52740
gtcctatgca	tatgactagg	aatcatagaa	tttttagagct	ggaaaatgag	tgagacatta	52800

tctagtgatt	ctgcaaatga	agaattaaaa	ggcccaaaga	ggttaggtga	ctcacgcagt	52860
atcatagcag	tacctgggtga	ctagaactct	ggccacctac	tgcagcacta	aaaattaacc	52920
caaatgtttt	tatctgaaaa	tttgagact	tcaggctagg	cctgtaaata	aataaataag	52980
aagttaaaa	atatttgaga	aaggtaagct	taatatgcca	catttgaggaa	aagatgtgcc	53040
tgacacaaat	gtatttggtg	taatagagaa	cattcttcca	ttataaccgaa	atgaaaattt	53100
tgaacattct	caaaattctt	gaatlttgag	acatttatgt	taagcacagt	ttattcagac	53160
tctctataaa	ctgtgctgtc	atccctgttg	ttttctccaa	gcggaatcat	acttaaatta	53220
caacttttagg	gagtttaatg	tttctatltt	ttgcactcct	gggatatttt	tcagtgactc	53280
agaagcataa	actgacactg	tgaagttaag	gctgtgttcc	agtgggaatg	acagcatgtc	53340
tctaggacgc	tgatggagaa	agccctcctc	atgacagtgt	cttgccggagt	ctccctgctg	53400
gtggtgaatg	tgagatcaca	cagggccagc	agccagggca	gtacatctct	gagtctcgct	53460
tctggtttta	cctagagcca	acccttggtg	attglttgcc	tccttgccca	agcccccaca	53520
caataggaaa	actgtgtctc	aaggtcgaat	tctattaata	cctgagaggt	gaatlttataa	53580
acatttaaga	tgttttagca	tctctgcagc	cagtgtctct	gtaaatgaaa	attgcttctc	53640
gaagtagaaa	agcataaggg	agtacaaggg	cttcaaaaaa	taatcctltt	aggaataaga	53700
atattgccag	ggttaggtgt	tcctaactgg	tttcaagcag	aggagttagt	aaaattccaa	53760
aagttaatca	gcttcatgta	ctcaactltt	gctaggactt	tgcagaaact	cctcagggat	53820
ccctcagagt	tagattaggg	agatgaacc	tgccaaagga	cagtaaccat	tcaacagctg	53880
gatagcctgt	tgggccccac	tgtcctcagc	ctttccta	gttgccctggg	aacaccactt	53940
ttctgctccc	tcctlttttca	gtgtagcctg	gagacaatta	tttatttatt	cactagctct	54000
tttaacaaat	attgattaag	taggtactgg	ttctgttcta	ggggttggaa	aaacagagaa	54060
aattaaatag	tgctttgtc	ctcaggaaac	aatccattta	atagagagac	gaagatatgc	54120
ccttaaatac	ctgaatcacc	agcataacca	gcacctgcgg	ctgccatgtg	ggaattgttg	54180
aacaagataa	tttttgaatg	aaagagtaaa	tgacctaat	gctcta	aaagataaat	54240
ttctaagagt	cggtcagttg	ggatgattat	agaaggattc	aaggagagaa	tgtatgaaag	54300
catagatcta	acgagagaaa	acagcacagc	agaaaaagca	gcaaaggctc	aaaagtagaa	54360
atctctgaga	tccaatggag	aatagtaaat	aatgtctgg	aatgaagagc	acgtgaaagg	54420
caagggtggt	aagaaggctg	gagatagtag	ataaggccaa	atcatgcaag	gatttaaac	54480
gtatgttttt	agaaaatggg	taagctatag	aaatltttata	taggaatgag	aaattatcag	54540
cagcattgtg	ctttaggact	acaaatctgg	tagcaatctg	ctaactgata	ttggaagggg	54600
aaggcccaaga	gacactagtt	ggaagaattg	cagtgattct	tcatgagcta	aactaagagt	54660
tcaagctaag	atagataaac	taaggaatga	gaatggaaga	aagggacaaa	ctgagatttt	54720
tggggtggtg	ctcagctgaa	gtttggcaac	tggttaaaca	taaaagacaa	gagacagaga	54780
ggaatccaag	atgaaaagac	gattlttgctg	cactltttt	gaaggcagca	tttgtatttc	54840
catttccagg	aggtggagta	gctttgagaa	gaaaggatg	tagttcagtt	ttgggcacat	54900
tgagctgtaa	cggtattatg	gacaggaaga	taccctacaa	acagctggaa	atltttgcaca	54960
tgcttaaaaa	gaagatgaga	acatgagatt	tcaatlttagc	catcatctgc	atggagtaga	55020
caattcaatc	caggagactt	gataagaatg	tcaaggaggt	gatcacgata	aagggtgagaa	55080
atggactgag	catcgatctc	tgtgaaaca	tctctttgag	caggaagaag	agtgcccttag	55140
caaaagcagc	cagtgaaatg	gggagttggg	gggagacttt	aaggagggaa	tggtaacata	55200
tcccattccc	aaagaggtca	agttagggtg	aggaataata	aatggctagt	gggtttggaa	55260
acatggaatc	tgtcatgacc	tttacacact	ttttcatttg	atggatcggg	ggattactta	55320
catttgcaaa	gggcctcaga	ttaagtggta	atggttcagc	attagtaatt	agagattttc	55380
ttatgtactt	tgtagggaga	aatagaatgg	cattcaaa	ggtttaagtt	cctcttaaga	55440
acctttctca	ttggattgta	gagaagagca	aatgaaagaa	tcgttcagta	tttcttggtg	55500
tcatgccccag	cccataggtt	tcaattaatg	ttaacctt	cagttgtcat	catcattatc	55560
cagaaggggc	tttttttttag	aataaggaag	aaaagcagtg	ctcatctgta	gacaaggggaa	55620
aaaatccttt	ggaagagaga	aagagaaggg	taattcaaga	agatcaggaa	taaacattaa	55680
gggtaaaaa	agaatggtta	gccctggaaa	agggaaacaaa	catgtttctc	tgaattagga	55740
gaggatagt	gaagtaacag	ggatgttttg	agcctcagtg	acagtaagga	gaagagagag	55800
tgaaggaact	tgcacgcagt	gacttctacc	ttctcattaa	agtcaagaga	gaatctcaac	55860
tgcagatata	tgtttaaagg	aggaagagag	aaataagaat	tgtgtcatt	tattttgtgg	55920
ttttgatata	gcaaaaactg	tactagacac	ttacctcct	ttaatcctca	gaaaacttag	55980
agattatata	tttgtattca	cattctacaa	atgagaaagc	aagtaaaaaa	gttaagtaac	56040
tctcccagag	tccccagat	ggtcatggga	gccagattc	agagccagct	atgtcttact	56100
ccaaagcctg	tgtctttat	tgaaacatac	tccactagtt	tgagatcttg	gaggtgtacc	56160
cctgcactac	tatcaggact	accctgata	aagtctgtg	gggtagttgt	tcctatccat	56220
caccacagtg	aatatcaaa	aagggccctc	tcatlttgagg	aataacagac	agtgaaattg	56280
agatggacca	gaaatgcaaa	tcctggatcc	ctgagggaaa	caacaaaatg	aagcatagag	56340
gaaatatactg	agtctggtgc	caagactcat	cagtacaaga	gagaatgcct	aatgggcaat	56400
agcagtttagg	gtgggaaaag	agaagtacaa	gggggtgtct	tggaaatttga	gggaagaact	56460
gctgccttag	ttttcgaagg	atgattatc	gagagttgcc	ctccctcac	tttctcacag	56520
ctggcagaat	tcctacctct	tagtggttag	attcctlttt	accagatact	gtagggccag	56580

tgcagcaacc	agagccccc	gccagaaacc	ctgcctccaa	tttagaccag	tgttctgctc	56640
tggtgtgtaa	taatcatatt	ctaattttaa	tagcctattg	agatgctaca	ttgatatcta	56700
gccttttttt	tttttttttt	tacttttaag	ttttatgtgc	aggatgtgca	ggtttggtac	56760
ataggtagac	gtgtcatggg	ggtttggtgt	actaattatt	tcatcactca	ggtattaagc	56820
ctaatatctg	ttagttcttt	ttcctgggtcc	tgtctgtcct	cccaccctcc	accctttgat	56880
aggccccagt	gtgtggtggt	tcctctatg	tggcaatgtg	ttctcatcat	ttagctccca	56940
cttataagtg	agaatatgca	gtatctgtaa	taatgggttt	tctgttctcg	tgttagtttg	57000
ctaaggataa	tgacctccag	ctccatccat	gtccctgcaa	aggacatgat	cttgttcttt	57060
ttcattttctg	catagtattc	aattggccat	tttttaaaag	acaaaataac	aaaaaaaaaga	57120
gtacagttat	ctccactcct	caccactac	ctgccacctc	acccaacctc	ttatatttta	57180
gtaattgcct	tccataaata	acattttatc	ctgtcttaat	tatgcattca	ttagtgtatt	57240
aattattgaa	tgcccacaat	atgacaagca	ttattttcaag	cactgaggat	acagcgagaga	57300
ataaatcaat	atcctcactg	tttttattcc	attttttttaa	gagacagggg	ctcaccctgt	57360
tgcccaggct	ggagtgcagt	gggtgcgatca	tagcccaatg	ccaccttgaa	cttctgggct	57420
caaaggacac	tctacctca	gtctcccaag	tagccggaac	tacaggtgca	cactaccaca	57480
cccagcttcc	ccactctgag	cctccatcct	aatggagaag	agaggcagta	atcaaaatac	57540
atgaaatgtg	tagttattag	atggttatta	atgtatagag	aaaaattaag	cagagaaagg	57600
agcaagggat	taggggggtca	aagttttggt	aggggtagag	tggtcagtga	aggccacctt	57660
gagagatggc	aattatgtaa	agcctgaaag	caggtaagaa	atatacaggt	atacagatgt	57720
ccctggaaag	agtgttctag	gcagaagaaa	tagaaagtgc	caaagctaag	attgctcacc	57780
tggcaagttc	agaacacagt	agaaactgat	gtggctgcat	aggagtaaga	agaaaaagga	57840
cggagaggac	atgagatggt	cagatagcct	agggccttgt	aagccattat	aacgattttg	57900
tcttttaata	tagagaaata	ttaaagggtt	ttgttttaac	tttttaacat	agaaaaatgt	57960
aatcatatac	aaacacagaa	tagtataatg	agcccccttg	cactaatcac	tcagctttta	58020
cagctttcac	tttgggagga	ttttgagtga	aggagtgata	agacatggca	tggcatgaca	58080
tggcttgaac	aggatcactc	aggaaaataa	gccatgggga	gacaggaca	gcagaggaaa	58140
cacagggaca	aaagcttagg	agacagatga	tgggtgctgg	aaaccaaggg	agtgcagtg	58200
aaagtggtga	gaagtgatca	gatagaggat	atttttttga	agatttgaat	taatattata	58260
tatattatac	tttaaagaag	aatttgaaaa	tgcattgtag	gtagttaaaga	tggtaagaaa	58320
tacagaaaag	aggccaggca	cagtggctca	tgccagtaat	cctagcactt	taggaggctt	58380
aggtgggaag	ctcccttgag	gccatgagtt	caaggccagc	ccgggcaaca	tagtgagact	58440
ctgtctatat	ggaaaaaaaa	attaaccagg	tgtgggtggca	tgcacctgta	gtcctagcta	58500
cctaggaggc	tgaggcagga	agattgcctg	agccaggagg	ttgagtcctc	agtgcagccat	58560
gatcatacca	ctgtactcca	gcctgaatgg	cagagcaaga	ccctgtccct	ttaaaaaaaa	58620
aaaaaaaaag	agaaagaaaa	agaaatataa	gaaatggcac	tagaatatca	gtattatata	58680
cattattttc	tgtttaaaaa	tccacacaac	tggcaaaaaa	aagtgcata	catgaacatt	58740
tataagacag	tgcatttata	aattacaaac	tctctgctcc	tcccatatta	ttttgcagtg	58800
atgaatgatt	aggccatcca	aacgtaaaga	tttattttgta	atlttgctaat	gatggaatga	58860
cacctgttga	ggtacaagtt	cccagcaatt	cttggaaatta	gcaatagtg	gttacttctt	58920
tctcgaaaga	agcatgattt	gtaagcagct	atatctgatg	tagtaaaact	gaaagttaaa	58980
ataaaaaagg	aaaccgtggg	tcaaagtatg	agggaaaaga	taaaactttc	agagcaaagt	59040
tatacataga	gatttttattc	atcgtctctg	tgtaatccac	gagaacttct	tagcttattt	59100
attatgtcaa	atggcagttt	gctcttctaa	tcccagcctg	atatcatgag	ccatataatg	59160
tgtttggtcat	tcaaaaggga	cactaaacaa	ggtgaaagaa	tgtcagtgaa	tcaatgcaac	59220
tccatgagta	ctaccaggaa	aagaaaaaca	aaaaaacatg	ccattaatag	tgggtcaaac	59280
aggatttttt	tcatgccatc	ccctacctta	ctgagaatac	cacatttata	ttcagaagac	59340
tcataatgaa	ttccagagtc	ctctgtgtct	tggctgtatg	actttggggt	atgtcacttt	59400
gttaatctgt	ttgaacttct	gttttcttat	ctacaaaata	ggggtaatag	agtcaactct	59460
gcctccctca	cagggacttt	cggaggccca	agggctcttt	caaataatag	agaaggaaa	59520
aaactggcac	tttaaatagta	cctaccatgt	accagggact	gcgtagtccc	cacggcagcc	59580
ctctgaagtc	atgtgattgg	cccattgtgt	agatgtagag	cttaagactc	agagaggtta	59640
tttaatctgt	gtaaggccac	agagctagga	gggggaaaag	ctgggattgg	atcactgact	59700
agatcaactt	gaaatctcct	gcctgacaga	gaaagaagag	actaacttta	ctaagcatct	59760
ttttatgcca	gaaactgtgt	tggacataat	tctgtactat	cttatttggt	aaaggtcatt	59820
ctgtccctcc	tggttgcctt	ggttgctcaa	caagtaataa	acaataaagc	ctgactgttt	59880
ttcatccctg	agagaagaaa	tattattaaa	atagcgttat	tctctttctt	tctttccttt	59940
tttttttttt	ttttgtgtgt	gtgtgtgtgc	ctgataatct	gacttgcaac	ctcacagaaa	60000
agaatgaatg	catggtttca	tgtctgtggc	atgactctgt	gaaggagcct	tgcaagggga	60060
cagatacacc	tctaccactt	cttatagcca	ttcctgagac	ctctcttctc	acaacacata	60120
ccagcaaagc	caaacaacaa	aggtgtttag	gaataactgt	catctatcaa	cactctctag	60180
gcaaagtaga	actatgaaac	actgaggaga	ctgcacacac	acagaagaaa	aatgatcat	60240
gtcacatggg	agcacagagc	aatgggaaat	gtgaatagtt	tgttgagggtg	gacagaccca	60300
agctcaagga	ttgcctgatc	gctccattta	taggaacctt	ggcaacctac	cttatcttac	60360

tgagcctcag	ttcctccage	tgtgaaatgg	ggtacaacct	ctgacccccac	agggctgttg	60420
tggggattat	ctgagttagc	atgttccata	aaacacagta	agttagaaag	tatagctgta	60480
taggctctgg	gagtttaaca	agcaagagaa	atgtgacagt	aatcatttag	ttactgaacc	60540
ctgtcttcat	attgcgctag	gttgcatatg	gttttctctgc	ctgtcccttc	caatcacatt	60600
tcagaaaaag	gaggcagtag	tggagccttg	tgggctaaag	tgggtgaggag	ggtgtcatgg	60660
aagattcagg	ttcaggtcct	cctcttgaag	aatgggtgct	tctcaatagg	gaagtggagg	60720
aacaacctgg	gagttgtcag	cttgaagaaa	atcctgagac	gtgataatgg	gtaggtccaa	60780
ggaggtcctg	agtaggactc	tgagcacaga	gcctttcttt	gcatgtgctg	tttttctctgc	60840
cagcaagacc	ctctaaaccc	tttggcctca	cccacccctc	tgcttggtta	tactcctagc	60900
cttctttcag	atctccaccc	tcagtactcc	ctcaggaagc	ttccctgac	ctcctgacc	60960
agtcaagtgc	ttcttatata	tctcctttgt	aagctcttct	cagttacact	tttacattta	61020
tttgtgagat	tatttgatta	gtgtcagtc	cactctttta	ttctccacaa	gaacagagat	61080
tgtgtctgtt	ctgcattcac	catgcatcgc	ttcatcccct	agtttactgc	agtgtgtgga	61140
acataggacg	ggctttaaat	actcgcgtgaa	taaatagaga	aatggttggt	attagtgagg	61200
tattacctag	gtgggagaga	ggatttata	ttgggattgc	taatcccatt	aagtgccaa	61260
cactgcatta	actcatttaa	tcctaaaaaa	aagtcctatg	aatcaagtg	tattattcct	61320
tttaacttta	aagacagaga	aactgaaatc	cagagatggt	aaccatcttt	ccccgttgac	61380
acagctaagt	ggtaacagtc	ggtcttgagc	cgggcagcct	ggcttcagac	ttcctagact	61440
ttaccacatt	gttctgctgc	ttagtgcagt	agaggacaaa	gtgaggtgca	cacgtgaagt	61500
caggacagat	ttccgtttga	aaattgtgta	ttttcccctc	ctcttcttca	ttaccattgt	61560
catcatcatc	atcatcaatc	acttcacaag	caaagctaag	cagaaaagaa	ctacttcatg	61620
tatcacctct	tacattcatg	ttaactctac	attctgcca	agtgatttgg	ctgaatttac	61680
ccaaagagca	aagtggacat	ttcaaatcct	gattcctaga	aaattataga	ctacatcctg	61740
taaccacctt	tgaagaacca	gcatgtactt	tacccaacg	tgacaaaatt	gttttaata	61800
aaaagaggta	atgtgactaa	gattgggatg	atctgagacc	catggtttct	acatcttatt	61860
caaaaagcag	atccagcatg	tggtcacag	taggtattga	gtcataaagc	tcttgggaaga	61920
aaatcttaag	tttcatcaag	aatgccaaga	agtcctgggt	gtctccaaga	atgatagctg	61980
ttactataat	aacataaatta	ctactggaaa	attagcaaa	ccaataaaa	tatggcctgc	62040
aaaaaaat	ttaccctgga	aatagaagtg	acctaataca	gtcgtttatt	ccagccacct	62100
gcttttagat	agtacttaaa	aaaaaaactt	tcaggatggt	catattgttt	aaagttctct	62160
aggtggaaga	gtactttaca	gtaataaatt	aataaataag	acaagttaat	gcttttaaac	62220
tactattatt	tgttgagcat	tgttgtaaa	gctttacatg	cattaatgta	tttagtcctc	62280
acaacaaccc	tttgagatac	tattatcctc	atctcccctt	tacagatggg	gaaactgagc	62340
agtgcccaaa	gtcacacac	caggaaatgg	ggaactatct	tcaagccag	ctggtttgcg	62400
cctaaagtcc	atgctcttac	agtgtccctg	ggtagctgag	tactcagttt	tgtcaccttt	62460
gtctccttga	ctttaactga	aagcttaact	cttttttttt	tttttttttt	taaacggagt	62520
cttgctctgt	caccagggt	ggaggggag	tgtcttgatc	ttggctcact	gcaacctcca	62580
cctcctgggt	tcaagtgatt	ctcctgccgc	ctgccgaata	gctgggatta	caggtgcaca	62640
ccaccatgcc	cggctaatat	tttgtatatt	tagtaaagac	agggcttcac	catggtggcc	62700
aggctggtct	caaactcctg	acctcaggtg	atctaccctg	ctcggcctcc	caaagtgctg	62760
ggattacagg	catgagccac	cacgcccggc	ccgaaagctt	aactcttaat	aagagcctgc	62820
aatgttcaga	cgctttgaaa	aaaacctaac	agacacagtt	gctctctata	aacttaattt	62880
tcaaaggaac	cactattcaa	agaagtaaaa	gggagactga	ataaaaagaa	ctaagttctc	62940
cgtagagcaa	atgaatttct	gaatcgattg	caaacagttc	tccgtcatca	tgacattcct	63000
tgaagtattg	tctccccat	gttagagtg	cagtgtcttc	atgtaccata	taacttgcaa	63060
atagtatcac	tgtcttctca	cacttcagct	ttctctttc	atcagtattt	tggaaagtcc	63120
acaaaacca	gggggctccc	tgtctgttgc	cctgtggtct	ctgtgaaaac	cagatgatgc	63180
gatgctgact	tggactcttt	caaatggatc	caacagcaca	tgagtactg	gcagcatggt	63240
cagctccttt	acctcaggaa	ttaccaggt	cctcattctt	gccacccttc	agccatgaag	63300
tagtaatatg	aaaaatacat	gagtactttt	tgaggatacc	tccggacctc	ttccttcagt	63360
accagagact	aattgcctca	taatggtaac	attgaagagc	ccagttatct	gacgtgattg	63420
ggctttaatt	atggattcct	tctgggtgct	tattaaattg	gaaagcctag	ctgatttcac	63480
ccaaatgaag	cattacctca	tgcttgcctc	tcttgcattc	ctgtgctggt	gtcacttaaa	63540
agtgtaat	catggtttat	ttcgtgttct	ttcactcttg	atattattgct	gaagaagccc	63600
ctgtgggata	tatcatcata	acaaagactg	atctcagatg	tcaacaccaa	gaaacacaa	63660
tggcatcagc	aatctataga	gagtatctag	ggacagcagt	cagctttgga	gaaaaccag	63720
aacttctcat	acccatctcc	acatttaagg	gcaaagactt	tctccttggt	aaagggaaa	63780
cactgagttc	ataattagct	ttatacccag	agtttttttt	tttttaaatg	ttatacctgt	63840
ttaagaaatt	ttttgtgctt	tgaggtggtc	aagatcaaat	ttatttagca	accctcttcg	63900
tgattggctt	gctctgggga	ccctgctctt	tgagaaggag	gttagaagg	ttagaagcaa	63960
acctttgcag	cagttctagc	caagtgcag	catacaggcc	ttgaggtgga	gctgcacagt	64020
tgactgtagg	ggagtctgct	ctttgttgac	gagtgaaact	tctctccctg	caaaccctct	64080
ggggaataat	gccaaactctg	atcagctttt	cgactcttgg	atgaaatatt	gggttgggaa	64140

aaagtcccta	ctaagaaaat	tgtacccaaa	ccctgcttca	ataaaatatg	aatccattta	64200
atgaagttta	tagtagaagt	aggctagtcg	aaaaggattc	tgtctctttc	caagtattat	64260
tggcaggttt	agggctcttc	tcaagtttat	atcattagga	cttccatcaa	agagttatct	64320
ttaggtgtga	ttcccacctc	ccctccctct	ctccctccct	ccctccgtcc	catcgttcct	64380
tcctcccttt	ctccttctct	tttctacott	tctttttctc	tctgtctctc	tttctttcaa	64440
gctgtgggct	gcttgtacag	atztatgcat	tttgaattac	tgcgtagtgg	agagattttg	64500
ggcttaggtt	atlcagttct	tcaaaaagta	cagtatgagc	taaggagata	gggtgaccaa	64560
ctaactctagg	ttttggctcc	aaaaaccctg	tgtcccagaa	aaccctcag	tcctaggcaa	64620
accaggatag	tagttcatct	tgtgaggaga	ttatagtcca	tttccaagta	tttagctgaa	64680
tttatcacag	ggctctgact	tgataggatt	taagagggtt	aaaataaggt	ctttctctgtt	64740
atgttagtgt	gacttttagtc	ttggcacttt	ctcaaggaag	gaatccagtc	tactacaggg	64800
gctaggtgac	taagaagaag	aaagaggata	tctaagtgtt	ttttgctaaa	aatgtcatta	64860
tctccatgct	atltcctttt	tattgctatt	gtcatcattt	taaagacata	ccaataagaa	64920
ataaattact	ttaaatagaa	aactctaatt	ttatcaagca	acagcaaaca	ggggtgaaat	64980
ctaaggattt	gtacttaagg	agtacacttt	tttgaattga	agaaacttac	tatgacctga	65040
gcatatgtaa	ctcaattatc	agaagtcaga	gagggctact	gaaggctcag	gttttctaag	65100
agatgactgg	aggccaagtc	ctcaggcttg	agtgtttata	gccaaacttc	agaaccaggt	65160
ccctggcaag	atltctctgt	ctaatacacat	ggcacagagt	taggatggac	tgtttctgct	65220
tacctgcctt	cttccctttg	tttccatcaa	ccaccagttt	ctttctcatc	aatcatttac	65280
ccagcttttg	tgaccaagaa	ttttgatgag	gatgcagagg	aaggcatggt	cttggttaat	65340
aggaaaggag	gcttcatgac	aacacagcat	cctctaagat	gtgttgctcc	aactttcaca	65400
atacatattg	tgttttaagt	ggcctgcttc	ttggagtgt	tcttcccact	acacaaaaca	65460
accaccatta	acattttcat	ttacttccac	cctgtcattt	gttcatcaca	tactttttaa	65520
aacagggctg	taatcatgta	tatacatata	tgaataactt	tatattgtac	tttttatact	65580
tactggctta	tcataaacat	gtttccatgt	tgctggagag	tcagatatgc	taacttttgg	65640
aatgtgcttc	ttatatagat	ctgcaactat	gtgggaccag	caaaggttat	tgttcagttg	65700
gtcacaaatg	gaaaaaatat	ccacctgcat	gcccacagcc	tgggtggaaa	acactgtgag	65760
gatgggatct	gcaactgtaac	tgctggacc	aaggacatgg	tggtcgggta	agtagggtga	65820
tatgatgctg	tggaaggtag	gaacagatag	aatatgggat	gcaggaactt	agaatgaaca	65880
ggcccccttc	attagggacc	tttctgagac	cctcagatga	cctcaaaaaa	ctgtgtaaac	65940
ttgtgcttcc	atlttgactc	caggaagtaa	ggtgaccaca	tgtctggatt	tgcttgagac	66000
agccccggtt	gccccgacc	taattgttta	tagcaccctc	ttctactctt	aaagggtggc	66060
caatttggat	gatcacttat	atgtggtcac	ttgacctaca	aggtatttgt	gccactatta	66120
atlttttttc	tcctagaat	aaaaataagg	acaaatttaa	agaaacataa	ctatagcaga	66180
aatcatcact	ttatgtatat	ttttacattc	ttgatgattt	cttcagtgg	tttatggtgt	66240
gaatatgtag	ggctttaagt	gaatgcataa	atatcatttc	agctctctgc	tgcttagaaa	66300
gtaatgcaca	gataagaagc	caaggaatgc	aaatlttatt	tggcattcat	taggcttgaa	66360
atgtaaataa	aaaatgacgt	atlcatttaa	gggttgatca	aataaaaaca	gcaatlttta	66420
atgaatgaag	ttttatagaa	gtaatlttcaa	tccaaaagaa	ttaagctttt	aaataagaca	66480
tattttattg	gctaaaaaac	ttgtatlttc	atcttccata	tacactaaaa	tggcacacag	66540
aataatagt	tagcacacaa	tacaaactga	tatgtgcaat	caataattct	aaaaattggt	66600
gttttaagtc	tttcttttga	agtccctaaa	tgcaaaaagaa	gaaatlttta	atltttgttta	66660
atlttttaaa	acatlttttca	gggtltttcta	atcctggttt	aaatagttta	tgctgaaatc	66720
ccagtttaatc	tggcttattc	actcaaaaaga	aaggaattgt	ttaaatcaac	tataatlaag	66780
ctgatggttg	catttcaggc	tttgaattcc	gatcaagttt	caaattgggt	attatlttgg	66840
aggttgtgct	ttcatgttcc	taggtatlttc	tttgtttgac	tgtgaaaata	tttaagtgtg	66900
aaaaacctag	agagagagct	ttctltttaag	tcactaaaat	cggattcctt	tgatgttaga	66960
aaaaaaaaag	actctagatt	gaaggaagaa	gcttaaatgt	atlttgaaaa	ttaaagtgtg	67020
ctttatatga	acttgtttca	acatcctctt	gaaagactgg	cgtgtctcct	gttgtatgtc	67080
acagtttgtt	catcatgtgt	tgtggaatac	ccttccaatt	cctgattgac	ctaggagagc	67140
tttgaaatgc	aggctaatta	tcacagtttt	agactgattg	atcacttagt	gtttctgcag	67200
atlttattcca	gtagggttct	gtcagtttga	agtgtttatt	ttctttggtc	ttgtttaatc	67260
cctattataa	tcatatcctt	tagaggaaat	tttagatgaa	gttttctact	agtatlttatt	67320
attataaaac	ctccagtatg	gtgtctataa	tttgggtgtt	ctgtgggtttg	cttttagtaat	67380
ctttcaggat	tttagaaaga	actaatgggt	atlttaaatlt	gagaccttaa	agcgggaata	67440
gaagtaaat	gtttctaagg	aaagtgaggg	atltctttcac	tcttgtagt	cagtggtgtg	67500
tgggctcagt	agttgggaga	actcatcagt	cattcactca	ttcaacaaac	atltttgagca	67560
tctcagctcc	tgaatlttgat	cattatgatg	tctggttgt	gagcagtgag	atltttctaac	67620
cctatataat	ttcagtgaga	aatlttaatca	agatgccact	tgagagttac	aatagactca	67680
gtagtcttaa	cgttlttttagt	gtttcctatg	aaaagtcagt	actcactttc	taatlttgatt	67740
tttagctgag	aaatlttttgc	ttacaatgtt	tcccaaaaata	cactatlttct	ttcataatltc	67800
atlttglttct	atctctctct	atatatacat	ttttaagatt	ttcaatgtca	aaacttattg	67860
catttatgta	gaaagaacat	cgtgctagca	ttctggaaac	cagtatlttta	ttcccagtac	67920

tgttgctctc	aacagaggac	tgggggcaag	ttacatgact	tcttggggac	cttaatgtct	67980
tccctcataa	aatgagagag	tttactaca	gaatcttacc	ttcaggctgt	ttacatctcc	68040
agaattctgg	actgaactaa	cattacgtaa	tattatgaaa	taacatgagc	aaacttgcca	68100
cacacatatt	tatgggatga	cattgattat	tagtatttag	ttctgacttg	tagataagag	68160
tatcacatag	agaaacttag	gaagatagcc	aaaattatgt	cttagacttg	tcaatactag	68220
aatgaagct	aagataaact	gttttcaata	atacagatta	ggcaaagagt	atagattcac	68280
aagcaagaca	ctaataccaac	ataccaaaaa	agatatccaa	aaaatggcaa	tgagaagaca	68340
aataactttt	aaattgtcaa	aacccaaaaga	attactttct	ttggagtgtt	tatcttcatc	68400
tttccctcag	tatgaattct	taataaaact	agtttctact	ttcaaaagga	ttttatctat	68460
gttataaata	ttcatgtttt	aaatagccaa	gtcttgattc	tggtttgatt	gctgtaatgt	68520
aggggatttg	tcattttaat	attttttaag	ttagctttaa	ttttgtcttt	tttaaaattc	68580
atztatataa	ttagccttta	ctgcctttct	tggtaaaaaa	taataataat	aatcttagtt	68640
tgggtgttta	ttttaaaccc	tgaatatcaa	caatttgttt	caacatattt	tagttcgttg	68700
acatttttat	tccatggaaa	atatctgtgt	tcttgacttt	tgcttttaggc	cagttcactt	68760
accagtaatc	accacactct	ctctgctttc	tggcagttta	gagacatgga	atttttttcc	68820
aattaataca	tatagcatat	accaactggg	aagcactagg	agtagatata	taaatatcaa	68880
aatacagagg	agaaacaagg	ccttcttcag	tgtctgttgt	tccccttttt	gtccatgagt	68940
tctcatcatt	tagctcccac	ttacaagtga	gaacatgcag	tatttgtttt	tctgttcctg	69000
cattagtttg	ctaaggacag	tggcctctag	ctccatccat	gttccctgca	aacatatgat	69060
cttattcttt	tttatggctg	catagtattc	catggtatat	atgtaccaca	ttttctttat	69120
ttatttatgt	tattgatagg	gaatttaggt	tgattccatg	tctttgctat	tgtggatact	69180
gccgcagtga	acattaacat	gcatgtgtct	ttatggtaga	atgatttata	ttcctttgat	69240
tgtgtaccca	acagtgggat	tgtctgggtca	aatggtagtt	ctatttttag	ctctttgaaa	69300
aatcaccaca	ctgctacaaa	atcaatgtgc	aaaaatcaca	agcattccta	tacaccaata	69360
acagacaaac	agagagcaaa	atcatgagtg	aactcccatt	cacaattgct	tcaaagagaa	69420
taaaatacct	aggaatccaa	cttacagggg	atgtgaagga	cctcttcaag	gagaactaca	69480
aaccctgct	taatgaaata	aaagaggaca	caactaatg	gaagaacatt	ccatgctcat	69540
ggataggaag	aatcaaatatc	gtgaaaatgg	ccatactgcc	caaggtaatt	tatagattca	69600
atgccatccc	catcaagcta	ccaatgactt	tcttcacaga	attggaaaaa	actactttca	69660
agttcatatg	gaaccaaaaa	agagcctgca	ttgccaaagc	aatcctaagc	caaaagaaca	69720
aagctggagg	cgtcacacta	cctgacttca	aactatacta	caaggctaca	gtaacccaaa	69780
cagcatggta	ctggtaccaa	aacagagata	tagaccaatg	gaacagaaca	gagccctcag	69840
aaataatacc	gtacatctac	aactatctga	tctttgacaa	acctgacaaa	aacaagaaat	69900
ggggaaagga	ttcctattta	ataaatgggtg	ctgggaaaac	tggctagcca	tatgtagaaa	69960
gctgaaactg	gatcccttcc	ttacacctta	tacaaaaatt	aattcaagat	ggattaaaga	70020
cttaaatgtt	atatctaaaa	ccataaaaaac	cctagaagaa	gacctaggca	ataccattca	70080
gcacatgggc	atgggcaaaag	acttcatgac	taaaacacca	aaagcaatgg	caaccaaaagc	70140
caaaattgac	aaatgggatc	taattaaact	aaagagcttc	tccgcagcaa	aagaaactac	70200
catcagagtg	aacaggcaac	ctacagaatg	ggagaaaatt	tttacaatgt	atccatctga	70260
caaagggcta	atatccagaa	tctataaaga	acttaataaa	atttacaaga	aaaaatcaaa	70320
caaccccatc	aaaaagtggg	caaaggatat	gaacagacac	ttctcaaaaag	aagacattta	70380
tgcagccaaa	agacacatga	aaaaatgctc	tattatcac	tggccatcag	agaaatgcca	70440
atcaaaacca	caatgagata	ccatctcaca	ccagttagaa	tggcaatcat	taaaaagtgc	70500
aaacaacagg	tgtctgagag	ggtgtggaga	aataggaaca	cttttacact	gttggtggga	70560
ctgtaaaacta	gttcagccat	tgtggaagac	agtgtggcga	ttcctcaagg	atctagaact	70620
agaaatgcca	tttgaccag	ccatcccatt	actgggtata	taccxaaagg	tttataaatc	70680
atgctgctat	aaagacacat	gcacacttat	gtttattgca	gcattattca	caatagcaaa	70740
gacttggaac	caacccaaat	gtccatcagt	gataaactgg	attaagaaaa	tgtggcatat	70800
atacatcatg	gaatactatg	cagccataag	aaaggatgag	ctcatgtcct	ttgtaggggac	70860
gtgggtgaag	ctggaaacca	tcattctgag	caaactatcg	caaggacaga	aaaccaaaaca	70920
ctgcatgttc	tactcatag	gtggaaattg	aacaatgaga	acacttggac	acaggggtggg	70980
gaatatcaca	cccctgggccc	tgtgggtggg	tggggggagg	gatagcatta	ggagatatac	71040
ctaattgtaa	tgctgagtta	ctgggtgcag	cacaccaaca	tggcacgtgt	atacatatgt	71100
aacaaacctg	cacattgtgc	acatgtacc	tagaacttaa	agtataataa	aaaataagca	71160
agtttacaag	ggcaaaaata	aaacaaaaaa	gaaaaagcac	cacactgctt	ccacagtggc	71220
tgaactaatt	tgcactccca	ccagcagtat	ataagtgtac	cctcttctcc	acagccgtgc	71280
cagcatctgt	tatcttttga	ctttttaata	aaagccattc	tgacaggtgt	gagatcatat	71340
ctcattgtgt	tttaatttgc	gtttctctag	tgagcttttt	ccatagtgtt	gttggtggca	71400
tgtgtgtctt	ctcttgaaaa	gtatctaaaa	cagtcactta	tcttttaaaag	aaacttttta	71460
aatcagaaaa	aaggtgttta	tatttaacca	cgtattttatc	atltgcagtg	ctgttcattc	71520
tgtttcttag	gtcaaaattt	ctatctggta	tcattttctt	ctgcctcagg	cacttctctt	71580
tattatactg	ctgatctgat	gctgattaat	tctttcagta	ggtgatgtt	ttcatagctt	71640
tttattttat	ctttgttttt	caaagatatt	ttgaagagta	tagaatttta	ggtagacagg	71700

ccgggdcgag	tggctcacgc	ctgaaatccc	agcactttgg	aaggccgagg	cgggcaggtc	71760
acctgaggtc	aggagttcaa	gaccaacctg	accaacatgg	agaaaccccg	tctctactaa	71820
aaatacaaaa	ttagccaggc	atggtggtgc	atgcctgtaa	tcccagctac	tcgagaggcc	71880
gaggcaggag	aatcacttga	acctgggagg	cagaggttgc	ggtgagccga	gatcgacaaa	71940
ttgcaactcc	gcctgcgcaa	caagaaagaa	actccgtctc	aaaaaaaaag	aattataggt	72000
tgacagtatt	attctttcac	atccttaaac	tatgttgttc	cactgtcttc	tgatttgctt	72060
tgttttccaag	aagtcacctg	tcaatctaata	ctttgttccct	ctgtatataa	tttttttttc	72120
tctctagcag	cttttcagat	tttctcttcc	tactcgtttt	taagcaattt	gattatatgg	72180
atattagcat	agtttccttc	atgttgcttg	tgcttggggg	tcacgcagat	ccttagatct	72240
ctggggttat	atatttagta	cgttttaaaa	ctttttggcc	attatttttt	caaatatatt	72300
ttctgtccac	tcctcttcat	cttcttctgg	aacccagttt	gcacatatat	ttggctatgt	72360
gaaatttcct	acagctcact	gatgacctgt	tttttaaaaa	atcttttttt	tctctttcat	72420
tttgaaagt	tttattactg	tgtctgcacg	ttcaccaata	tttttgtctg	tagtgtctaa	72480
tatgttctta	attccatcta	gtgtattttt	tctcttaga	cattgtaatt	tgcaatttct	72540
atagatttgt	ttggggtctt	tttttttcat	atctgccatg	ttactcctta	acataccaat	72600
gctttcttct	ttttctgac	atatggaata	tataatagct	attcaatgta	cttgtgtaca	72660
aattctgtct	tctggatcta	tttttgttta	gtttttgtcc	taattatgaa	ttatattttt	72720
ctatttcttt	ccatgcctgt	tagtttttta	ttggatgaca	ggtattttga	attttgtatc	72780
gtaagtctt	ggattccttt	tttttttttt	ttttttgatg	tgctttttaa	tacgtttgag	72840
gattgggatg	aagttaaatt	tgggaacagt	ttgatttttt	tgattctttc	taaacttact	72900
tttaagcttt	atcagagaga	ccagagaaac	ctttactcta	gggttaattt	gacatcattg	72960
ctaaggcagt	acctttctga	attttcaacc	tgatgctcca	tgtattacaa	gatttcttga	73020
actattccag	ccccatatgt	gttacagtaa	tttttctgcc	tccacctctg	tggtggttct	73080
tttcccagct	ttgacatatt	tcctcacaca	cagcactcag	ctgaagactc	cagtgatctc	73140
tgagtgtatc	tctgtttgcg	gtttcttctt	ttccggact	ctgcttgtga	gttttagcct	73200
ccttggcttc	ctccaatatt	taactgtgtc	tcctcaacct	cagagattgc	caggctctgt	73260
tggggttctt	ccttctgtg	ctgcagctg	ggactcctta	ggcattaagc	cagagtaatt	73320
acagggttca	ccttatttat	ttcccttttc	ttaaagatta	ctgttctgtg	ctgacctgtt	73380
tctagtgtct	aaaaaccatt	tcttcatgta	tttttagatat	ttaaagttca	aaccagctctg	73440
ttttactcta	tcgttacctg	aagcagaaga	ctgacttctg	tactgtttca	tttgttaacc	73500
agagtaaatc	cttcattatt	cacataataa	attaataagg	atgatgtttt	tctcacaggg	73560
actagattag	gcaatataca	tgaaaagcat	attattgaca	gtaaagtgta	agatgctaca	73620
cagatgttta	tcattgctat	tacaaaggag	ataaccccg	tttctctgag	ttagggaagt	73680
tctatatggg	agtaaggctg	aaagggccaa	aagatatagg	tattgtttct	gaaaaactgc	73740
ctatgcttct	atgcatataa	gtatgtcatg	ttgcatattt	ttctgtgctg	tattaattca	73800
tgcaattcct	tatcaacaga	tacttattaa	acactcatat	gtcaggcatt	gttctagggg	73860
ctagagatct	ctgccttcaa	ggagcttatt	ttctagtgg	atattttctg	ttctgtgtct	73920
tagctatcca	cttttttcat	ctgcctggac	acgtgactta	ttctgtctct	gggcctctgg	73980
tatgagtgt	catttcattc	tgctttataa	ctcctatfff	cttccctact	ttatctgacc	74040
ttcctacctt	agcttgttca	ttctttctct	caatccagtt	gtcatgaaat	ctctttcttt	74100
cctctactaa	tttttttttt	ctttctttct	ttctgagtaa	aagccagaga	tctggccccc	74160
tgcttacctc	tctgaattct	tcacttactt	ctgacaactt	gctcatttca	ctccagctac	74220
attgacctcc	ttgcctttgt	tgtgttttga	aaacaccggc	gtggctctac	cgcaggaatt	74280
ttgtacttac	tgttcttttt	gccacattca	tcattcatat	gttcatgtct	tcccactcgc	74340
ttccttcaag	tttttctca	gttgtcatct	ttttactgag	tgtccttctt	gacctctccc	74400
tactttaaaa	tgttatgctt	ttttctacta	cctctcctgt	tcctcattcc	taccttattt	74460
ttctggataa	cacttattgc	cttctaaatt	gtatcgtata	atftacttct	ttgtttcttc	74520
tccgttgtca	cactagcata	taaattcagt	gaaggtagag	attctttttac	tgctgacaaa	74580
agcatctagg	acatttctctg	gcaactgataa	ggatctgcat	aaatatttgt	tgagtgaatg	74640
aatctccttg	gtaaagtctt	tttttgtttg	cctgttatat	ttattgaata	gacttctttg	74700
tttcatgtac	tttaatttca	aaagtgaatg	gctggaacat	tttatatatt	ttcttataaa	74760
tcattttcat	tgcttttttaa	gcttatcaca	tattttgttt	tataaatatg	tagccttctg	74820
gagataaaaag	attctccatc	cctgttttacg	tgtatactta	gatgacaact	ctaattggtca	74880
taaaataattc	caaccttata	gataactcag	gagaagatga	gattataagt	agactttaaa	74940
tcccattcag	aaaccaaggg	acaattcaaa	aggaaaataa	tcattccaaa	tataatattc	75000
ttcttattct	taagaagtgg	ttagtatttt	gaattttgaa	tttttaatac	agctcccata	75060
gaaaataactt	taaaatgaac	ccggtaagac	ttcctcatta	agacatatag	acacatatgc	75120
tcccactccc	gtaatcaaat	ttggaagtca	aataagctct	gaaaacccaa	acattcttcc	75180
aagtttattg	cagactcatt	tggtagttaa	aaccaatctg	acctgatgtg	tagctgttta	75240
tagtctttat	ttttccattt	ggtgagtcca	attatatatt	tcgctgagga	aaactaacg	75300
tgtttgacta	cattgtgtgc	cccagacctg	cttagagtat	tatgtaatat	gcagtatagg	75360
ccatatattg	cctttttaac	atcaaaaata	ccctaaattc	tgaaatgcat	gtagccccaa	75420
gagatttghta	taaagcattg	agggcctgtg	tatttttttt	taatttacia	gtgaagccag	75480

attccctaga	cattaagtgc	ctaacttttg	gttggtgttg	ctgctgctgt	tactgttttt	75540
tctccagctt	cgcaaacctg	ggtatacttc	atgtgacaaa	gaaaaaagta	tttgaaacac	75600
tggaaagcacg	aatgacagag	gcgtgtataa	ggggctataa	tcctggactc	ttgggtgcacc	75660
ctgaccttg	ctatgtgcaa	gcagaagggtg	gaggggaccg	gcagctggga	ggtaagcatc	75720
atthttcctgg	ccttgatcct	ccaaggggtc	caggtctttg	ttttcatctg	tatgaattat	75780
atgttcatct	gcatcccttc	cagtctctac	cccacactgc	tgtcaccttt	tccttgctca	75840
gaaacctttg	atggcatcct	gctacttcta	ggataaaaaac	tatagctcca	tagcctgtca	75900
tacaaagccc	tgcttctctg	gccccagcaa	ctttcagcct	catctccagc	ccaccttgca	75960
tcctcctctt	gccatctctg	ctctctgaat	aactgaggca	tatttatacc	tttgtatgtg	76020
tcttccctta	ccaaaaacac	cccaccgttt	ccatthccacc	ctctcgaaaa	ccaatgcaga	76080
aatcaagact	ttgtctaaag	aacacctctg	ttttaccttc	cccaactcac	cttattataa	76140
ggcatttttc	tttctttggg	ctctgcagac	acattataaa	ctattatctt	tatcataaaa	76200
attgtatgat	tttccatttt	cttgcccttt	ctcaaatttt	tttttcaacc	ccattccctg	76260
tcccaccaca	tgccccattt	ctacttttgt	atthttgtcct	ttactctggc	cgtccagtcg	76320
tcctctgata	ctcatgtgat	tcaaaaccga	ttatcagttt	tccactaaat	atactccatc	76380
ttctgatacc	cagactcaaa	accttcccat	cctcactgac	tccccctcct	cgctgtgct	76440
gagggctgt	ggtccagcca	ttccgtgctc	tctggcattc	cacactacat	tccattttca	76500
ttgttccact	tatagtagtc	ttctccctgg	tctctgtccc	tccccacttc	taatcaagtt	76560
tacatcttgt	agccagatag	atattactga	agttctgtat	cttgttgctg	ctccgtgtct	76620
ccgttttgcc	tacaaaatcc	aaattctgta	agttggcttt	ttggatctcc	caagagctgg	76680
cctcaggctg	catttccaat	ctatthcccg	ttttgcccct	tcagggtcaaa	gtctactact	76740
tggtaggagc	accatgattt	ctcactttcc	tgccctggca	cattctttct	atthtttgctc	76800
tctcctcttc	ctggaatgcc	tttatccact	ctcttatatg	aatgtgttca	aattctgcca	76860
cctthttcaat	atthcagagca	aatacctctt	ctgctccaaa	gccctctgaa	ctctctcctt	76920
ctthtgaaatc	ccacatcact	tcattttgtag	ctctcttgta	gtacttgtct	cttgaatcac	76980
tacctthttat	gatattatag	cttaattatg	actatatcca	tcagcgtgaa	aactccagca	77040
ggagggaag	aaacagatgt	ccctgagtca	ttcagttcct	tcagaagttg	ttthttgagta	77100
cctactatgt	gccaggctgt	ctgcttgcca	ctgtggaatg	agctcactcc	ctgtgcccac	77160
gcagctcttg	gaaataatttg	cacacttctc	aatacagctg	gtgcctagta	gggttattca	77220
attccattcc	atcacatcct	gtgtgccttt	aactcttact	gtagagagga	aagggaaagg	77280
tgggggaagg	acaggagagg	agggaggoga	tctgatacac	ggaagagagt	ttthactgta	77340
atccggagaa	aatgcaggtc	ttctthtgatg	cctthtcatat	tggatgacat	aaatgagact	77400
gtthtttaaca	ctthtattagc	aatatgaaga	gtthcaaaag	aggaaaaatg	ggthttttatt	77460
gtaagtttac	atthtthtggg	ctthtataaaa	gcatggctct	ttaaatgttc	acacttccct	77520
gggcatgaat	ggactgtgct	gtatggccct	agatcgggaa	aaagagctaa	tccgccaagc	77580
agctctgcag	cagaccaagg	agatggacct	cagcgtgggtg	cggctcatgt	ttacagcttt	77640
tcttccggat	agcactggca	gcttcacaag	gcgcctggaa	cccgtggtat	cagacgccat	77700
ctatgacagt	agtgagtagt	tcacttccaa	cagggggcac	accaagaata	gacttccagc	77760
cctgccctgc	catttacttg	ctagctgagt	cctggggag	gtaacttaat	cactthtaagc	77820
ctcagcttta	tcatctgtaa	aatgtgaata	ggaaaatcta	gcttgaaagg	ttgatgtcca	77880
ggttaaataga	ggtatthttaa	gaggggctca	atacatgtaa	ttctthttcc	tttgatgtac	77940
atthttttagt	ctthttacatg	aatgttcaca	tctcatctta	tttatgaatg	tcttgctata	78000
aagatataatg	gttgatactt	ttagaaggga	gaataatccc	aatthttctt	ggtggtgggg	78060
ggactctgga	aaggagtthta	taaaagacaa	ctatthttct	taccatthtt	ctthtccata	78120
tgttactagc	tttatcaaga	gagaaacttg	aagttaaatg	aatgagttagc	atagacagca	78180
tgtgacttca	aaatcctatt	tcaagccggg	tttggcgtca	tgccctgtag	tctcacctac	78240
ttgggaggct	gaggtgggag	gatatggagt	ttcagcccag	catgagcaac	ataatgagac	78300
cccatctcaa	aaaaaaaaat	atatatataat	atatatgtat	atatatatta	atthtatagtt	78360
cctaggactt	tttaagagtt	ttacagtaat	cttcagcatt	taccatgcaa	ctthtctgtt	78420
tgattatgca	taggattgat	tagacaggta	ttthcaaaaa	gcctgcaagc	atagtactca	78480
gactcattga	aagtttatag	aatthtggcct	gtgtggaaaa	ctctgtgctc	caagtacaac	78540
aactaactga	atthtcttaat	ttaaacaact	ttgaagggaa	gtgaaagggt	ataaaatgat	78600
acagactcat	accgcagaat	caccttaaaa	tgcagctggt	ggagaaaaaa	aaaagggaag	78660
ctthtatgcta	ttaccacaag	aaagttthtgc	ctcttcacca	cacagaatcc	taatthtagtt	78720
tgggaaaaaag	aaacataaca	tccccatttt	ccttacctgt	aaaataaaaag	gtagtaagta	78780
gtthtaagaaa	actgtacttt	tcctaaagtt	tttaggactc	ttgtaaatag	aataatagca	78840
gaatcatgga	aacaaatttg	gaattgaagt	cttgacctca	ttgaaagccc	agaaatcaat	78900
tagcttggtg	ctthcccaata	catcagaaaa	gctctthtct	ttthttgtgtc	agtctctctg	78960
tgtttagagg	agaaacaaat	acctgttct	ttctacctca	tttgtthttgg	tgatcataaa	79020
tgacctatgc	ccaagaagtg	ttccgagaat	ttcagaagcc	atthctgttt	tatthacttt	79080
gttagtgaaa	gcatgtatth	aagctthtgtt	ttggctcatgt	gtgctaagg	gaggttccca	79140
cctaaaggac	tggcttggtg	agctgaggat	taatcatggt	atthgttggt	ttthccctgt	79200
gaacagaagc	ccccaatgca	tccaacttga	aaattgtaag	aatggacag	acagctggat	79260

gtgtgactgg	aggggaggaa	atztatcttc	tttgtgacaa	agttcagaaa	ggtaaataca	79320
ttctgtgatc	tctgatctca	agaggtgtga	tcttgacaca	ctacagttct	gagtgtgtct	79380
gtgagtcaca	tttcagcagt	ggacaagaaa	catccctctg	ctgccacaga	aagtcttaaa	79440
aagcatttac	gttttacctc	ttccaaatgt	aaattgtctg	tgttatTTTT	tcctaagtca	79500
actaaatcac	ttttagattt	cccatggaag	taaaaagaaa	taagaaaacc	gtgataatta	79560
taatcagtga	ctttcagtat	ctttatacat	taaaattaat	atctgtactt	tgtaaaca	79620
aaataaataa	tagcccatc	ttgacacaca	tacaaacaca	cacacagaat	aatgttttac	79680
atagtattaa	attgttttta	tttcttttgc	aatgctttga	tataacactg	agagaacttc	79740
tctgaacact	tccacagatg	tgatgtttaa	gaaaaggaaa	gaaaacaggg	aatacaggga	79800
aattctcaga	gcacatttct	ctcacaatTT	tccctttgag	gaaaggttct	tggcgtttat	79860
ctttcattag	atatattaca	acattgatag	attagtaaaa	gctgaggaaa	atgtgttatt	79920
ttctcaaaact	gcattctttt	tttaataaaa	atgatagttg	gaaagtgtag	tataatatct	79980
atztatcaca	gggtgagcat	tttcaaagta	agcagatacc	taactgaaaa	tataaataag	80040
taaaataaat	caataaaaaga	catgtggcct	ttaaaaaat	tatcatatga	gattaaattc	80100
tctgaggtat	atagtcagaa	aaaaatggga	tcagatTTTa	aagtaaacac	atatatactt	80160
tatccaaaaa	aatttacagg	ccaggcatgg	taactcatgc	ctgtaatccc	agcactttgg	80220
gaggctgagg	tgggaggatt	gcttgaaccc	aggagtTTga	ggctgtagtg	agctattatc	80280
atgctgctgt	actccagcct	agatgacaga	gogagaccct	gtctcaaaaa	aaagaagttt	80340
acactttctc	tgccctacact	agtgtcagcc	ttcttccaat	ccactctgtc	caagtaatac	80400
tcatttccag	attcctgggt	gtacatactg	tgagtaaaaca	caatctgagt	acctttattt	80460
gtaaatagaga	tccttagtca	ttatcattac	attggaatgg	cttagtaaga	aatgtcttgt	80520
acttggctta	agaatctca	ataactaggt	ccagtgtagt	cctacctgaa	ggcaaaggag	80580
attgtaagat	gttttatcca	ttcctagtat	ttctaaaatt	ctacttacat	agagataaaa	80640
actttgaaca	aagtcaatag	tgtggccctt	tctatgaaac	ggaaagtgaa	gccaggaaga	80700
tgccaaccta	agttacattg	tcacatttct	gtagaagtga	atagagtatt	tataaacatg	80760
ctgaacatgg	agtatttata	aacacactcc	atgactagag	tgtgcaattt	aagcattgca	80820
ttttaattag	aagggacctg	attattatag	tattttgacc	aattactcaa	tatgaactaa	80880
gagactatta	tagtgagaca	gtttaatag	gtgttaagag	cctggactct	gaaattatac	80940
tgtctatggt	aaaatcctgg	ttcctccaag	tactagctgt	tcagccttgg	ataagtactt	81000
aacctctttg	gacccagttt	tctcttttgc	aaagtgagga	taataatagt	acccatctac	81060
atcacaaggt	tgtggtgagg	atgaaatcag	ttaatatgtg	tatatatgaa	gcacttagaa	81120
tagcatctgc	catacattaa	tagtaaaaact	tatataagtt	aattatTTTT	atgtacatct	81180
atatattgaa	ttgcaactgcc	tcgttggatt	ctaataattct	tccaccatcg	ttcgtgtttc	81240
tcaggattgg	cttaaggatg	gagaagcagt	aaggtcaaag	attaaaagaa	aattcaagtt	81300
aactaggtaa	atctagtatt	ctgtcattgt	gaatgaaagt	tggggcgcac	tactgtggta	81360
aataatgaaa	aaagtcagtg	atTTgtgaag	atTTtaaaag	actgaacctt	ttgatcttgt	81420
TTTTtaaaag	tgtaaataga	tagtaggtag	aatattaaac	cagttttatt	tttcagcatg	81480
tttataaata	ctatTTacac	tatgtgaaat	tacacacttc	aatgtgattg	tttgcagatg	81540
acatccagat	tcgattttat	gaagaggaag	aaaatggtgg	agtctgggaa	ggatttggag	81600
atTTttcccc	cacagatggt	catagacaag	taagtgattt	attattatta	ttaatcctta	81660
ttatTTtttag	agatgggatc	tcaactctgac	accaggctg	cagtgcagtg	gtacaatcac	81720
agctcaactgt	atcccccaac	tgttgggctt	gagggatcct	cctgtctcaa	cctaccaa	81780
atctgggact	acaggcatgc	taccatgccc	agctagtTtc	ttcagtttta	ttttttttgt	81840
agagatgatg	tcttgccatc	ttgctcaggg	tcgctttgaa	ctcctggact	taagcgatta	81900
tcccacattg	gcctcccaaa	atgctgggat	tataggcatg	atccatatta	ctatcatcat	81960
tttatacttt	ctgccttatt	gaaatttagt	acttagcttc	catctataaa	aaagaaaaat	82020
cataaatatt	taacttccat	aaaacagtac	tatttttaag	actcatgcag	gtcatccaaa	82080
aaagttacct	actgtagagt	tatgggcaag	gttctgttag	atcgtttgct	ctgagatggt	82140
ggcaagatat	tttaattgctg	cctaataccc	taaccataa	gacagtgcc	cacaggtcct	82200
ttaatgaaaa	tgTTTTtaag	tgttctacca	aagtaattat	gatgagacct	atTTtatgat	82260
agcaccta	tatgataaca	ccttaaaagg	gtgttctagg	agtcatcttc	taattgaagc	82320
tgatgtcatc	ctgttaa	aagatTTccc	aatggcaact	gattaaatga	tcagttta	82380
catttaataa	catgataatg	ctgagccccc	accttaatta	ttattctcct	atTTacaagt	82440
aattgaagag	tattctccta	tttacaagta	attatctgga	ttggaaacaa	tccagatatt	82500
catcagtaag	tggccagtta	aattatggtc	tgctcttttg	atgaaatatac	atgtagttat	82560
tcaaaagaat	gagtactctg	cgaactaata	tagaaagatc	tcagttatac	agtgttaaaa	82620
tatttttaaaa	gatgggtgta	gaacaaagtg	tgtgtagaaa	tgattctatg	ttcatgcata	82680
aagaaattct	ggaaggatac	ctaagaaatt	aataacagta	tttaccactg	gctggtacac	82740
tgtaggaact	gcatggatgg	ggaacaagaa	tgtcaaagag	aataccactg	tatgctTTTT	82800
tatatTTtat	aagatctTTa	tccctgtgaa	tatattacat	agtcaaaaaa	tcaactgaa	82860
aaatgcttaa	atccctaaca	taccaccaag	aactaatgtg	ttatgatgcc	aatgtaagca	82920
atgTTtagtt	tcttctcttc	atcactggcc	tgtagccatc	tctctctttc	cataccag	82980
ctttctgatg	ttgctctaaa	taatcttgg	ggctTTtaag	gctgcttgg	aagagaagaa	83040

agtatatgca	gtgaatthttta	taagcatgat	atthacaact	agaagacatt	tgaatatagac	83100
aatgaaata	ataaagcttc	gtagtacatt	agcatagcat	tgtatthttga	thttacagta	83160
gcaatthcat	aaaaatgtat	cggtatagaa	ttctgagtht	ggaactthct	ccaggacacg	83220
gtgthttthta	gtacactgtg	tctaaacatt	gggtataaag	aaaagcataa	ggaatgtgtt	83280
taatgagtag	cattactgca	aaaaaaaaa	aatgtagtc	ctacaccaac	atgtggttct	83340
tcgtatcctg	cagthttgcca	ttgtcttcaa	aactccaaag	tataaagata	thaatattac	83400
aaaaccagcc	tctgtgthttg	tccagcttcg	gaggaaatct	gacttgghaa	ctagtgaacc	83460
aaaacctthc	ctctactatc	ctgaaatcaa	aggtaagtca	gttgtthtaa	atcttatgct	83520
catatthttat	thttatthttat	thtttggttht	tgtthttgtht	tgtthttgtht	tgagacagag	83580
tctgactctg	tgtcccaggc	tggagtghaa	tgggtghaatc	atagctcact	ghaacttgha	83640
actcctggcc	tcaaacagtt	ctcctgcccc	agcatctcaa	atagctghga	ctacaggtgt	83700
gcccaccat	gcccggctaa	thttthtttht	thttthacttht	taatagaaat	gaggacttcc	83760
tacattgtcc	aggctggcct	thaaactcctg	gccttaagca	gtcctccggc	cttggcctcc	83820
caaagtgtg	ggattacagg	cttgagctgc	catgtcttgc	cattgtgctt	gttctgagaa	83880
gaggacaagc	taattagaaa	agatcagthta	gtcacctcct	ttgaacagct	thctagthaac	83940
aggthccctgg	atccatggthg	ctthattthttta	ghaagagacag	tagthataatta	thtttgaggthc	84000
atghaattag	tctagctthtt	thaaaataatg	thattthccac	caagctthata	tghagatthtag	84060
acattghagaa	thttgtctthttg	aatthtgagaa	tctaacattht	atthgactaac	thcagagthtca	84120
agcagctghg	atghaaaaat	caggctthgct	gtthtaggha	atcagccagth	tagthcaacca	84180
gcctcagggc	gtghaacaga	aaactthggcc	aacatghcact	gtghaaactat	ghaaaatghagth	84240
aaggcatcat	tctthctctc	acaaaagatg	ctthtaagaaa	ggghcactcat	aggthttcttha	84300
aatagthtata	atghaaatta	tghatththtaat	aagthaccghaa	agthghaagcat	ccataaaaaat	84360
ataagagaaat	gtthghaaggha	ghagccctthgg	thccctthtatt	ctaaagcagc	ctccaaaaag	84420
aaggctthcgt	caaggghagata	thcattthggcc	ctcagcattth	ggghgtatatt	thcagcagthtg	84480
ggtgtthaaac	agaghaagghag	aggghthctct	aggththaaagth	tactthghaggha	gctthaaagag	84540
agaggthaaac	acagcghthta	tghcagagghgha	aaaaagthgth	ctghagcghctc	ghgathghagat	84600
ghaagghcaat	gtghghthaag	aagghccagghg	ccagghcthaa	ghagghctghg	aatghghcagct	84660
thaaagatthtt	ghcattthaatc	tghghagghgha	tagccghghcc	tghcctagghth	tghghaatghagth	84720
gctctghactth	ctthtatghthca	ccactghagghg	taccattthtag	ghagghcagatgh	atghagthcaggha	84780
agagthaatghc	aaghaatccaa	gtghaghaaaca	gtghcagthtag	thaaagghctct	agthghccaggha	84840
atghaaagghag	atghghthghact	thaaagagagghag	tghcagthghata	ctghthghataca	gtghgatactghth	84900
caagagghghcc	tghagghthcghg	aggthghthaggha	ghagacghghgha	gtcatagatgh	ghgthcthaagac	84960
thccctghacca	ghghaagctthgt	ghatghthghthttg	actthghatghaa	agghaacaaggh	ghagcaaaaagth	85020
agatththghghth	ghghghaaagghaa	ghghagctcaggha	ghthaaacatgh	thtatatththta	ghgthccctghthg	85080
ghghaaatcaa	gtghthaaagththc	thtagthagghca	ghatcaaaaaggh	caghaactghgha	actcaagghaggha	85140
ghghacagghghthg	aghaaatthtag	cattghaghaatc	atctcaaaaac	ghagatataaac	agghcaccac	85200
tghagthcatca	ththcaagghthta	ththctthaac	tagagthccac	tghaccccaaa	agagthctghthg	85260
ghatghghaaatgh	tactththghata	thcatcagctth	ctthththataat	cctghthththgt	atthththacata	85320
ctghaaaacca	tghattctghag	aagagatthcca	tagagththcac	cagactghcag	aagghghctghth	85380
ghghcacaaca	aaattghaghaa	cccctcagth	ghghagghghaagth	ghagactghgha	agghghagghthca	85440
ghthaaatghat	tghccacghghghg	cacccagatc	ctthghctghaggh	thghghaaaccg	caaaagghthghca	85500
ghcagcaaca	ghccacatghghg	tghghthghthgt	ctcctghthghag	agcaagatghth	ghatagghthaat	85560
ctththghaagghag	ghcctththcctth	thcctghaghaat	cghthghthghcca	cagghagthghth	tghaghaaacghg	85620
thctcaagatgh	tctthghthctct	ththctghagghth	tghthghcctct	ccattghthththg	ghcagatthththg	85680
tagthghcactc	tatatcctghg	tghghththghaa	acattghthcag	cacaataact	ththctthctct	85740
cacatghagat	ththcatacaaa	atcccagthghth	atghghacatghg	tagghctththgha	ththaaaataggh	85800
ghgthghaagghc	cctghccagct	cghghcctthccg	agagghctghthc	ccacctctcc	ththactthccct	85860
atcagghagct	ghctghghagghthc	thththghaatghc	thctghcctac	acaaaatghat	ghthghaaaatca	85920
ctghctththaat	ththaaacaccc	thctthththaaa	ghthghacacag	aaghaaaaata	tghghataatthth	85980
thththtagactth	tctghagghghaa	aaaatghagatth	thctthctccag	aaatathghthct	thcaaaataatgh	86040
ccagthththththg	cthaacacaggha	ghaatcatghaa	ghaaaghaaaac	ccagghththacc	tghthathghthgha	86100
tghaacctghaggha	aacattthcaaa	ghctcagctththg	ghthathctagghc	tghcctghthctc	cctththccag	86160
tghghthathctat	ghcctcagghaa	agthathghththth	agthghghghghth	taththcagghthg	atthactthththaa	86220
tghcctcghthta	thcatagthtaggh	aactatthcca	tghcagghghatth	agghaghaatghghg	ghthcactghghaa	86280
agththcaaaaat	tghcacctghthta	tghctthcatghc	acctacctthc	cagghctghthca	ththghatghaaa	86340
ghctthcataca	atacaaaagthth	thaaaghaactghth	ctghghaghaaat	actthaccct	tghghagctctgha	86400
agghaaaghaat	ghghacaacata	taththathathth	agghacaaca	atthactthghat	thctathaghaa	86460
cctthctghghat	taththaaaact	caagathata	ghghaccaaggha	ghaaaataatct	ghaccagghghaa	86520
taththaaactghghth	caghaaaagthta	ghtagghcctatth	tghagcattgha	ghthaaagthghat	aghaaatghghat	86580
ccaaaactghthta	caaccagghghg	aaacattghthca	tathctatthctc	aghaagthcatt	ghaacacactth	86640
thctctthacc	ccagthctctgh	tagthcattthcc	ctathctcatt	ghccthaatthth	atghthctththca	86700
thththththththth	caathathghthaa	acctghthctthta	thctatththththth	tathghghthctha	ththghctthctct	86760
accacccgha	ghthacaaagghaa	thctctththththth	ghthcatagact	atctghaghaaca	ghthataagththg	86820

catagaaaat	gctcattaaa	tatctgtgga	ctgacttatt	gattgaccag	ccaagctgcc	86880
atccatcctc	atctataagg	ctagtaatat	gttgggtatc	atcaggtaa	acattataca	86940
taaatataaa	gcatcataca	gaaccagccc	ggagctttgc	atcctctatg	gtcatcaaca	87000
ttgtacttca	caaaaaatta	ttggagatgg	ttgggtccag	gggagacgat	cgaaaaaatc	87060
aagagaagga	tgattggcag	aggaggaaga	tagttgagga	actgctgtac	aaaagcaaaa	87120
aaaaataaaa	aaaaaataaa	agagaccata	atgatttttc	agtctgaaag	atggagatta	87180
gggataaata	atcttttaaat	tatgaaaggt	atggccaaga	taaatgcagt	cacctttact	87240
ggtaaactaa	aacctgaaaa	gtgagaatga	ggtactttta	aggcacatgc	acagaaatag	87300
gtagcaaaaca	ctaggagatt	atccatattt	gtgaattgaa	ctattatcta	aagtcatcaa	87360
ctgttatgta	aagtcattga	ttattaaagt	cactggttat	tattatacaa	agctattttg	87420
gagtgttttc	aaaagaatga	cagcctaaca	taatgaaaac	atcactgcac	tttgagactg	87480
atcttgactc	cattgtgacc	tcagataagt	cacctaaccc	ctcctagctt	cagtttcctc	87540
tcctgcaaaa	ggagaacttg	tagtaagtgg	ctgctttggg	tccttctaaa	ataggttgat	87600
gtttcatagt	acatcccattg	gtgccattgt	caaaagcaga	ccgcaaggat	aaatgatccc	87660
ttgaatatgg	agtgtgaaag	tctccatatt	caattctgtg	gagattcaaa	cagcaggttc	87720
ttttataaag	cttatgtgga	atgttctgta	tcagtttctt	gtcattggaa	tcttactagc	87780
tgtgttataa	ttaatatattt	gcccttaaaa	ttcccatttt	acagtgaaat	acagccaata	87840
aatatctctc	tgcttttaaaa	ggtaaaatga	atacatagaa	aataactaact	agtctctttg	87900
ctggaatcca	tgtcaataga	taacattttat	ttctgaagat	aaataagttg	cctgcttccc	87960
tcttggtgtt	catatgtctg	cagtgaacag	taatgagtat	agctgtaa	tagttaagat	88020
agaaccgatg	gggaaattat	aaatctgaat	ctaaaacata	tttgataagt	aagtcaaagt	88080
ttctccactt	aaaggtcatc	cccttctagt	ggaagcatat	ttttctcaaa	atgtggcaac	88140
cttggttttt	tttttttctt	gggaagtctg	gagatgctca	gcttttaaac	aactattaaa	88200
gtgtactttg	ttaccctgct	ttcccctgct	tcatctttca	actgcagtta	gatgatcatg	88260
agataatcag	taaacagaga	ccttctatct	agccctaaga	tgactgaaac	aaccacagaa	88320
ttagaaaataa	tcgaagttct	ttctgaacat	aagcatgaca	aaactgacat	tgaagaatca	88380
gaaatagaat	aattgtaag	ggttcagcac	taatcaaaaa	aaagaatacc	tcattgactg	88440
tatttaattt	gaaaaaacga	aataaaacct	ccttaactgc	tccagcccaa	aaaaagagaa	88500
gaaaggtata	tgatagaaaa	agaagagaaa	gaaaaggaaa	cagaaaggag	aaacaagaac	88560
acagtaacac	cacataggca	gtaacggaac	tcaaaagggc	attggggctg	gtgagaagca	88620
cagatagcga	gaaacagaaa	gatgaaaaca	aaacaaaaag	aaaagcaatc	agaagtctca	88680
gagggcatca	ctgtattgta	gtcaaatagt	ggtcttagac	ttttagcccc	agtatctcat	88740
cagtcaccag	aggttacaga	tcccctgggt	actgtttttc	tggcatccac	cccattttta	88800
ttatcctggg	gaccactaag	gaatgggct	ccatcactta	tgtccgcatt	gtctctgcct	88860
ctcactttaa	ctcttttagta	tgtcccacac	acacgtaaaa	gatgaacttc	ctaaaatacc	88920
atcccctaca	cattatttcc	ctgttcaaaa	acattcagca	gctttcttgc	ctgtaagttc	88980
attctccggg	tgctccgcag	tgttgtecca	aacagttcca	tttctcagga	attccttata	89040
cagtcatagc	ttgtttcttt	atattttgca	aatactgtga	tttttacaaa	ttgaaggttt	89100
gtggcaatag	tgtcaagaaa	gtctattggg	gccatttttc	ccacagcatg	tactcacttt	89160
atgtctctgt	gtcacatttt	ggtaattctc	tcaatactcg	aaacttttcc	atgattatta	89220
tatccattat	ggtgatctgt	gaacagtgat	ctttgatggt	ttgggggtac	cacaagaagt	89280
gtccatgtaa	gatgacaaac	ttaatcgata	aatgttctgt	gtgttctgac	tgctctactg	89340
actggcaatt	cctccatctc	tctcccctctc	ctcaggcttc	cctattccct	atcacacaac	89400
catatggaaa	ttaggccaat	taataacctt	acagtgccct	ccaagtgttc	aagtgaaagg	89460
aaaagtcaca	cctctcactt	gaaatcaaaa	gccaaaaatg	attaagctta	gtgaggaagg	89520
catgtcaaaa	gctgcagata	gcccaagct	aggcctcttg	tgccagttag	ccaaggtttt	89580
agtggctctga	gtagaagatt	aaaccagcca	caacattccc	ttttaccaaa	gcctaatacca	89640
gagaaaggcc	ttaactctct	tcaattctat	gatggcttag	agaggtgagg	aggctgcaga	89700
aaaaaagttg	gaagctagca	gaggttgggt	catgaggttt	aaaaaagaag	ccatctcgat	89760
aacgtaaaag	tgcaaggtga	agcaacaaat	gctaacagag	aagctgcagc	aagttatcca	89820
ggagatctag	ttcagaaaat	tgatgaaggt	ggccacacca	aacagatttt	cagtgtacaa	89880
gaaacaacct	tccattggaa	gaagatgcca	tctaggactt	tcataactag	agagaagatg	89940
tagaaatgcc	tggcttcaaa	gcttttaaaa	acaggctgac	tctcaggagg	ttgaggtggg	90000
aggatcactt	gaacacagaa	ggtcgaggct	gcagtgagct	ataattgcac	cactgcactc	90060
cagcctgggc	aacagagtga	gaccctggct	caaaaaaaaa	aaaaaaaaaag	gcagactttc	90120
tcattaggag	ttaatgcagc	tggtgacttt	aaattgaagc	cagtgtcat	ttatcattct	90180
gaaaatccta	gagctcttaa	gaattatgcc	aaatcttctc	tgcttttgct	ctgtaaatgg	90240
aacaagaaaa	cctggatgac	agcacatctg	tctacagcat	ggtttactga	atatttttaa	90300
acccactggt	gagacctact	gctctgagaa	aaaagaaaaa	aaaaggattc	ctttcaaaat	90360
ggtagtgtct	attgacaata	cacctagtca	ccaagagct	ctgaaggaga	tcttttcatg	90420
gctactaaca	gccattctgc	agcccatgga	tcaaaaagta	attttgactt	tcagtcttat	90480
tgtttaagaa	atacattctg	taaggctgta	gctgccgtag	atagtgatta	ctctgatgaa	90540
tctgggcaaa	gtaaatgaa	aacctgtgg	aaaggattta	ccattaacca	catttgtgat	90600

tcatggaagg	aggtcaaaat	atctacatta	ataagaat	ggaagaaatt	gattccagcc	90660
ctcgtgggtg	acattgaggg	gttcaaggct	tcaagtgaagg	aagtaacagc	agatgtgggtg	90720
gaaatagcaa	gagaatgaga	gtgagaagta	gagcctgaag	atgagactga	actgctgctc	90780
atgattttaac	tttcatgggt	gaggaattgc	ttcttatgga	tgagcaaaga	aagtagtttc	90840
ttgagataga	atctactcct	ggagaagatg	ctgtgaacat	tcttgaaatg	acaataat	90900
agaatattcc	ataaacttag	taaagcagca	gcagtgtttg	agagaattga	ccctagtgtg	90960
gaaagaagtt	aaaactgtgg	ataaaatggt	atcaaaacag	cattgtatac	tatagagaaa	91020
tcttttgtga	aaggaagagt	gaattgacaa	atttcatttt	tgtcttattt	ttaaaaattg	91080
ccacaaccac	ccagccttca	gtagccacca	cccttatcag	tcagcagcca	tcaacattga	91140
ggcaagacct	tccaccagta	caaagattac	aacctgctgt	aggcttaggt	gatcattagc	91200
ctgttttagc	aataaagtgt	ttttaattaa	gatatgtaca	ttgcttttta	agacattctg	91260
ttgcacactt	aatagcctat	agtatagtgt	aaacataatt	tttttgtgta	ctgggaaacc	91320
aaaaacatca	tgtgacttgg	tttgttgcag	taatgtggaa	ttgaaccttt	caatatctca	91380
gaggcatgcc	tgtactaaac	tttcacttca	gccaaactta	tctactcctg	ttctcaaaag	91440
caccctgtgt	acatcttctt	tttccctctc	ttatataaaa	ctgattctga	gaagcctttc	91500
ctgaatttcc	catccctcag	tgaactccta	aaagggtttc	cccaaactcc	tagaacactg	91560
atctgcacca	tgaatttaat	gtatgtcctg	ttatagtgtc	gtctcactaa	gtctttccc	91620
cactatctta	aaattatggt	ggagggttct	tggcagcaaa	gacattatgt	catgcttttt	91680
tttatttcca	gcatttagct	cattgtagat	gcataataaa	tgttaacttt	ttaacatgag	91740
ttattttgtg	tgaccaagca	aaagggtaa	taatttttta	attcagcatc	ttcaggatct	91800
ttttgatgga	taatcaaata	tttcaactag	tttaacaaca	ctggggactt	aagaaactgt	91860
tgtagagtgg	atgtgggtgt	gtactgctct	gtgggtctct	tggagctaac	tttcagcctt	91920
cataccatt	ggaataaata	taacgcttct	tgaatattac	catctcttcc	tctttgagtg	91980
ctttctat	ccctttaaga	tgtttaaaaa	taccattaga	atcagtggtc	tttctgtggc	92040
tagtgggtggg	accaaataca	tcttttctcc	tctgggttct	cttcccttaa	atacagataa	92100
agaagaagtg	cagaggaaac	gtcagaagct	catgcccatt	ttttcggata	gtttcggcgg	92160
tggtagtggg	gctggagctg	gagggcggag	catggtttgt	agtggcgggt	gagggagggg	92220
cactggaagt	acaggctcag	gtacaaaaat	acttattctt	cctaaaactt	tttcatattg	92280
gagagggtag	aattttcttt	tctttgggtt	ctgagcatgt	ctgtgagttg	agtggctatg	92340
atattattga	gtatattaat	taaaatttcc	tgacaaatgt	aaatttattt	ttcaaagaaa	92400
tccatgttca	ttttacaata	tgtaggtaat	ctcaaaagtc	attaagaaga	aaaaaaagta	92460
ccccaaagcc	agttattttaa	tgaatacctt	cctaaagatt	ttggtatatt	tctcttttac	92520
attttttgac	atagttgtct	tgtttttggt	tggaaacatt	gaaaagattg	tatattatca	92580
tactacaata	tagctatata	ttaaacatct	ctatatacta	cattgtagaa	actttgaaaa	92640
tacataaaat	ctgccatcaa	aggttaaacta	ctactatttt	tatgtatatg	ttatagtata	92700
tatttgtaaa	ttttaccctg	aatacagctg	tgatcatcat	tatgcatttt	attttaatcc	92760
atttatgtgc	aatactat	tactatcatt	tgcaccatga	ctgtgtgtat	agagtcatag	92820
gtgcaacggt	tacctgagat	gttaacataa	acatttcctc	cagtaaatatg	aactttaagc	92880
ataaatttta	agcatcattt	taatgactca	tttctcaag	tgaacaaacc	atagtataac	92940
ttacttacat	gtagtttctt	gttttctata	taaaatgcta	tactgaacct	ctgtccacct	93000
aacttttcac	ttattccaga	ttacttttgt	aaattagagt	ctttgtagta	aaattactac	93060
gtcagagggc	atgacatcta	atgccatctg	ttttcccaaa	gagttgtacc	agtttatgct	93120
tccaccaaaa	atgcctaaga	atgaacagtg	gtggccattt	ttccattgag	gagtcagtat	93180
gtttttctgt	gctttgtttg	attaagtttt	tttctcaag	gggttatttt	aatgtcttct	93240
acataggcaa	gtctgagttt	ggttggtgac	cctcactaatt	agcctctccc	cttcacatag	93300
gagtgaaggc	tttctccatt	acaaccctc	cccaaatctg	gggtgctgtc	agagttgcca	93360
acatgtaaac	tttaccaaag	tggaaattctg	atagtccecat	gacccccacc	atgtgtctta	93420
gtcccaacag	aaaaaccatg	tgtgggcaca	atactgtcct	gtcacaccaa	aggctgtgct	93480
cacctgagag	acagacacta	agttgtgctg	agtctttgta	aaatatcttc	atgatgtttc	93540
atgtgtttta	cttgccgttt	cagggatag	cttcccacac	tatggatttc	ctacttatgg	93600
tgggattact	ttccatcctg	gaactactaa	atctaagtct	gggatgaagc	atggtaagta	93660
atgctttggt	cttaatacca	agaaaggaaa	aaaataatta	atgctaaaaa	gggtttttaa	93720
aatcattact	tatcacaaca	gtattatcat	cttgacaaat	aattgatgaa	tgcaaataaa	93780
ctaagaagat	acttttccca	aaagatatta	tttctgtgg	ctagtataaa	ctctattact	93840
tttatatatt	ttatatat	actttgtgta	tggcatgaac	agaggaaaga	aaagagcatt	93900
gaaaagagac	aacagagacc	tgactattca	aatattttta	acatcatcaa	acttaatgta	93960
ttctgtctct	ttttttctca	aatagtacac	ttctgaaatc	attttgagtt	ttataggatc	94020
ggtcttttcc	catcaagtca	tcccctgaga	agctgcagtt	aaaccacatg	ttgatagttt	94080
atattacagg	tccattctag	tgtaccatg	gaagaaataa	tactataaag	aagtcttccc	94140
atttattgaa	tacctat	tgtgccaagt	gcttttacat	gttttaactg	ttatcttcat	94200
gactgctcta	tatggaaaat	agtaactcca	ttttgcacac	aaaagcattc	aaagttcaga	94260
aatgttcgta	ctcactgaag	gcacacagaa	gttagtggca	gaacaagaat	ttgaagcagg	94320
tctcctgcag	aaaagctaga	tgctctcata	gtatctgtca	gataacatag	ttgaacctga	94380

aagaggggtga	ttaggaatgg	tacactggat	aactcccaca	ctaaagaatg	tgagtgcaca	94440
acacgtcttt	atgatttgct	ttgttcatta	gcattaggaa	aaaactgctc	tgttttcaag	94500
aacttttaaaa	atlcagcttt	cctgcaattc	atagaagagc	tttatttcat	ttttctcctt	94560
tacaaataag	caaaatgaga	tttaagattt	tagaagtata	ctaaaaatga	tttttagaaa	94620
tgagtttaga	atatctccaa	aacatgggat	ttatgatatg	accattttta	aaagaatttt	94680
aaattattat	ttttcttttc	cttttgccgc	aaacttgtct	cttaccttta	tctgacctac	94740
attggaatag	cgaattatca	ctaaatacat	tttactgaga	aaaatctgat	gtttttgcat	94800
ttatcttagg	aaccatggac	actgaatcta	aaaaggacc	tgaaggttgt	gacaaaagtg	94860
atgacaaaaa	caactgtaaac	ctctttggga	aagttattga	aaccacagag	caagatcagg	94920
agcccagcga	ggccaccggt	gggaatggtg	aggtcactct	aacgtatgca	acaggaacaa	94980
aagaagagag	tgctggagtt	cagggttaagt	gagcacacaa	attacgttct	gttggttggc	95040
tggggagggg	tcagtcctag	gtgcagaaag	atatctgcta	atctaaagat	gatatatcaa	95100
tatctagttt	agtgtactct	tcaaagttct	gtatgccttt	ggaaaagcat	atgtcagatc	95160
attttattca	caactgggatt	tccattttttg	ctctgttatc	tttgaatgta	aaggacagaa	95220
atttatatgt	acattctcca	gtcataatca	tgcaagttta	gggtatttg	agagataatc	95280
aacttctttt	ctggcacaga	taaatagaga	agtatttcca	caagcttaat	agtcaccctg	95340
tctagattct	ggcttaaccg	tcatactgaa	atagaacttt	gccttaaaat	aggaactttt	95400
ctttttatct	tgtgccctct	ttgaagaagt	aggattagga	gaaaatgtac	ttttgcgttt	95460
actgtgaacc	aatacttatt	agcatatgtg	tcatgattct	aggtcatcct	agatcgtact	95520
aagaagacgt	ctataaaaagc	aaaggtagta	aatattttaga	gttggtggcc	acatgtgggtg	95580
tctatcacat	atgctttttt	tttacacccc	tttaaaaatg	tataagccat	gatttagctag	95640
ggagctatat	gaaaagcagg	ccataaacag	gttttgcccc	aaaggtcaca	aatgccattc	95700
cctgacctta	atggaacaaa	ctttacaaaa	acgtgagtg	ctcattgaac	gtctctgttt	95760
atggcagaga	tgtgtgtttt	ttcacacatt	gcctaacaag	ctaattgtta	gagattccaa	95820
tgaaggatta	tttcaccaag	atattgggtga	tttaaaatca	tggtaaaatc	taacattggt	95880
tggagattgt	tttccttaaa	ataacagata	atggctgttc	ccttaaaata	atacatttct	95940
aaactttttt	cctctaacaa	atcatacaca	gattctttta	gatcaatctc	taactatatt	96000
tgtcagtgac	ccagtgcca	attctgtctt	ttctagtcca	cacaatccaa	aagcattgaa	96060
agaacatttt	caactaaaat	gatatgtcaa	ggtgtcagaa	caactgatgct	ggtcagtttg	96120
tccttaagca	tgccataacc	ataaaacaaa	agttaggaaca	ctcaactatg	attgtggtca	96180
ttgccttaca	gataacctct	ttctagagaa	ggctatgcag	cttgcaaaga	ggcatgccaa	96240
tgcccttttc	gactacgagg	tgacaggaga	cgtgaagatg	ctgctggccg	tccagcgcca	96300
tctcactgct	gtgcaggatg	agaatgggga	caggtaagtc	agaacttttg	catgataggt	96360
tgtcctgggt	ggggaagaag	aagagcatcg	tataatgcat	actgactaga	gataaaaata	96420
attgttcaaa	tatattgagt	cctctaactg	gaatgatgaa	gaaaaataat	gtgtgaataa	96480
ggttaagtag	cacaatttgc	tgctccatcc	tgctgctgtc	atctgttggg	atctgtagta	96540
gctggaggac	tcatctaaga	gtgaatctct	ctgggcaaga	aaactaagat	gtgtgtaggt	96600
aatggactct	tttgaaaagc	cttgctttgt	ttattgaagt	aatatttggg	gaattgttaa	96660
gagtcctacc	aaatccctga	agcattgtta	tcccagctgc	atatttatga	cagtgtactc	96720
aagaaaaagc	ccaataaagg	cagcaacaac	aacagaaaga	ttaagaggga	ctggtcatta	96780
tttcccagtt	actggtttct	tctctgctcc	ctcttctgat	ggtcatcagt	ctatgactgt	96840
ttcagacttt	tgtgactgct	ccagcccata	tgtgggagtg	gaacattcca	aacaccatgc	96900
cttccattct	tgctattact	gagattgtat	ttgcaaagcc	acctggcttc	tttctaaaac	96960
agttctctta	gtcctttcat	tgagacttct	aaaatgatct	caaaagccta	taaaaataac	97020
aagagcagc	agccttcaca	ttcaagtcaa	gtgccttata	taaaaccttc	ctaaaaatagc	97080
atcaacatag	agaatcctt	ttctgtggaa	gagctcttga	gtgctgtggt	ttagacttca	97140
gtttaaaaat	taaaccaagc	actttaggaa	agtaacaacc	tcagggtttc	aagcagagac	97200
acctttgttc	tcattccttg	caacgtaacc	aaggatgtgg	tataaccact	ggccttggtta	97260
tacagtatga	gaggaaccag	tacaaccttc	ttggtataaa	gccatgaaca	gcagaattct	97320
ttttcagggg	taaataatcc	agttagcatt	cagtagcata	caaccacaag	aaaaagcagt	97380
taaccaagac	agtacagcag	tgtttcaagt	ggcatttcca	gggacctgtt	aaattgataa	97440
gtctaagaag	atgagcacat	acaggttaga	aagggaagtgc	tgatatctga	agggaggatt	97500
gttggaaggg	atacaaggcg	aggcacatgc	aagttccctc	ctaagacca	agcacactca	97560
cacaagccgg	ctctcagaga	ggccacagat	ttgggacttg	gagagaccag	aggatcctca	97620
taagagcata	ggtatagggc	agcttttggc	catcacagcc	caagtctctt	gttttaattc	97680
agctcgtcat	atltggctaa	tagtttaaat	cctgtggcca	ttagtcatca	tagaaaaat	97740
aataaagaaa	aatatataaa	acttctgcta	ttggggaaat	tcccataagg	gtgtgaggat	97800
ttgaggggga	gggggaatgt	acttctgcta	tgaaatgctg	agcggcacat	ggaaattttc	97860
gagcagtttt	agaagtatga	cctttttctt	ggtgtatgtg	catcatgtct	atgtcagagt	97920
ttaggccctt	ttcagaagtc	ttcttccagt	atcacatttc	aagaagcaat	agtgaaccc	97980
tgagatcatc	cgttttaaaa	tatttctcaa	gtagcaaaat	cacaatttag	ttttttaggc	98040
tcttctgtgc	cggagttaat	cccaagtacg	atatacttgc	tattgctaag	gaagaggctt	98100
gagtaaaagt	gcacctgata	gcttattttta	gagaagatcc	agcctgtacc	tcgtgtccca	98160

gatgtagtgc	tgctgcgaga	tgcttttagtg	tgctctgcac	ctcaatctgt	ccatgctctg	98220
gagtggtcat	cttcttagac	attcatctga	atgtctttag	aacagtgcac	atgtatcccc	98280
tatgcaggat	tgcttaaggg	attaagagat	ggctttggag	taagacaggc	ctgggcttga	98340
atcccagctt	caccacgtat	tggccttgac	tgagttatat	gacgcctgca	agtctcagtt	98400
tcattagctg	aaaagtgaag	ataatattac	ctaactcata	ggattattgt	tatagtaaaa	98460
agacaatata	tatcaaatgc	ttagcatagt	ctggtaaadc	aaagctccca	acaaatagta	98520
gccactggta	aaatgattgt	tattgttatt	gttttgaatt	ttaatagtat	gttttttaat	98580
aattaaaaga	attacgctcc	tgtgagtgac	tttgacacca	ccagtatggt	cagcctcatt	98640
agcgtaaagt	cttaagttcc	ttctatcatt	cttatttttg	tgctctact	gcatgctagg	98700
ggtgtaaggg	tgactcagac	agaacctgcc	ccagagatga	caggacagag	aacgagaaaa	98760
atgtgtagaa	aactgcagtt	gcataaccaa	gcagtaaatt	tgagagggac	aacttgctcc	98820
acctaggagg	ttaggaaagt	attctctgag	gatgtcaggt	ttgaactgga	atataaagga	98880
tggagtaggc	attgttcagg	cagaagaaag	gagcaaaaac	attccaggca	gagggaaat	98940
ttgctggaat	gtttgcagga	gtggtgggaa	atacaatcac	tttgtttctt	cacaagttta	99000
ctgcaagaat	tttcttccag	tagttaaaag	cttcaactca	ttctccactc	ttgggatctg	99060
gaaagatctt	taaaaaacca	ccacactgta	ttttggagga	gggcagcagg	gctaagttag	99120
gtaactaagt	ttttctgaac	aattcctagt	gccaggcatt	cattttacat	agaatctgtg	99180
tgtcaggaaa	agtcaggggg	aaaggtagag	aagaaaaccg	cccaaagcca	tggtagagag	99240
gcaggattgg	gatttaagct	taggtctttc	tgggctggaa	gcctcagtg	gtttatacat	99300
caaggggtca	agacctgaat	gctcccagag	gccaggaagg	taccacaaat	aacgtagcag	99360
ccttgggtag	gcagttggga	gggaccagtc	ctctggagac	agcatcccac	ctcagattca	99420
atgcatttta	tagattcaaa	acattttagg	gccaaataaa	actaggtatg	agagcagatt	99480
ccattcttga	gtctaatac	atcttgggaa	tcttttcttt	ttcattaaca	tttttagtta	99540
ttattgccac	tgtgttttca	ttccagtgtc	ttacacttag	caatcatcca	ccttcattct	99600
caacttgtga	gggatctact	agaagtcaca	tctggtttga	tttctgatga	cattatcaac	99660
atgagaaatg	atctgtacca	ggtaagcaga	aatctcaaga	aaacaactga	agaaaaatct	99720
gtagtttact	ttttctctg	ttatgtttgg	gtgcagtgtta	tttttagtaa	tgttaacagt	99780
agcaaaaaaca	aaaacaacc	tttgtaggta	atatctaaaa	tcccattagt	tgagaaggtt	99840
actttatgat	gtaggatcct	ttgatctgtg	gggtataacag	ccatcaagcc	acaatgaaat	99900
tcagcatccc	gctgggggaa	ggcaaacctt	aaactttaga	aatcaaacag	ttttttcatt	99960
taagagggag	aaactaaagt	aaaaatgtca	catctgtcaa	gaaaaataaa	gttaaaaaaa	100020
gtttgaaaag	ccagtaattt	ataataattt	tgaagtctac	tgaaacatac	cttgacaaca	100080
tccagattaa	atgtatatca	aatgaagcat	tctgaaatca	ccacacagaa	aggttaaaag	100140
tttgcttgag	gaggaaaagg	tgtctttcaa	aagcagaaag	acagctcaa	gtgaggaaaa	100200
gtgggaacac	cagagttttg	cccaaatcag	gttttcttag	gaattaatta	ggtgggctga	100260
aaatacaagt	tgaggaactg	ttttttccag	aggctctcca	acactgcaaa	gggagagtta	100320
gctggagaca	cagcgaggcc	ccttgatggg	catatgcaga	attcagggag	aggcaaggag	100380
cctgggagcc	acttcggcag	aagcagagct	tggacgttgg	tgatgggagc	ccagtgaccc	100440
cagccagcct	ttctggctga	gcgactgcac	tggcatgaaa	ccaagatggg	gttcggctcc	100500
tgaggtttcc	tcttctctgc	ccctgattgc	ttttcccacc	tcactgtctt	tcccctactc	100560
ccaccagtct	gctgtatggg	gctcctgccc	ttgcccactt	cttacctttc	catttgtctc	100620
cttcccttca	tcgacccgaa	gcaccttctt	catcctcctt	ggagagatgg	tttgctggtt	100680
cacgtgtatc	tctcactcca	aaactatggc	caaaatcctg	tgtaattatt	tacttagtaa	100740
agatatttgt	tctgctctc	tcagttttta	tagcagtgat	gtgaatcatt	tctatttctt	100800
cactttaaag	gaaaatgctt	ttattatttt	aaagaaaatt	aattaaaact	tcattttctt	100860
taaaggaat	taaaatatct	atcttcttat	ttttatttcc	attctttaaa	atgtgcttta	100920
ggctgggtgc	ggtggctcac	acctataatc	ccagcacttt	gggaggccga	ggcaggccga	100980
tcagtagatc	aggagatcga	gatcatcctg	gctaacatgg	tgaaaccccg	tctctactag	101040
aaatacaaaa	aaaaaaaaaa	aattagccag	gcatggtggc	aggcgcctgt	agtcccagct	101100
actcgggagg	ctgaggcagg	agaatggtgt	gaacctggag	gctgagcttg	caatgaggcg	101160
agatcgcgcc	actgcactcc	agcctgggtg	acagagtgac	gctctgtctc	aaaaaaaaaa	101220
aaaaaagtgt	gctttaaagt	gcatttaaag	caaaactact	aaaacgttta	catgtggctc	101280
ttaatagttt	ttacctgtga	ctaggtaaaa	attaataggt	ttcctgatag	gggaaaatga	101340
ccatttttca	ttcaatataa	gtcaccatta	ggcttcttca	ctggctcttg	tgcttcttgt	101400
caaaggaaaa	gtaaagttag	tgactcttca	ctgctgttta	atataaaata	actagtatga	101460
agtgtgattg	tagattttaca	tttaaaggat	gtcttcttga	aactttcata	ccgttttggg	101520
gtcattggta	tccgtaaggt	cattttgcoo	gtaaagcttg	attctcgcag	acttttggct	101580
gattgttctt	tgtagtcatc	acaaatctat	gaataaaaacc	aggaaatggg	cattgtagct	101640
tgtcagtcct	cttttcaaac	cctgcttaac	agtcataatc	aaggaattac	ttattttatg	101700
tttataaata	ggatctgcaa	aggacacagc	acaacaggat	tagtagctgt	gatttttttt	101760
tggagacaga	gtctcactct	gtcaccacaga	ctggaatgca	gtggcgcgat	ctcggctcac	101820
tgcaacctcc	acctcccagg	ttcaagcgat	tcttctgcct	cagcctcctg	agttagctgg	101880
attacagggc	tgaccacca	caccagcta	atctttgtat	ttttagtaga	gatgggggtt	101940

caccatggtg	gtctggctgg	tcttgaactc	ctgatctcgt	aatctgccag	cctcggcctc	102000
ccaaagtgct	gggattacag	gcatgagcca	ctgcgtctgg	ccagtagcta	tgattttttt	102060
tttatatcct	aaactcttta	ctgtatcatt	tggttacata	tgttgagact	ctccagtgty	102120
ttagagacaa	aaaccctgaa	accgccacca	ttgatacttc	tatcccttct	gatttgggga	102180
ctctcagaag	actatacgtc	catttttccc	ctaccttacc	accagtctga	ttaatgggca	102240
gtgattctgg	cttccctagt	atgccttcta	gggtgcaaac	acacacccaa	tggaactttt	102300
gatttgagaa	ttagaaactg	ctaagatttg	aactcttgat	tatctgttgt	aaaggttctc	102360
tagtaactat	tcttaatgga	aaatgatata	gttctctaaa	taatttgat	tatttgacag	102420
ttaagcattc	ttcccaata	cctttcacta	atctaagtac	atctctgtga	ccatctgtca	102480
tgatcaaatt	cctctcccca	cccacctct	agaaacacac	tcaaaatagt	ccaagtgcac	102540
cgagttagga	ttttttatga	aaatattctc	tttaagcctt	tttctccttt	cattctcctt	102600
cccccaacat	agacaaccac	tctatcgtgt	ttggatgga	ttgttttatt	tgtgtatggt	102660
cccataaaac	attattggag	ggttttatgt	atttttatgt	ttttaattat	tatacatatc	102720
atgtatattc	atagttttaa	aaatggtaca	gaagaatcta	cattggaaag	tcaaagttgc	102780
ccaccctgac	aatgcccagg	tctgctagca	caaatgtcac	tattgtgttt	ataggtagtt	102840
tttcaagtac	tgatatacaa	tgtacgtata	cttgaaatac	atagatattt	tcatatactc	102900
tcacatacaa	tccacattat	attaaatgta	cttctcttgc	cttgcattaa	cctttaaaat	102960
ttttttaatt	taattttaatt	atagattcaa	aggaggttac	aaaaacgtac	taggaagtcc	103020
tagtatttac	tgcaaggaaa	ccagaggtct	cttcacccag	tttcccccac	tggtaacatc	103080
ctgcataacc	tcagaacagt	gtcaaaacct	ggaaatagac	gttgatatac	tccacagatc	103140
ttaatcagat	ttcaccagtt	ttacacacac	ttgtgtgtat	ctgtatagtt	ctttgtgcat	103200
atatttttta	aatgcctaag	tggcattgtg	ctacatgtta	ctgtatttct	gccttccactg	103260
cttatccaca	cagttctaca	tatagctagt	ttgttgtttc	agctcctgaa	gagaatctag	103320
tatgggtctt	tcacctataa	catccttgtt	tcttagtagt	agacatttaa	ccaacttcta	103380
acttcttacc	tcagtagata	atactgcagt	gactgtcctc	acttatgtcc	tcttgtggat	103440
ttgtgtcaga	atcttaccac	gatacatctg	caagagttgg	gttgctggga	catttgtata	103500
tttggctttc	cagaatgtct	gtgtaagttc	ccatgcccac	agccatagca	tgaaggtata	103560
attgtttaag	atataatcct	tggatttaag	aactagaagg	tttatatcat	ggaaaacctat	103620
tgattggact	gtggaagaaa	atattaaaaa	aaaaaaacct	ctccgactca	taagatattt	103680
tttaattaaa	ttcaagctac	agataattta	taattcctga	atggataact	atcttataat	103740
ttcagatcct	tttttcacaa	tctcattctc	tttctttttc	ccatctcccc	aagtagcatt	103800
tcagaaaaca	cagattagta	aacacagttt	ccattgactt	atttttgaga	agaaggctct	103860
tggcaacaat	atctaaagtt	ttgaggacat	cacttcattt	caggccaggt	tgatagtcct	103920
agaaaatgaa	agaaataagg	gcaagtaata	atltggcaaa	aaaaaagggt	cttgtatagt	103980
aaataatcac	tgtagttgag	atlttagacta	ccctcccatc	attcatcctg	ccagttatca	104040
tgtgctgtgg	tcacctacac	agctaggagg	ttgggtggctc	acctgctgct	gtagccagta	104100
actgctcaat	gaaaagggaa	ttttaggcaa	attgtcacia	gactggctgg	atgtcatagt	104160
taggctcctg	tgaataaac	tgatttgtat	aaagatacat	tgctgttctc	tgtcagtgaa	104220
ctcagttatt	tgaagatac	gtttgtgatt	gtatltgtct	tactcatttt	tgaaaaacaca	104280
cagtttgcaa	aacatcttat	ttgcattcac	cgaagtaata	ccttgtgggc	aggatagtca	104340
aatggactat	ttaagtacct	attaggtatc	agcagctcac	cttttttatt	cagctgagcc	104400
cccttgggtga	gatacttghta	ttatcctggg	tatgttattt	agaatcttat	aatacctttt	104460
atgaaatggg	tgtaggaaaag	ctatattgac	tggtctcagg	agccagttca	tgggacagta	104520
ttttttaatt	tagtaaatltt	agtttccatg	tcagcataga	atcatggcac	ttttgttaat	104580
tggtttctat	tgagtacttt	atlttaaatltt	cttcagtgaa	aacatagcct	taatttgatt	104640
tgtttaataa	aaattatcag	ctggaggtaa	ctcctaccag	atatttaaga	aaactaaatt	104700
tactactagg	tgtgctcaaa	atcaacaatc	agtgggttgt	agtgagaaac	aagaagctat	104760
taagacttgt	aaatatgaaa	ataaccacc	acagaaaaaa	ttgtaagtat	atgaagtgat	104820
ggatttghtaa	cttagcctga	tttaatcatt	ttatgttghta	aacttagatt	aaaacatcac	104880
attgtacctc	ataaatatat	acaattacta	tttgtcaatt	aaatttaaga	taaataagaa	104940
ttttaaaaca	tgaattattg	aatggctaag	tgttagtaca	gtatatgtac	ttcattagca	105000
tatagtatgg	aacaggataa	cttgggtgcc	aaggctcagaa	gttaatctgg	gaatgagaaa	105060
tattcctgca	gtatggcccc	acctattgca	gtaacagcta	ccaagctgtg	agttgtaagt	105120
aagtattcac	tgctgaccag	tgaatctcct	gccctttcac	tttccagacg	cccttgcact	105180
tggcagtgat	cactaagcag	gaagatgtgg	tggaggattt	gctgagggct	ggggccgacc	105240
tgagccttct	ggaccgcttg	ggtaactctg	ttttgcacct	agctgccaaa	gaaggacatg	105300
ataaagttct	cagtatctta	ctcaagcaca	aaaaggcagc	actacttctt	gaccacccca	105360
acggggacgg	taagagacaa	tcacacatca	ttgggtgtaac	tttctccacc	ttctaaatat	105420
ctactaggta	tttgataaac	gtgtgttatt	tgatttgcac	ccaaaagtgc	tttcttagt	105480
cacctggagt	tcatcatctc	ttttgggcat	ttctgttght	caccaaagct	aattttttta	105540
aagatgattt	ggaatagtta	gtaggaggag	aaagcagagg	cctgagttaa	gattcatctt	105600
gaagtacaca	aagcgtcgtt	tattcagaga	atgtttatltt	atgttcatgt	ctcctgagaa	105660
cataatagga	gactgtgggt	cttcaaagca	gaacaataga	cttatagtat	ctttactgtc	105720

cctccccatg	attcagtttt	tgccatttcc	ttcagcttca	caagggccat	cttgtgagtt	105780
agccatccca	tcctgtgact	gtccctttgc	ttggactcta	ggtctgaatg	ccattcatct	105840
agccatgatg	agcaatagcc	tgccatgttt	gctgctgctg	gtggccgctg	gggctgacgt	105900
caatgctcag	gagcagaagt	ccgggcgcac	agcactgcac	ctggctgtgg	agcaccgaaa	105960
catctcattg	gcaggctgcc	tgctcctgga	ggtgaagggc	acacttattt	gcttttgcat	106020
taaatctctg	agggagattt	aaggaaatct	tttcaaagaa	ggaagtcagt	agctgctggt	106080
ctcccttaca	atcagctcta	tttgtttaac	atztatggag	ggcttcagag	taccaccttt	106140
agacattccc	ccaacccctt	tgcttggcct	ctctaactgg	ggatttcctc	aatgacagag	106200
ccagcccaaa	gtagcaattg	ggctagtaat	aggaccaag	gagccatgca	cactgggagg	106260
tggggacaaa	agggcaaaag	aaccttcac	taacgctttc	ttgtgtgggc	tggattgtag	106320
ggtgatgccc	atgtggacag	tactacctac	gatggaacca	caccctgca	tatagcagct	106380
gggagagggg	ccaccaggct	ggcagctctt	ctcaaagcag	caggtaagat	ggtgatctgg	106440
cggtcattaa	tgaaaaatgt	taccaggaat	gcaaacccaa	cttcaataga	gcagtcattg	106500
tgcttctttt	aagccacaga	cctactgctg	aaaaacaagg	gtaaataaaa	attatatggc	106560
aatcacattt	ttatctgcca	taaggcactg	tttggactag	taatcttggg	ctttaccctg	106620
atagtcattt	tagtctttac	tttctgattc	atctgtttgt	ttggggtttg	attgtttaga	106680
ttgactccca	tgacaaaggg	tcttttcaaa	gtagagtttg	attccttata	gaattctgag	106740
tggtattagt	ctcagatcat	atcagaaggc	cccagaagaa	aaagattatt	ggtataagaa	106800
atcattttaa	gacttcattt	tgaagaaat	atctcttaga	aattgaagtg	taggaaaaag	106860
aaaatgggcc	atgtattaag	accattatg	tggaggcac	taaaaatggc	tagcacttat	106920
tgacctttct	gtgtaccagg	cactgtgata	tgacctttat	gtgcacagtc	tcatttaatg	106980
cccaatcacc	ccttgtgaca	aataccatta	ttccccatct	tagagtcaag	gaaacagact	107040
agagagacta	ccagatccca	cttcagggtt	ccagtaagtg	acagagctat	gaatcacact	107100
tcggcagtg	gaacttcaag	actttattct	ctgtactatg	tttctctctc	ctattttgc	107160
cataggtttg	cagatgttat	tccatttaat	tctctagtcc	tgtgaagtat	agaaaattat	107220
ccatgctgat	ctttgaatct	ccagtgcctt	gcatatttag	aacctcaaaa	tatgtgtaat	107280
gaaattggca	tctgaagcct	gccctgacat	atctgatata	ctttagaggg	tttttttttt	107340
tttaacttaa	aaggtaaatg	cttcataaat	tcaagaaaac	aaagcaaaag	acataggaac	107400
tttttctttg	ggaccacata	tttttctttt	ctcttttggt	aaatagaact	ttttcttgaa	107460
caagaaactc	tgattgcagt	gggtattaat	agttttagaa	gacactgatt	aattaaatgc	107520
cttccaacaa	gaagctataa	ccagccagac	gtgatggctc	acacctgtaa	actcagcact	107580
ttgagaggct	gaggtgggag	ggtcacttgc	actaggagtg	tgagaccaac	caggttaaca	107640
ttgtaagacc	tcatctccat	taaaaaattt	aaaaagtagc	caggcatggt	ggcatgcgcc	107700
tatagtcgca	gctagttttg	aggccgaggt	agaagtatca	cttgagcctg	tgagttcaag	107760
ggtgcagtg	gctacagttt	caccactgca	ctccagcctg	agctatagaa	taagaataag	107820
accctgtctc	aaaaaaaaaa	aagaaaaaga	aagaaactat	aaccctttta	aaaatgcttt	107880
atattgaatt	ctcagaatcc	catgaaagga	aaagcaagta	acagtttctc	tgatatataa	107940
atgaagaaac	tcagatgaaa	aaccaagtcc	taatcttaat	gtcgtggaaa	aggtcagtta	108000
agtccgagtg	tggtggctca	cacctgtaat	cccagcactt	tgggaggcca	gggtgggtgg	108060
atcacctgag	actggcagtt	cgagactcac	ctggccaaca	tgacgaaacc	ccatctctac	108120
taaaaataca	aaacttagct	gggctggtg	gcatgcatct	gtaatcccag	ctactcagaa	108180
ggctaaggaa	ggagaataac	ttgagccctg	gaggtgaggg	ttgcagtgag	ctgagactgc	108240
gccattgcac	tccagcctgg	gcaacagagc	aagactccat	ctcaaaaaaa	aaaaaaaaaa	108300
aaaaaagcgt	cagttaaag	atagctcatc	cctccacact	ttggtcctgt	aaattgttca	108360
tcttaatttc	tccatggatt	acatttattg	cctcatagat	caggccagaa	ctgggagaat	108420
aaaatcaaga	aacagcatga	agatccttct	ttgtttccca	ttaagtactc	ctctattatt	108480
gatattgacc	catctgatgt	tctcccagca	agataaaaaac	aagttcctcc	ctcaaaaaatg	108540
gcatcattag	acatcaagct	aaacactcat	aaaaatcatc	taagcctctg	agaagtaact	108600
ctagctctag	tctttgagtt	actttgatgt	tttgtttatt	tgtttggtgt	ttttgttttt	108660
gctggatgct	aaagagcaga	ctacatttcc	caaaatattt	caataattat	acatcctagt	108720
aggtttgttt	atlttaagat	cagaacctg	gcattgctgt	accagcaat	gaaactggcc	108780
atgctgtcac	tagacatcaa	gcacttttgc	tcttttgagt	gtccaagaaa	aggggctgag	108840
aaatacacat	tgtcatgcat	aaatttgaac	agttaggacc	ctaactctga	gggtgcacc	108900
tagtggctgt	aatcatgctg	tccatcagcc	ctaagattaa	agatgcacta	ttcagttgag	108960
aaatatcctg	tagagttaaa	tgtgaaagag	tatttgaagt	ctttttttct	tcaatagtat	109020
ctttggctat	ttcaggtgtc	ataagacact	ttaacaatca	aagtaaatta	caatttttaa	109080
ataatctctc	tgatatttcc	agtagaaatg	ttttatgatt	taaaaattat	ccaggagatt	109140
gcctcaagct	gctacattgc	tttgcccttg	ggaatctgac	ctttgcaggc	agttggaagt	109200
tgacaagatc	tgggtttacc	taatgctgtg	taatctaact	tcgcaggagc	agatcccctg	109260
gtggagaact	ttgagcctct	ctatgacctg	gatgactctt	gggaaaatgc	aggagaggat	109320
gaaggagttg	tgcttggaac	cacgcctcta	gatatggcca	ccagctggca	ggtgagtgcc	109380
gctccatctg	tctgatggct	gccccgagg	gagtcagagg	ttcaggaatg	taagaacaga	109440
tggtcttctt	ggtgctttat	tccccaaaga	acatgccttt	tatttttaag	aaagtctggt	109500

tgtcagagac	cattttttatc	ttgaaaaacc	ctatccatga	aagatctagg	tcagctgagt	109560
tctgagtacg	aaagtgtatg	cctaatacaga	tcagagttga	gatgtgagaa	aaggttagaa	109620
gaaaaacaca	aaattcacat	aaaagttacc	cattccaaat	tcacaccata	attgtgacca	109680
tctcaatttc	tgaagctagg	ataaatgtta	ctgtttgctt	aggacttagg	taagtgattt	109740
caggatgtaa	aaataaacta	agaattcttc	ttagaatttc	aataaatata	aacagagtaa	109800
atagatttaa	agccttcctc	aaaactccac	agggctgaga	tctgaaggta	taaagcagtt	109860
actaggtcat	ttggccccag	gaagaaaagc	cagagggagg	aggtgggcag	catgcaagat	109920
ctccaacatg	acaagatcag	ttcttctaga	gacgagagct	gctccacttc	taaaactgct	109980
catgtgcctc	ccacagcctg	tatgtgtcca	gctcactgac	gttagcatgg	ttctcccttt	110040
atgttagcac	ctcatttccc	cagaaggcct	tgccacagaa	cacaaaaaga	tgatgcactc	110100
agtgacccca	cgctctcctt	accaggtca	gccagcaaca	gagtgactgc	agagaacacc	110160
acaaatgcct	cggcagctac	agaataatth	ttcttttagc	ctaagacaat	tctggaccct	110220
cagttaaaat	gtcagtattg	ccagaggggt	aacaccaagc	cttgtgaaca	tctagacatc	110280
tcaatttgag	caagtttata	caattcattc	tcataagctt	gttcctatgg	aagaagggag	110340
acagcttcac	agctctgagt	aagctcttca	ctagccttag	gtctctgagc	aggagatgat	110400
tgacatggtg	gcttgactg	cctgttccct	ccaaaaggct	atagctctga	ctctctgcag	110460
tttggttggg	tattctgacc	cagctcagag	tttgtgcaaa	gcactatthc	ccagtaccag	110520
agcccctaca	gctgttcttc	ccccaaaggg	taccatattc	ttggagggtg	gtcctgattc	110580
ctcttgccat	tcctccatca	ttagggtagc	agggcctcct	aaggaggaca	tgctgagttg	110640
tttattataa	agaaacagac	tgccctagtg	gtcccttcga	tgtataacga	tttctgggtg	110700
ttttctttcc	aacaggtatt	tgacatatta	aatgggaaac	catatgagcc	agagtttaca	110760
tctgatgatt	tactagcaca	aggtggggtg	tgataaaaacc	agattctctt	aaccattatt	110820
atctccacac	tgtcatttaa	agggaggaac	cagcattatc	cagggctctac	tgttaaaagt	110880
tcttattttca	gaacccaaaag	atgctggagg	tagataagga	gaatatccag	ttttaatcta	110940
ctgtaaagtgt	atactgcctt	ctactcagct	gggctttgac	cttcaagtag	agttagcttg	111000
ttggttccac	tgggagttgg	acagcaagcc	agggcagcaat	gatcagctcc	tccagagtgt	111060
ctatggcatg	ttagaacaag	tgtgttccct	cttcatttcc	ttcaggagac	atgaaacagc	111120
tggtggaaga	tgtagaagctg	cagctgtata	agttactaga	aattcctgat	ccagacaaaa	111180
actgggctac	tctggcgcag	aaattaggtc	tggggatact	taataatgcc	ttccggctga	111240
gtcctgctcc	ttccaaaaca	cttatggaca	actatgaggt	aacaccttac	cttacagatt	111300
tagcaattht	catttgactt	tactctgtta	acatctctgg	ccagggcata	atctccttcc	111360
cttttcctta	actctgaaga	agaaaaccag	tcattgcccc	aggcctggga	gggtgaccca	111420
ggccaagttg	gcagcccac	ttcctgagaa	tgctgttttc	agataccttc	agatthtccc	111480
cgthttcaaa	tacctggaga	cttctgtgta	aaatgctacg	tagagggta	ggatthttcac	111540
agaactthaa	cggccctgag	caaacaatcg	actgtaatca	acgtgtagct	tctgtcccc	111600
aagaacacac	cttaccat	ggcagggcat	tgagtcatgt	tctgtgaggt	gactcctagt	111660
ggagccatta	cccggggatt	ttttttttc	atthtcaaaa	ataaaatgta	gaaaagcatg	111720
gggtgaagtt	ttctgttgaa	aatthcatgg	ttagctthttg	tttctgcatg	gatttcagag	111780
cttcagctta	cagagggaga	ctgtgtagac	gtcactgtag	gcagagttc	actgcctcag	111840
cgcttctctc	gctgtctctc	tctctgctta	ctacaaaaca	cttctctgtg	atthcctgag	111900
tggtctttga	gccgaaacag	gaaacttgat	tcgaagactg	tatthtctta	gtcgtcttcc	111960
tctgcccttt	ccatthtctc	ctggctcctg	agtgaggagg	gcagcatgga	agaggggaagg	112020
gtgggctgtc	agtgtctaca	gcctgcactg	ggactcgaac	acaagaacat	gctcctcctt	112080
cctthtcttc	tcacaggtct	ctgggggtac	agtcagagag	ctggtggagg	cctgtgagaca	112140
aatgggctac	accgaagcaa	ttgaagtgat	ccaggcagcc	tccagcccag	tgaagaccac	112200
ctctcaggcc	cactcgctgc	ctctctcgcc	tgctccaca	aggcagcaaa	taggtaaaaa	112260
aaaagacaaa	agacagtgga	gatatthtcc	agctccccc	ggctgggtgc	ttcagctctt	112320
tttgatgatg	gtgtggcagt	tttctttctc	gtthtctgga	tacacttccc	tgtgtgtctc	112380
tctaccccct	gggtcacc	tctgctctc	ttgatagtac	cattcagatg	agggggctgt	112440
acccttgga	aatcacattg	acacatgaac	tacttagtaa	acactaaata	atacaataaa	112500
tactaaaaac	aacatgatgt	gggtgattaa	atthaacaca	tgagagaaat	aatatthtacc	112560
ttaaagagag	aaccatctcc	ttcttctctt	gctcctctc	tcaagcttat	gactgacc	112620
ttgtcccca	ccatataatg	gactacgtgt	catgccacca	aaagtctcgc	aaccatataga	112680
aatggactct	caaccagcc	cagtaatcct	atatthtcta	caatthtatt	ctcccactct	112740
gtaaagtgatg	attccatgct	ttctatthtct	aaacccccaa	cactccttcc	ctccccttac	112800
tcatgcaaca	cccttgcttc	acactctgtt	gaaaacagaa	gaaaccagaa	ccctctcacc	112860
tttgaccaa	gtgccagccc	acctgtgctt	gtgccacat	tggcagcctt	ccatccggac	112920
ttggtgggtt	aaatthtctt	gcccagctga	ggagccacct	ctcccctgag	tctaaccctcc	112980
tcactthtacc	taggttggtg	ttcctgttaa	ttcttacctc	tctctcctgt	actagccgtt	113040
cctcctcccc	actctccgac	taggtcacct	agcaagcatt	tcatgatttc	ctcatcttta	113100
aaaacaaaa	acaccgaaac	aatcacctc	ttgatccac	atcccattta	gctacagtcc	113160
aattgctcta	ttcccataca	tagcagagct	ccttcaaaga	atthttaga	gttattcttt	113220
ccagcttgcc	accttcacc	ctctgcttgg	cctcctgcag	ttgggatcgc	atccccaccg	113280

ctccaccagg	cctgctgtcc	tcacagtgac	cggtcacctc	cacattgcca	gatctgggtca	113340
cctccttttc	accttgacca	cttgacagagt	gtgtcatggg	tgacgcctac	cttcaacttc	113400
agaccgtctc	cattcctggc	tcctccacag	cacactcccc	tggctggctc	ttctacactc	113460
accttttaaa	gtcacagccc	tccaggggtca	gtcctaaacc	ctccctgctt	ggtacctcac	113520
ccaagcccaa	tactggctac	atctgtcaga	agegctgcca	tcttccagga	gattaagaca	113580
aaacccaaga	attcctcagg	agtcctttct	gccactaatc	acttcgtatg	cgacgcatcg	113640
agtgtcatcc	tgtctgcaac	caccgccccca	ggccagcctg	ccgtcatttc	ctgccccaaat	113700
tcttgacagg	ctcctactca	gtcccccttgt	ttccttctctg	tccacctccc	ttcagtccat	113760
tctctgcccc	acagacggta	tgattcttct	aaaaaatcag	tgacattgta	ttaattctgg	113820
gttatgccct	tcagttcatt	cagtcattca	ttcagcaaat	cctgatccag	catacaactgt	113880
gtgcctagca	gtgttcgagg	ttttaaagat	aaaactgtgt	ccctgcttta	ctcgttttgc	113940
ttcttaaaca	ttgctgtgga	agctcttct	ccacactgcg	cctccattcc	caagtgtttt	114000
ctctgctccc	ctggctcact	agtctgacca	accttttgac	tgtttcttcc	cattccctgg	114060
aaagctctta	attggctggc	tctttcttgc	cactcagttt	cagcacccat	ctcaccctgc	114120
cagggggcct	tcccagggga	gcaagggcag	acgtcattgt	ccgcacttga	gaaaggaata	114180
atgtatccgc	cggaaaacaa	cccagatctc	ctgagtcaca	gcccagtgct	ccttctgcac	114240
agatattaaa	aaagaaaaaa	agcaataact	taacatTTTT	ttaaaaagta	aatacctaag	114300
cattaagccc	ttaatttgta	gttatTTTTa	ggatatcgca	tagtttgtaa	cccataatag	114360
acaccaaata	aagattgggt	gattaaacia	atcagtcaat	acaaaaatga	tagtctgtcc	114420
actggcatta	aagtcttaat	attctaatat	tggaatttgg	tacataagaa	gatagcattt	114480
tgattagtgt	atgttagact	tctgtttct	tcctcactgt	ataggaaata	atgtgtcttg	114540
gtcatatccc	taaggacact	tataaacaaa	gggaattcaa	cctgattttc	cagtatagac	114600
tcattttcac	caaaatcatt	ttacttttat	tgctaccaa	aatgttttca	aggcaatgta	114660
tgctgtaata	gcatatgagg	cccagagaga	gatctcattt	ttagttcttg	cttctgtcac	114720
caatttatTT	tgctgagggt	cagcagtttc	cccagctatg	aaatagataa	tacagtgggt	114780
ggaaaactac	acttgatttc	taagggaaaa	aaaggtccac	tgtgagtcaa	gagaattcag	114840
aaaggattct	cataaacaca	agactagatt	gcaggaagat	gtgaaagcat	ttggctaatt	114900
ctgacatttg	gctaataaca	tcctcacagt	atgtcccaag	tatcttctgc	ccttcccacc	114960
acggtgagca	gtcatgacag	tgaggggtgg	ataggtggga	tgtgtggctg	gcagaagcca	115020
gtgggcaaga	gttgtccaca	gaatagtcca	tgagcttttt	agagcccggc	cattccccca	115080
gtgaatttgt	gctttctccc	ctcagacgag	ctccgagaca	gtgacagtgt	ctgcgacagc	115140
ggcgtggaga	catccttccg	caaactcagc	tttaccgagt	ctctgaccag	tggtgcctca	115200
ctgctaactc	tcaacaaaat	gccccatgat	tatgggcagg	aaggacctct	agaaggcaaa	115260
atthagcctg	ctgacaatTT	cccacaccgt	gtaaaccaaa	gcctaaaat	tccactgcgt	115320
tgtccacaag	acagaagctg	aagtgcattc	aaaggtgctc	agagagccgg	cccgcctgaa	115380
tcattctcga	tttaactcga	gaccttttca	acttggtctc	ctttcttgg	tcataaatga	115440
atTTtagttt	ggttcactta	cagatagtat	ctagcaatca	caacactggc	tgagcggatg	115500
catctgggga	tgaggttgct	tactaagctt	tgccagctgc	tgctggatca	cagctgcttt	115560
ctgttgcat	tgctgttgct	cctctgctac	gttctatttg	tcattaaagg	tatcacggctc	115620
gccacctggc	attccttctg	accacagcat	cattttgcat	tcaaattaag	ggttaagaaa	115680
agagatattt	taaaatgaga	gtcacttgat	gtgccatttt	aaaaaaaaaag	gcatattgct	115740
ttttctaattg	tggttatTTc	tctgatttgc	aaaaaaaaaaa	aaaaaaaaaaa	tacttgtcaa	115800
tatttaaaca	tggttacaat	cattgctgaa	aatggatTTT	tccccctttt	ctgcattttg	115860
ctattgtaaa	tatgtttttt	agatcaaata	ctttaaagga	aaaaatgTTg	gatttataaa	115920
tgctatTTTT	tattttactt	ttataataaa	agggaaaagca	aattgatgac	ctca	115974

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2018/050583

A. CLASSIFICATION OF SUBJECT MATTER
INV. C12N15/113 A61K31/7115 A61K31/712 A61K31/7125
 ADD.
 According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
 Minimum documentation searched (classification system followed by classification symbols)
C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
EPO-Internal , WPI Data, EMBASE, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	wo 2004/005551 AI (ISIS PHARMACEUTICALS INC [US]; BAKER BRENDA F [US]; FREIER SUSAN M [US] 15 January 2004 (2004-01-15) cited in the application page 105; table 1	1, 2, 5, 7-9, 11-18
A	-----	3, 4, 6, 10

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search 21 March 2018	Date of mailing of the international search report 03/04/2018
---	---

Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Romano, Al per
--	---

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2018/050583

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
wo 2004005551	AI	AU 2003256269	AI 23-01-2004
		US 2004005569	AI 08-01-2004
		WO 2004005551	AI 15-01-2004
